

AD _____

Award Number: W81XWH-06-1-0373

TITLE: Investigation of a Putative Estrogen-Imprinting Gene, Phosphodiesterase Type IV Variant (Pde4d4), in Determining Prostate Cancer Risk

PRINCIPAL INVESTIGATOR: Wan-Yee Tang

CONTRACTING ORGANIZATION: University of Cincinnati
Cincinnati, Ohio 45267

REPORT DATE: April 2008

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 01-04-2008		2. REPORT TYPE Final		3. DATES COVERED 15 mar 2006 – 14 Mar 2008	
4. TITLE AND SUBTITLE Investigation of a Putative Estrogen-Imprinting Gene, Phosphodiesterase Type IV Variant (Pde4d4), in Determining Prostate Cancer Risk				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-06-1-0373	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Wan-Yee Tang E-Mail: tangwy@uc.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Cincinnati Cincinnati, Ohio 45267				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Estrogens are known to play a role in the initiation and progression of prostate cancer. Recently, environmental factors such as xenoestrogens have been reported on their prevalence of prostate diseases or cancers. Estrogen imprinting of the prostate gland is believed to associate with an increased incidence of prostatic lesions including inflammation, epithelial hyperplasia, squamous metaplasia, dysplasia and adenocarcinoma. And DNA methylation may be one of the possible mechanisms of the prostate reprogramming. By using one of the global methylation profiling techniques, MSRF, a gene called phosphodiesterase type IV variant 4 (PDE4D4) was shown to be hypomethylated following neonatal exposure to estradiol (EB) or bisphenol A (BPA). We further confirmed the persistence of PDE4D4 promoter hypomethylation and gene up-regulation in the adult life by using bisulfite genomic sequencing and real-time PCR. PDE4D4 has function of cAMP-degradation to maintain the second messenger, cAMP, in a narrow range of concentrations that is critical for growth and differentiation of the hormone target cells by activating several downstream signaling molecules. Taken together, these findings supported that PDE4D4 dysregulation, via CpG island hypomethylation, at its promoter regions in early life, by EB or BPA, can alter its expression and activity of the gene. Present data also suggested that PDE4D4 can be used as a biomarker for prostate cancer assessment.					
15. SUBJECT TERMS DNA methylation, phosphodiesterase type IV variant 4, prostate cancer, estrogen reprogramming					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	74	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	6
Key Research Accomplishments.....	19
Reportable Outcomes.....	19
Conclusion.....	22
References.....	22
Appendices.....	24

Introduction

Background:

Steroid hormones such as estrogens are known to play a role in the initiation and progression of prostate cancer. Recent studies have also proposed environmental factors such as xenoestrogens on the prevalence of prostate diseases or cancers. Estrogen imprinting of the prostate gland is believed to associate with an increased incidence of prostatic lesions including inflammation, epithelial hyperplasia, squamous metaplasia, dysplasia and adenocarcinoma. However, there is little information about how estrogen imprints prostate gland.

DNA methylation induced by estrogens may be one of the possible mechanisms of the prostate reprogramming. Using the technique called Methylation-sensitive restriction fingerprinting (MSRF), I have successfully cloned and identified one candidate gene, phosphodiesterase type IV variant (*PDE4D4*), in lateral prostate lobes in Sprague Dawley rats. *PDE4D*, a cAMP-phosphodiesterase gene, has function of cAMP degradation to maintain the second messenger, cAMP, in a narrow range of concentrations that is critical for growth and differentiation of the hormone target cells by activating several downstream signaling molecules. My preliminary result data showed that *PDE4D4* was hypomethylated following neonatal exposure to estradiol (EB) or bisphenol A (BPA). Importantly, the expression remained at a high level during adult life. Taken together, these findings supported the possibility that *PDE4D4* dysregulation, via CpG island hypomethylation, at its promoter/exon regions in early life, by EB or BPA, can alter its expression and activity of the gene. These events could then activate several cAMP-dependent signaling pathways leading to abnormal cell proliferation or differentiation in prostate gland.

Hypothesis:

Early estrogen exposure was demonstrated to alter epithelial cell differentiation, predispose the gland to the development of hyperplasia, severe dysplasia and carcinoma. I hypothesize the *PDE4D4* gene dysregulation, via CpG island hypomethylation, at its promoter/exon regions in early life by estrogens or xenoestrogens can alter the expression and activity of the gene. It will then trigger

several cAMP-dependent signaling pathways that lead to cell proliferation and differentiation. Since the proliferative rat DP/LP lesion closely resembles human PIN that are the purported precursors of prostate cancer, I further hypothesize *PDE4D4* plays an important role in determining cell proliferation of human prostate gland to the development of prostatic dysplasia and carcinoma.

Specific Aim1: To investigate the gene regulation of *PDE4D4* under the influence of estrogen or BPA by studying its promoter activity

To achieve this aim, genomic DNA isolated from samples will be undergone bisulfite genomic sequencing to study the estrogenic effect on *PDE4D4* promoter methylation status. Moreover, using serial deletion analysis and luciferase reporter assay, I can determine how *PDE4D4* promoter is regulated by EB and BPA. Results from the transcription factors binding assays such as ChIP, I can identify and characterize which transcription factors regulate the promoter activity of *PDE4D4*.

Specific Aim2: To investigate whether *PDE4D4* is responsible for determining cell proliferation and can be used as a biomarker to diagnosis prostate diseases and prostate cancer.

Rat prostate epithelial cells (NBE-1) will be transiently transfected with full-length clone of *PDE4D4*. The intracellular cAMP level, PKA, Ras-PI3K, PKC activity and cell proliferation markers expression will be measured by cAMP assay, Western blot analysis and MTS assay. Also, by using technique of immunohistochemistry, localization of *PDE4D4* in normal or tumor epithelial cells of rat prostate can be examined so as to understand whether *PDE4D4* involves in tumor cell development.

Specific Aim3: To study whether *PDE4D4* expression is linked to human prostate disease.

Full-length clone transfection or suppression of *PDE4D4* variant by methylated oligonucleotides or siRNA will be performed in human normal prostate epithelial cells (NPrEC) and prostate cancer cells (LNCap, DU145 and PC3) to examine the role of *PDE4D4* in growth of human prostate cancer cells.

Relevance:

Recently, the National Toxicology Program released a report from the Endocrine Disruptors Low-Dose Peer Review Panel which sighted the need for the identification of molecular and biochemical markers as sensitive indicators of prostatic abnormalities following low-dose estrogen and xenoestrogen exposures during development. MSRF is a highly innovative and reliable technique to find out specific and novel genes undergone methylation or demethylation following estrogen exposure. My study in characterization on *PDE4D4* in prostate cancer development will be the first to investigate how environmental factors may affect early gene imprinting and the incidence rate of prostate disease. If hypomethylation of *PDE4D4* promoter was shown to predict prostate carcinogenesis and regulate the cAMP-dependent signaling pathways such as PKA and Ras in prostate cancer development, a new paradigm for prevention and/or treatment of prostate cancer could be derived. With the advent of phosphodiesterase inhibitors new preventive therapies could be devised based on expected findings from this proposal.

Body

I. Tasks outlined in the approved Statement of Work

Task 1

Target: a) To confirm the methylation status of *PDE4D4* and b) to study the relationships between transcription factors (TF) binding and promoter activity following exposure to low- or high-dose of estrogen (EB) or bisphenol A (BPA)

Time Period: Month 1-6

Method: a) Bisulfite Genome Sequencing will be applied. Genomic DNA will be first modified with sodium bisulfite using the CpGenome™ DNA Modification Kit (Intergen, USA). Bisulphite treatment of DNA specially converts unmethylated cytosine residues, but not 5-methylcytosine (5mC), to uracil by deamination. When modified DNA is subjected to nested PCR, uracil residues are amplified as thymine and unmodified

5mCs as cytosines. Using Primer3 and MethPrimer analysis, two pairs of primers were specially designed complementary only to the completely converted DNA to allow nested-PCR to amplify most of the putative CpG islands. The amplified products will be cloned using pCR 2.1 TOPO vector (Invitrogen, USA) and 8-10 clones will be sequenced to reveal the methylation status of CpG dinucleotides in the CpG island of *PDE4D4* in each genomic sample.

b) Rat prostate epithelial NBE1 cells are used to perform transient transfection with a plasmid construct of different deletions in the TF binding sites located on the promoter region. Plasmid construct is made after cloning nested PCR products with different deletions into pGL3 basic luciferase reporter vector and the estrogen-induced promoter activity will be examined by luciferase assay.

Task 2

Target: To investigate the expression of other *PDE4D* variants following neonatal exposure to EB or BPA

Time Period: Month 7-8

Method: I will identify which *PDE4D* variants expressed most in prostate after estrogen exposure by Western blot analysis or real-time PCR with specific antibody or pairs of primers complementary to each *PDE4D* variants respectively. Using the Genome Browser from the Center for Biomolecular Science and Engineering, University of California, I identified eight more *PDE4D* variants. Theoretically, only *PDE4D4* contains CpG island at its 5' flanking regions. However, I will design 8 exon-exon spanning variants-specific primer pairs (which ensure detection of RNA transcripts and not products from genomic DNA, if any) to detect all the variants expression. By using the SYBR Green Real Time PCR, I will detect expression of all 9 RNA transcripts in all tissue samples. Gene expression level among different variants will be analyzed by $\Delta\Delta C_t$ method and determined whether there is significantly changes among groups by use of ANOVA statistical analysis.

Task 3

Target: a) To investigate whether *PDE4D4* variant is responsible for determining cell proliferation and b) to determine whether *PDE4D4* can be used as a biomarker to diagnosis prostate diseases and prostate cancer.

Time Period: Month 9-18

Method: a) Rat prostate epithelial NBE1 cells will be transient transfected with full-length clone of *PDE4D4*. Intracellular cAMP in cells transfected with *PDE4D4* will be assayed. Furthermore, protein extracted from cells can be applied to the PKA assay kit. Beside cAMP-dependent PKA signaling pathway, Ras-PI3K, Ras-Raf or PKC signaling molecules will also be investigated by Western Blot analysis of the whole protein lysate. To see whether PDE4D4 affect cell proliferation, MTS assay on the cells that transfected with the full-length *PDE4D4* clone will be examined. Also, gene expression level of proliferation markers such as p42/p44, cyclin A, cyclin D1, p21^{WAF}, and p27^{CIP1} will be studied by RT-PCR.

b) Immunohistochemistry (IHC) will be performed by using a specific antibody for PDE4D4. Different prostatectomy tissue sections from rat with BPH, PIN, HG-PIN and adenocarcinoma will be undergone IHC. Positive staining of PDE4D4 is defined as continuous and dark cytoplasmic or apical granular staining pattern in the cells of the glands. Each positive case is evaluated for the percentage of the glands/cells that reacted with PDE4D4 and scored as <5%, 6-50%, 51-75% and >75%. RNA will be extracted, reverse transcribed and undergone real-time PCR with specific primers of *PDE4D4* from laser capture microdissection (LCM) samples.

Task 4

Target: To study whether the *PDE4D* transcripts expression linked to human prostate disease

Time Period: Month 19-24

Method: *PDE4D* variants expression level in human normal prostate cells (NPrEC) or prostate cancer cells (DU145, PC3 and LNCap) will be illustrated by real time PCR. Thereafter, normal cells will be transfected with of full-length clone of *PDE4D4*. I will examine the intracellular cAMP level, protein expressions of cAMP signaling molecules

and cell proliferation markers in PDE4D4-transfected NPrEC and compare the results from that of prostate cancer cells. Suppression of *PDE4D* variants by methylated oligonucleotides or siRNA in cancer cells will be performed to see whether inhibition of PDE4D activity or expression can promote tumor cell death. Cell death can be illustrated by Annexin V binding assay or caspases 3, 8 and 9 assays.

II. Work accomplished under Task 1

Part a) Investigation of the methylation status of PDE4D4 among all tissues samples

I successfully used the bisulfite genomic sequencing to identify the methylation status of *PDE4D4* in rat prostate that neonatally exposed to EB and BPA. Figure 1A indicated the gene organization of rat *PDE4D4* 5' flanking region and the schematic of CpG content in its 5' regulatory region. As shown is Figure 1B, although most CG sites were unmethylated, a methylated cluster was noted between CG sites 49 to 56. The methylation frequency at this cluster progressively increase in the oil-control prostate as




Figure1. Methylation status of *PDE4D4* and expression levels in rat prostate samples. A) Schematic of CpG content (%) in the 5' flanking region of the rat *PDE4D4* identifies a CpG island between -310 to +390bp. Vertical lines, individual CpG sites; TSS, transcriptional start site and ATG, translation start site. Region between -310to +390bp for BS-PCR was shown. B) Percentage methylation represents methylation status of *PDE4D4* assayed by bisulfite genomic sequencing. Diamond, oil-treated control; triangle, low EB; square, high EB and cross, BPA.

the animals aged, reaching by 100% methylation by day 200. In contrast, this cluster remained unmethylated throughout life in EB/BPA-treated prostates. The data suggested that EB or BPA hypomethylated *PDE4D4* promoter in rat prostate and this phenomenon persist in aging. It also associated with the incidence rate of dysplasia in rat prostate (Ho et al., 2006). In order to study the promoter activity and transcription factors binding assays *in vitro*, a cell line model including normal prostate epithelial NBE-1 cells and prostate tumor AIT cells should be included. We found that *PDE4D4* was hypomethylated (active transcribed) in tumor AIT cells while silenced in normal NBE-1 cells (Figure 2). It mirrored the data we obtained from *in vivo* studies. We further used this cell line model for experiment proposed in Task 1b and Task 3.




Figure 2. Methylation status of *PDE4D4* and expression levels in NBE-1 and AIT cells. **A)** Schematic of CpG content (%) in the 5' flanking region of the rat *PDE4D4* identifies a CpG island between -310 to +390bp. Vertical lines, individual CpG sites; TSS, transcriptional start site and ATG, translation start site. **B)** Methylation status of specific region (+190 to +380bp) of *PDE4D4* assayed by bisulfite genomic sequencing in NBE-1 and AIT cells. ○, unmethylated; ●, methylated. Boxed region, differential methylation pattern as compared between NBE-1 and AIT cells. **C)** Expression of *PDE4D4* in NBE-1 and AIT cells. mRNA level of *PDE4D4* and RPL19 assayed by semi-quantitative PCR.

Part b) Characterization of *PDE4D4* promoter activity and transcription factors binding at its promoter region

I completed to characterize the promoter activity of NBE-1 cells by both in *silico* analysis and promoter luciferase reporter assay. I first used 5' Rapid amplification of cDNA ends (5'RACE) to characterize/localize the promoter region of *PDE4D4*. Transcription Start Site (TSS) was found at -251 away from the translation start site (ATG). Next, I used the Promoter Scan Program provided by UCSC to identify the potential regulatory elements along the promoter. Estrogen response element (ERE) half site, Sp1 and cAMP response element binding protein (CREB) were computationally identified in the CpG island of *PDE4D4* (Figure 3).

Luciferase reporter plasmids containing different deletions in this 5' flanking region were constructed and transfected into NBE-1 cells to determine which region is specific for *PDE4D4* transcription. As shown in Figure 3, the promoter activity had a 30-fold increase in luciferase production as compared with a promoter-less construct. The promoter construct contained the entire CpG island (-310 to +350) therefore, suggested that this CpG island directed transcription more efficiently. Notably, construct encompassing CREB binding site (R4) showed a 20-fold luciferase production as compared to CREB-deleted construct (R2). It consistent to the data reported that *PDE4D* promoter could be induced by cAMP thru CREB binding (D'Sa C et al., 2002; Vicini E and Conti M 1997). Our findings confirmed this fact and suggested *PDE4D4* may involve in cAMP-dependent signaling pathways that may contribute to cell proliferation of prostate,




Figure 3. Characterization of 5' *PDE4D4* promoter. Upper panel, Schematic representation of the 5'-flanking region of *PDE4D4*. Bases are numbered from the translation start site. Potential regulatory elements are boxed. In lower left panel, a representation of the PDE-luc plasmids containing different 5'- and 3'-deletions of the -400 to +400bp genomic region is reported. Transient luciferase expression in NBE-1 cells transfected with the PDE-luc plasmids described in lower right panel. Luciferase activity is expressed as RLU normalized by β-gal activity.

III. Work accomplished under Task 2

Investigation of the expression of other *PDE4D* variants following neonatal exposure to EB or BPA

Based on the NCBI and UCSC nucleotides database, there are nine *PDE4D* variants in rat genome. 9 exon-exon spanning variants-specific primer pairs were used to detect all variants expression by real-time PCR. Gene expression level among different variants were analyzed by $\Delta\Delta C_t$ method and determined whether there were significantly changes among groups by use of ANOVA statistical analysis. Results from




Figure 4. *PDE4D4* mRNA transcript levels as determined by real-time PCR. $\Delta\Delta C_t$ method was used to quantitate the mRNA transcript level. *PDE4D4* expression level was normalized by a house-keeping gene, *RPL19*. Relative expression ratio of *PDE4D4/RPL19* of day 10 oil samples was set as 1.0. Results represented the mean \pm SD of three independent sets of experiment. All EB/BPA groups at day 90, 200, and 200/testosterone+estradiol were significantly different from the respective groups at day 10. *, $P < 0.05$; **, $P < 0.01$ versus oil controls at the same time intervals; +, $P < 0.05$ versus day 200 oil controls; ++, $P < 0.05$ versus day 10 oil controls.

real-time PCR showed that there was no difference in gene expressions of eight variants (*PDE4D1-3*, *5-9*) among the oil-control and estrogens-treated groups. Only up-regulation of *PDE4D4* occurred in EB/BPA-treated groups (Figure 4). It matched our preliminary results from *in silico* database analysis among nine variants, suggesting that only *PDE4D4* contains CpG island at its 5' flanking regions and its gene regulation can be regulated by DNA methylation. As shown in Figure 4, *PDE4D4* down-regulated in oil control samples with aging. In contrast, *PDE4D4* expression levels of prostate neonatally exposed to EB and BPA were markedly higher at Day 90 than oil control and remained elevated with aging. It concluded that *PDE4D4* is normally silenced with aging but remained active transcribed in the neonatally estrogenized prostates. Furthermore, I found that the elevated expression of *PDE4D4* in EB/BPA-treated prostates occurred before a second

hit of exposure to hormones (testosterone+estradiol). It suggested that *PDE4D4* may have potential as a marker for early prostate cancer risk assessment.

IV. Work accomplished under Task 3

Part a) Investigation on the role of *PDE4D4* in cell proliferation.

Full-length transcript of *PDE4D4* was constructed in a pcDNA3.1 plasmid and transfected into normal and tumor cells followed by cell proliferation assay and cAMP assay. In Figure 5A, normal NBE-1 cells, having lower expression level of *PDE4D4*, increased not only *PDE4D4* mRNA level but also cell viability (>60%) after transfection. Transfected AIT cells were also found to increase cell proliferation (~30%) but the increase was less significant as compared to normal cells. *PDE4D4* is known to hydrolyze intracellular cAMP. Therefore, intracellular cAMP level after transfection with *PDE4D4* construct could reflect *PDE4D4* activity in cells. Cells transfected with *PDE4D4* construct showed decrease in cAMP level suggesting up-regulation of *PDE4D4* in cells resulted in greater amount of cAMP being hydrolysed. Although more functional assays such as cell death, PKA activity should be performed to study how *PDE4D4* regulates cell growth and involves in prostate carcinogenesis, present data indicated that *PDE4D4* could alter the cell proliferation in normal NBE-1 and tumor AIT cells. We further decided to investigate the underlying




Figure 5. Cell viability and cellular cAMP level in NBE and AIT cells after transfection with full-length transcript of *PDE4D4*. Panel A. Cell viability assayed by MTS assay, Open bar, pcDNA3.1 plasmid only; solid bar, plasmid construct containing full-length transcript (2.4kb) of *PDE4D4*. Panel B, cAMP level assayed by cAMP HTS Immunoassay (Upstate) according the manufacturer's protocol. The chemiluminescence intensity was measured by a luminometer (Wallac 1420, Perkin Elmer) and represented as the Relative Light Units (RLU).

mechanism of how PDE4D4 alters prostate cancer growth by using the human prostate cancer cells. It is more relevant to human studies and useful for designing new treatment for human prostate cancer.

Part b) Determination of the possibility of using *PDE4D4* a diagnostic marker for prostate diseases and prostate cancer

Immunohistochemistry (IHC) was performed using a specific antibody against PDE4D4. This antibody was custom-made by FabGennix International Inc and could be specific for both rat and human homologues. However, I gained the troubles in optimizing the IHC working conditions and performing laser capture microdissection (LCM). Therefore, I finished this task partially by comparing PDE4D4 expression by IHC between normal and cancer samples. Using this antibody I have established that normal epithelial cells, both luminal and basal, expressed low levels of PDE4D4, but expression is dramatically increased in pre-cancerous lesions (Figure 6). Using the Noble rat model established in our laboratory (T+E2 induced PCa model (Leav et al., 1988), our data showed that PDE4D4 is strongly expressed in the nucleus of hyperplastic epithelium of prostate gland and highly expressed after T+E2 treatment (Figure 6B). This suggests that *PDE4D4* may play a role in early neoplastic transformation of prostate epithelial cells.





Figure 6 *PDE4D4* highly expressed in T+E2-induced atypical hyperplasia in Noble rat prostate. Assayed by IHC, cytosstatic staining of PDE4D4 was observed with less expression in oil-treated prostate (A). However, *PDE4D4* highly expressed in nucleus of hyperplastic epithelium of prostate gland of rat exposed to adult T+E2 treatment (B).

V. Work accomplished under Task 4

I have already established PDE4D4 plays an important role in rat prostate carcinogenesis and its gene expression was epigenetically modified by early exposure to estrogen and BPA (tasks 1-3). Herein, we aimed at finding the target pathways regulated by PDE4D4 in human prostate. We first a) investigated the methylation status and gene expression of human *PDE4D4* homolog in normal prostatic epithelial NPrEC cells and prostatic carcinoma DU145, PC3, LNCaP cells. Second, b) we knocked down *PDE4D4* in cancer cells by siRNA and determined whether knockdown of *PDE4D4* affects the cell proliferation, apoptosis, PKA and PKC activities.

First, I analyzed the human homologue of rat *PDE4D4* (AF031373) using NCBI database. Human *PDE4D4* homologue (L20969) was found to be



highly similar to the rat one with average of 92% homology in their mRNA sequence. Moreover, their 5' regulatory regions including 1kb upstream from translational start site (ATG) and exon 1, showed 85% homology to each other. Figure 7 showed the gene organization of *PDE4D4* at its 5' regulatory region. Two CpG islands (CGIs) were located at the 5' regulatory region of human *PDE4D4*. First CGI (CGI 1) of 179 base pairs (bp) (-405 to -225) located at upstream of the transcription start site (TSS) and another CGI (CGI 2) of 538 bp (-111 to +427) encompassed the 5' UTR exon and exon 1 (Figure 7A). There were total of 75 CG dinucleotides allocated in these CGIs. Several putative transcription factor binding sites such as Sp1, AP2, CELF, H4TF2, CIIS1 and C/EBP were found in these CGIs (Figure 7B). Specific methylation clusters were first identified by comparing the methylation status of the 5' regulatory region of *PDE4D4* among normal prostate and prostate cancer cell lines. Results indicated that a specific CpG rich region with 35 CG dinucleotides from +190 to +450 showed differential methylation pattern between normal NPrEC cells and prostate cancer PC3 cells (data not shown). Specifically, CG sites 41-42, 60-65 and 70-73 were hypomethylated in prostate cancer cells. Methylation specific PCR was next employed to determine the methylation status of this CpG cluster of DNA samples from human non-neoplastic prostate epithelial and PCa cells.

I demonstrated that *PDE4D4* was demethylated and over-expressed in prostate cancer cell lines *in vitro*. As shown in Figure 8A, *PDE4D4* was up-regulated in DU145, PC3 and LNCaP cells but almost silenced in normal epithelial NPrEC cells. Relative expression level of *PDE4D4* was normalized by β -actin. Moreover, *PDE4D4* promoter was hypomethylated in all tumor cells but methylated in normal NPrEC cells. Results from MSPCR and real-time PCR illustrated that *PDE4D4* promoter could be demethylated after treatment with 5-aza-deoxycytidine (5-AZA-dC) for 8 days in NPrEC cells. *PDE4D4* was also reactivated and increased in 4-fold expression in NPrEC cells (Figure 8B-C). DU145 and PC3 cells also showed 6-fold and 2-fold increase in the expression level after 5-AZA-dC treatment. LNCaP had the highest expression level among the prostate cancer cell lines and it might explain there was no further increase in gene expression after demethylation treatment.




Figure 8. Methylation status of *PDE4D4* and expression levels in human normal NPrEC and PCa cells. (A) Gene expression of *PDE4D4* assayed by semi-quantitative PCR and real-time PCR among normal NPrEC, and DU145, PC3 and LNCaP PCa cells. (B and C) *PDE4D4* promoter methylation status and gene expression were analyzed by MSPCR (B) and real-time PCR (C) respectively after exposing to demthylation agent, 5-AZA-deoxycytidine for 8 days.

*b) Down-regulation of *PDE4D4* inhibited cell proliferation and enhanced apoptosis.*

Over-expression of *PDE4D4* was found to be associated with growth of prostate cancer cells. I performed gene knockdown by using siRNA oligos against *PDE4D4* (Dharmacon, Lafayette, CO). Negative control siRNA (siCONTROL pool), and transfection siRNA control (siTOX) were included to ensure the specificity and transfection efficiency of siRNA.

All cells showed down-regulation of *PDE4D4* after siRNA transfection (Figure 9A). Since *PDE4D4* was silenced in NPrEC, the effect of siRNA knockdown on normal cells was not as obvious as that on cancer cells. Except DU145 cells, PC3 and LNCaP cells transfected with siRNA oligos against *PDE4D4* decreased their cell viability (Figure 9B) and DNA synthesis (Figure 9C) with the increase in the caspase-3 activity (Figure 9D). These results suggest that *PDE4D4* plays an important role in cell proliferation/cell death in prostate cancer cells. On other aspects, *PDE4D4* functions degrading

intracellular cAMP. In our studies, inhibition of *PDE4D4* was found to increase the intracellular cAMP level (Figure 9E) and lead to PKA activation within 24hr (Figure 9F) in PC3 and LNCaP cells. It further suggested that *PDE4D4* regulates cell growth is mediated by PKA-dependent pathways. Increased cAMP can both inhibit and promote apoptosis or may disturb the cell cycle.




Figure 9. Effects of siRNA *PDE4D4* knockdown on (A) *PDE4D4* gene expression, (B) cell proliferation, (C) DNA synthesis, (D) Caspase 3 activity, (E) intracellular cAMP level and (F) PKA activity.

Key research accomplishments

- By completing task 1 and 2, I successfully showed that *PDE4D4* is regulated by DNA methylation and its expression is associated with the incidence of prostate PIN in rat prostate.
- We published the results from task 1 and 2 in *Cancer Research* in June 2006, *Reproductive Toxicology* in October 2006 and January 2007, *Basic and Pharmacology Reviews* in February 2007, *Reviews in Endocrine and Metabolic Disorder* in June 2007 and *Fertility and Sterility* in February 2008. We were the first group who reported neonatal estrogen exposure could reprogram the rat prostate via DNA methylation.
- Specific antibody against PDE4D4 was custom-made and it was ready be used for IHC studies for normal and tumor sections (task 3). PDE4D4 was found to be highly expressed in tumor sections. In the future, I can pursue this study including the rat and human samples by using this antibody to find out whether PDE4D4 can be used a biomarker for prostate disease/cancer.
- I found out PDE4D4 plays an important role in prostate carcinogenesis (task 3 and 4) by modifying PKA activity and its downstream apoptotic pathways. Results will help to understand the development of prostate cancer and tailor the treatment for prostate disease/cancer.
- Results from task 3 and 4 were presented in IMPaCT meeting 2007, Department of Defense Prostate Cancer Research Program and I have prepared to publish this findings.

Reportable outcomes

- **Published papers:**
 1. Prins G.S., **Tang, W.Y.**, Belmonte, J. and Ho, S.M. (2008) Developmental exposure to bisphenol A increases prostate cancer susceptibility in adult rats: epigenetic mode of action is implicated. *Fertility and Sterility*. Feb;89 (2 Suppl):e41.
 2. Prins G.S., **Tang, W.Y.**, Belmonte, J. and Ho, S.M. (2007) Perinatal Exposure to Estradiol and Bisphenol A Alters the Prostate Epigenome and Increases

Susceptibility to Carcinogenesis. Basic & Clinical Pharmacology & Toxicology. Feb;102(2):134-8.

3. **Tang, W.Y.** and Ho, S (2007) Epigenetic Reprogramming and Imprinting in origins of disease, Reviews in Endocrine and Metabolic Disorder. Jun;8(2):173-82.
4. Ho, S., **Tang, W.Y.** (2007) Techniques used in studies of epigenome dysregulation due to aberrant DNA methylation: an emphasis on fetal-based adult diseases, Reproductive Toxicology. Apr-May; 23(3):267-282
5. Prins, G.S., Birch L., **Tang, W.Y.**, Ho, S. (2007) Developmental Estrogen Exposures Predispose to Prostate Carcinogenesis with Aging, Reproductive Toxicology. Apr-May; 23(3):374-382.
6. Ho, S.*, **Tang, W.Y.***, Belmonte, J. and Prins, G.S. (2006) Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4, Cancer Research. 2006 June 66(11):5624-5632 * **co-authorship**

- **Abstract for national meetings:**

1. **Tang W.Y.**, Barker J, Prins G and Ho S.M. (2008) Bisphenol A demethylated rat PDE4D4 promoter via alteration of expression levels of demethylases, 99th Annual Meeting of American Association for Cancer Research 2008.
2. **Tang W.Y.**, Barker J, Prins G and Ho S.M. (2008) Bisphenol A demethylated rat PDE4D4 promoter via alteration of expression levels of demethylases, 99th Annual Meeting of American Association for Cancer Research 2008.
3. **Tang W.Y.** (2007) Investigation of a putative estrogen-imprinting gene, Phosphodiesterase type IV variant 4 (PDE4D4) in determining prostate cancer risk, IMPaCT meeting, Department of Defense Prostate Cancer Research Program

4. **Tang, W.Y.**, Ho, S. (2007) Bisphenol A demethylates *PDE4D4* promoter and reactivates gene transcription in a rat epithelial cell line (NbE-1) via up-regulation of DNA demethylases, Endocrine Disruptor Meeting, NIEHS/EPA.
5. **Tang, W.Y.** (2006) Early developmental exposures to estrogen/bisphenol A impact a specific prostate epigenome, Environmental Mutagen Society 37th Annual Meeting.
6. **Tang, W.Y.**, Prins, G.S., Belmonte, J. and Ho, S. (2006) Neonatal exposure to estradiol or bisphenol A epigenetically alters phosphodiesterase type IV variant 4 (*PDE4D4*) and increases susceptibility to adult-induced prostate carcinogenesis, 97th Annual Meeting of American Association for Cancer Research.
7. **Tang, W.Y.**, Prins, G.S., Belmonte, J. and Ho, S. (2005) Neonatal estradiol or bisphenol A (BPA) exposure increases susceptibility to adult-induced prostate carcinogenesis: association with epigenetic changes in gene methylation patterns and phosphodiesterase type 4 expression, Environmental Epigenomics Conference 2005.
8. **Tang, W.Y.**, Prins, G.S., Belmonte, J. and Ho, S. (2005) Discovery of phosphodiesterase type 4 variant (*PDE4D4*) as a gene susceptible to neonatal imprinting by estradiol or bisphenol A in the rat prostate, Endocrine descriptor Workshop, Endocrine Society Annual Meeting 2005.

- **Invited presentation at national meetings:**

1. **Tang, W.Y.** (2006) Early developmental exposures to estrogen/bisphenol A impact a specific prostate epigenome, platform session - environmental and physiological impact of the epigenome, Environmental Mutagen Society 37th Annual Meeting, Vancouver, British Columbia, Canada.

Conclusions

I have made significant progress and obtained important findings during the funded period of this training award. In the first year, I successfully found that *PDE4D4* is reprogrammed by early exposure to estrogen and bisphenol A and its expression associated with incidence of prostate cancer. This data not only earned me six papers but also made me get into several national meetings. Moreover, our findings have already raised public concern about the effect of estrogen or environmental estrogens such as BPA in the prostate disease and cancer. In the second year, I completed the work proposed in Task 3 and 4. First, I optimized the IHC assay to use *PDE4D4* expression/methylation pattern as a biomarker for prostate cancer. Second, I found out *PDE4D4* regulate cAMP signaling and its downstream apoptotic pathways that involved in prostate development. By all respect, this postdoctoral training experience helps me to equip myself with basic and clinical aspects of cancer research and to become an independent and highly competitive researcher on the prostate cancer. I believe these findings will yield new approach that will be relevant to prostate cancer prevention and therapy.

References

D'Sa, C., Tolbert, L.M., Conti, M. and Duman, R.S. (2002) Regulation of cAMP-specific phosphodiesterase type 4B and 4D (PDE4) splice variants by cAMP signaling in primary cortical neurons, *J Neurochem.* 2003 May 81 (4):745-757.

Ho, S., Tang, W.Y., Belmonte, J. and Prins, G.S. (2006) Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4, *Cancer Research.* 2006 June 66(11):5624-5632.

Ho, S., Tang, W.Y. (2007) Techniques used in studies of epigenome dysregulation due to aberrant DNA methylation: an emphasis on fetal-based adult diseases, *Reproductive Toxicology.* 2007 Jan 8; [Epub ahead of print]

Vicini, E. and Conti, M. (1997) Characterization of an intronic promoter of a cyclic adenosine 3', 5'-monophosphate (cAMP)-specific phosphodiesterase gene that confers hormone and cAMP inducibility. *Mol Endocrinol.* 1997 June 11(7):839-850.

Leav, I., Ho, S., Ofner, P., Merk, F., Kwan, P. and Damassa, D. (1988) Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. J Nat'l Canc Inst 1988 (80):1045-1053

Developmental exposure to bisphenol A increases prostate cancer susceptibility in adult rats: epigenetic mode of action is implicated

Gail S. Prins,^a Wan-Yee Tang,^b Jessica Belmonte,^a and Shuk-Mei Ho^b

^a Department of Urology, University of Illinois at Chicago, Chicago, Illinois; and ^b Department of Environmental Health, University of Cincinnati, Cincinnati, Ohio

Similar to the testes, male accessory sex glands are also vulnerable to environmental endocrine disruptors with adverse effects in adulthood. The developing prostate gland is particularly sensitive to estrogens, and high-dose exposures during a critical developmental window results in intraepithelial prostatic neoplasia (PIN) in adult rodent models. Bisphenol A (BPA), a ubiquitous environmental contaminant leached from plastics and epoxy resins, has estrogenic activity. Although neonatal exposure to environmentally relevant doses of BPA produced no prostate pathology in the adult rat, we asked whether it would sensitize the adult prostate to estrogenic exposures. Relative estrogen levels rise in the aging male and adult estrogen exposures can be carcinogenic to the prostate gland. To test this possibility, newborn rats were exposed to a low dose of BPA (10 µg/kg body weight) or to a low dose (0.1 µg/kg body weight) or high dose 2.5 mg/kg body weight) of estradiol (E) on days 1, 3, and 5 of life. In adulthood (day 90), the animals were given prolonged E exposure with normal levels of testosterone (T) via T + E implants or empty capsules for 16 weeks. Prostates were examined histologically at 7 months. Rats treated neonatally to high-dose E with or without adult T + E had a high PIN incidence and score. Although low-dose neonatal E exposure alone mildly increased the PIN incidence/score, neonatal BPA alone had no pathologic alteration in the aged prostate. However, rats exposed neonatally to BPA followed by T + E in adulthood showed a significantly higher PIN incidence and score compared with controls, rats exposed only to BPA neonatally, or those given only T + E in adulthood (1). The PIN incidence and lesions in rats given BPA with adult T + E appeared similar to rats treated neonatally with high-dose E. Thus, the present

findings suggest that an environmentally relevant dose of BPA may increase the susceptibility of the prostate gland to carcinogenesis following additional adult exposures.

To determine whether neonatal exposures to estradiol or BPA may be mediated through epigenetic mechanisms, we screened these prostate tissues for global DNA methylation changes. Over 30 gene candidates were cloned that showed consistent methylation changes as a result of neonatal E or BPA exposures. Phosphodiesterase type 4, variant 4 (PDE4D4), the enzyme involved in degrading cAMP and regulating the cellular levels of this key cell-signaling molecule, was identified as a novel imprinted gene (1). In normal prostates, the 5' CpG island of PDE4D4 is gradually hypermethylated, and the gene is silenced with aging. Following neonatal BPA or estradiol exposure, PDE4D4 showed early and persistent hypomethylation of its 5' CpG island resulting in elevated PDE4D4 gene expression in the adult prostates. HPCAL, a gene that drives cAMP production, exhibited a specific methylation and expression alteration in neonatal BPA animals with aging. Together, these findings indicate that the prostate epigenome is permanently altered by early exposures to BPA, resulting in changes in gene expression. We hypothesize that this epigenetic alteration may be a molecular underpinning that leads to heightened predisposition to prostate carcinogenesis with aging.

REFERENCE

1. Ho S-M, Tang W-Y, Belmonte J, Prins GS. Developmental exposure to estradiol or bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase 4. *Cancer Res* 2006;66: 5624–32.

Supported by NIEHS- ES12281.

Reprint requests: Gail S. Prins, Department of Urology, University of Illinois at Chicago, Chicago, Illinois 60614.

**1 Developmental exposure to bisphenol A increases
prostate cancer susceptibility in adult rats:
epigenetic mode of action is implicated**

G. S. Prins, W.-Y. Tang, J. Belmonte, and S.-M. Ho
Chicago, Illinois; and Cincinnati, Ohio

UNCORRECTED PROOF

MiniReview

Perinatal Exposure to Oestradiol and Bisphenol A Alters the Prostate Epigenome and Increases Susceptibility to Carcinogenesis

Gail S. Prins¹, Wan-Yee Tang², Jessica Belmonte¹ and Shuk-Mei Ho²

¹Department of Urology, University of Illinois at Chicago, Chicago, IL, USA, and ²Department of Environmental Health, University of Cincinnati, Cincinnati, OH, USA

(Received May 6, 2007; Accepted August 21, 2007)

Abstract: An important and controversial health concern is whether low-dose exposures to hormonally active environmental oestrogens such as bisphenol A can promote human diseases including prostate cancer. Our studies in rats have shown that pharmacological doses of oestradiol administered during the critical window of prostate development result in marked prostate pathology in adulthood that progress to neoplastic lesions with ageing. Our recent studies have also demonstrated that transient developmental exposure of rats to low, environmentally relevant doses of bisphenol A or oestradiol increases prostate gland susceptibility to adult-onset precancerous lesions and hormonal carcinogenesis. These findings indicate that a wide range of oestrogenic exposures during development can predispose to prostatic neoplasia that suggests a potential developmental basis for this adult disease. To identify a molecular basis for oestrogen imprinting, we screened for DNA methylation changes over time in the exposed prostate glands. We found permanent alterations in DNA methylation patterns of multiple cell signalling genes suggesting an epigenetic mechanism of action. For phosphodiesterase type 4 variant 4 (PDE4D4), an enzyme responsible for intracellular cyclic adenosine monophosphate breakdown, a specific methylation cluster was identified in the 5'-flanking CpG island that was gradually hypermethylated with ageing in normal prostates resulting in loss of gene expression. However, in prostates exposed to neonatal oestradiol or bisphenol A, this region became hypomethylated with ageing resulting in persistent and elevated PDE4D4 expression. In total, these findings indicate that low-dose exposures to ubiquitous environmental oestrogens impact the prostate epigenome during development and in so doing, promote prostate disease with ageing.

Prostate cancer is the most common solid cancer in males and is the second leading cause of cancer deaths in American men. The most recent cancer statistics for 2007 indicate that prostate cancer incidence continues to rise in the USA [1]. The reason for this high propensity to develop cancer within the prostate is not well understood and is an area of intense investigation. It has been suggested that the unique embryological origin of the prostate gland – from the endodermal urogenital sinus, as opposed to the mesodermal Wolffian duct structures that form the other male accessory sex glands – may play a fundamental role in the high rates of abnormal growth as men age. During embryonic development, the prostate gland is highly dependent on steroid hormones and it is notable that imbalances in steroid levels during early life can result in aberrant prostate growth [2,3]. The present review will highlight data from several studies that support a hypothesis that early life exposures to oestrogenic compounds, including the environmental oestrogen bisphenol A, may predispose the prostate gland towards abnormal growth and carcinogenesis later in life.

Influence of oestrogen exposures during prostate development

In human beings, prostate development initiates towards the end of the first trimester in response to rising foetal androgen levels and glandular morphogenesis is largely completed during the second trimester as circulating androgen levels peak. During the third trimester of *in utero* development, foetal androgen production declines while maternal oestrogen levels rise resulting in an increased oestrogen/testosterone (E/T) ratio. This increased E/T ratio has been shown to directly stimulate extensive epithelial squamous metaplasia that regresses after birth as oestrogen levels rapidly decline [4]. Although the natural role for oestrogens during prostatic development is unclear, it has been proposed that excessive oestrogen exposures during development may contribute to the high incidence of prostate disease currently observed in the ageing male population [5,6]. The sons of women who took diethylstilboestrol during pregnancy were shown to have persistent abnormalities in prostate structure shortly after birth [7]. Furthermore, indicators of pregnancy oestrogen levels such as length of gestation, pre-eclampsia and jaundice have shown a high correlation between elevated oestrogen levels and prostate cancer risk [8,9]. Interestingly, African-American mothers have elevated

Author for correspondence: Gail S. Prins, Department of Urology, MC 955, University of Illinois at Chicago, 820 S Wood St., Chicago, IL 606012, USA (fax +1 312 996 1291, e-mail gprins@uic.edu).

levels of maternal oestrogens and androgens during early gestation as compared to their Caucasian counterparts and it has been postulated that these elevated steroids may contribute to the 2-fold increased risk of prostatic carcinoma in African-American men [10,11].

Unlike human beings, the rodent prostate gland is rudimentary at birth and undergoes morphogenesis and differentiation during the first 2 weeks of life [12]. Thus, the neonatal rodent prostate gland is a useful model for foetal prostate development in human beings. Our laboratory and others have shown that brief perinatal exposure of rats to high doses of natural or synthetic oestrogens alters the prostate gland in a permanent manner resulting in reduced growth, differentiation defects, aberrant gene expression and perturbations in cell signalling mechanisms [13,14]. This process, referred to as developmental oestrogenization or oestrogen imprinting, leads to prostatic lesions as the animals age including chronic immune cell infiltration, epithelial hyperplasia and prostatic intraepithelial neoplasia, the precursor lesion of prostate cancer [15]. We thus propose that excessive oestrogen exposure during the developmental critical period may be a predisposing factor for prostatic disease later in life. It is noteworthy that a comparable rodent model for female perinatal diethylstilboestrol exposures accurately predicted the uterine and vaginal lesions found in daughters of diethylstilboestrol-exposed pregnant women [16] who provide credibility for the rodent model system in assessing similar pathologies in males. Whether similar effects may be induced by low-dose oestrogenic exposures has until recently remained unclear. This is currently a critical issue because hormonally active xenoestrogens are ubiquitous in the environment and have potential for adverse health outcomes in both human beings and animals [17].

Bisphenol A

Bisphenol A, a synthetic polymer, is a prevalent environmental oestrogen that was initially tested for efficacy as a synthetic oestrogen in 1936 [18]. Shortly thereafter, Dodds synthesized diethylstilboestrol that possessed much greater oestrogenic potency and the use of bisphenol A as a synthetic oestrogen was set aside. Today, bisphenol A is used as a cross-linking chemical in the manufacture of polycarbonate plastics, epoxy resins and several other common household products, and is one of the highest volume chemicals produced worldwide ($>6 \times 10^9$ lbs/year). Unfortunately, bisphenol A monomers leach from plastics and epoxy resins when heated or after repeated washings and bisphenol A is now found at significant levels in environments throughout the world [19,20]. As a result, unconjugated bisphenol A is found in the serum of 95% of human beings at levels ranging from 0.2–20 ng/ml [21,22]. Importantly, bisphenol A is found in 3–4-fold higher concentrations in amniotic fluid as compared to maternal serum [23] and placental and foetal tissue concentrations can exceed 100 ng/g with the highest levels found in foetal males [24,25]. While bisphenol A binds to classical oestrogen receptors with reduced affinity relative

to 17 β -oestradiol [26], it possesses equivalent activational capacity of the non-classical membrane oestrogen receptor [27]. Thus, there is potential for this compound as a toxicant for developing human tissues, particularly the oestrogen-sensitive reproductive end organs. In this regard, foetal exposures to environmentally relevant doses of bisphenol A in animal studies have been shown to advance puberty [28], increase prostatic growth [29], alter pubertal mammary gland development [30] and permanently change the morphology and functionality of female reproductive tract organs in mice [31].

Developmental bisphenol A exposure increases prostate gland susceptibility to hormonal carcinogenesis

It has been shown that that developmental exposure to low doses of oestrogen augments the responsiveness of female reproductive end-organs to elevated oestrogens at puberty and beyond. In this context, we asked whether low-dose oestrogens during development might shift the sensitivity of the prostate gland to adult oestrogenic exposures. This is highly relevant because prolonged adult exposure to oestradiol is capable of driving prostatic carcinogenesis in the Noble rat model [32] and oestrogens are associated with an increased prostate cancer risk in men [33]. Furthermore, the serum E/T ratio increases in ageing men, in part, due to increased body fat and aromatase activity [34], and this coincides with the increased propensity of ageing men to develop prostate cancer.

We chose to work with Sprague–Dawley rats as an animal model because this strain is less sensitive than the Noble rat to adult oestrogen-induced carcinogenesis [35]. A ‘two-hit’ model for carcinogenesis was established. The ‘first hit’ consisted of a brief exposure to a low dose of oestradiol (0.1 μ g/kg body weight/day) or an environmentally relevant dose of bisphenol A (10 μ g/kg body weight/day) on neonatal days 1, 3 and 5 when the prostate undergoes branching morphogenesis and differentiation. This bisphenol A dosage was chosen because it provides serum bisphenol A concentrations that are similar to those measured in the blood of human foetuses at term (i.e. 0.2–9.2 ng unconjugated bisphenol A/ml) [25,36]. To avoid intake variability between pups associated with lactation, precise doses of oestradiol and bisphenol A were delivered via subcutaneous injections using oil as the vehicle that provides slow release of the compound over several hours. While this non-oral route avoids first-pass liver metabolism, it is noteworthy that neonatal rat pups have limited metabolic capacity for bisphenol A [37]. When the neonatal-exposed rats in our study reached adulthood, they were given either oil (control group) or a ‘second hit’ 4-month exposure to ~ 75 pg/ml oestradiol that is by itself able to drive carcinogenesis in 100% of Noble rats but only 33% of Sprague–Dawley rats [32,35]. Our goal was to determine if neonatal low-dose estradiol or bisphenol A exposure could increase the susceptibility of the prostate to adult-induced carcinogenesis.

Individual prostate lobes were histologically assessed at 7 months of age for proliferation, apoptosis and pathologic lesions including prostatic intraepithelial neoplasia or

PIN, the precursor lesion for human prostate cancer [38,39]. While neonatal high-dose oestradiol exposure alone and to a lesser degree, early low-dose oestradiol exposure increased the incidence of PIN lesions, early exposure to bisphenol A alone had no effect on prostate pathology, proliferation or cell death as the animals aged. However, when rats were exposed to an environmentally relevant dose of bisphenol A (10 µg/kg body weight/day) early in life followed by adult oestradiol exposure for 4 months, the incidence of PIN lesions significantly increased to 100% as compared to 40% in control Sprague–Dawley rats that received oil neonatally and oestradiol in adulthood. Importantly, the lesions were mostly classified as high-grade PIN and the severity and incidence was similar to that found in rats exposed neonatally to pharmacological levels of oestradiol. As compared to controls, the PIN lesions in rats exposed to neonatal bisphenol A and adult oestradiol also exhibited significantly higher rates of epithelial cell proliferation and apoptosis that is considered key evidence that these are relevant precancerous lesions with similarity to human high-grade PIN, the precursor lesion to prostate cancer [40]. Taken together, these published findings suggest that early oestradiol exposures predispose the prostate to PIN lesions with ageing and that an environmentally relevant dose of bisphenol A is capable of increasing susceptibility of the prostate gland to carcinogenesis brought on by elevated oestradiol in the ageing male animals.

Developmental oestradiol and bisphenol A exposures alter the prostatic epigenome

DNA methylation is one of three epigenetic systems that regulate mitotically heritable changes in gene expression that are not coded in the DNA sequence. DNA methylation occurs at the C⁵ position of cytosine in cytosine-guanine (CG) dinucleotides (CpG). In mammalian cells, CpGs are often found as aggregates, or *CpG islands* (CGI), in the promoter or 5'-coding region of genes and methylation status at these sites can regulate gene transcription [41]. Simplistically, hypermethylation of CGIs will cause stable heritable transcriptional silencing while hypomethylation permits transcription. Once established in somatic cells, CpG methylation patterns within the genome remain relatively stable and are heritable through cell divisions except during early embryonic development and tumourigenesis when drastic alterations in DNA methylation occur. Alterations in DNA methylation have been shown to contribute to both cancer initiation and promotion [42,43] including prostate cancers [44,45]. Furthermore, there is some evidence that early hormonal exposures can alter DNA methylation in reproductive tract tissues [46–48].

In this context, we asked whether the molecular underpinning whereby brief exposure to oestradiol or bisphenol A during development could permanently affect prostate carcinogenic susceptibility might be a result of epigenomic alterations in DNA methylation of specific genes. To identify potential methylation-regulated genes in prostates

exposed neonatally to oestradiol and bisphenol A, we used methylation-sensitive restriction fingerprinting that screens for novel CpG-rich sequences whose methylation status undergoes alterations following treatments [47,49]. This approach allowed us to monitor epigenetic alterations over time as well as with different hormonal treatments. Importantly, this global screening method does not require the identities of the genes whose methylation status changes thus in addition to the suspected genes involved, one can identify novel genes that may play a role in developmental oestrogenization of the prostate gland. Our preliminary screens identified over 50 DNA candidate sequences with repeatable methylation alterations across multiple samples and prostate lobes [38].

The candidate sequences were subsequently cloned and 28 unique candidate clones were identified (complete table in Ho et al. [38]) Sixteen candidates showed no homology with known rat genes while the remaining eight genes were identified as PLCβ3, NVP3, CARK, GPCR14, PDE4D4, PDGFRα, CAR-X1 and SLC12A2. Several of these genes are involved in signal transduction pathways including Na-K-Cl cotransport (SLC12A2), MAPK/ERK pathway (PDGFRα), phosphokinase C pathway (PLCβ3), cAMP pathways (PDE4D4 and HPCAL1) and neural/cardiac development (CARX1, CARK). Because these signalling pathways play a role in cell cycle and/or apoptosis pathways within cells and tissues, it is intriguing to speculate that developmental oestrogenic exposures may perturb proliferation/apoptosis equilibrium in the prostate gland through an epigenetic gene (de)regulation mechanism. These findings may also provide clues to previously unrecognized participants in prostate carcinogenesis.

We observed overlapping as well as unique methylation alterations for high-dose oestrogen, low-dose oestrogen and bisphenol A. This suggests two important points. First, common prostatic genes may be epigenetically modified by different oestrogenic compounds and doses suggesting common pathways that predispose to prostate carcinogenesis with ageing. These identified candidates could be applicable not only to developmental oestrogenic exposures but may provide clues to new participants in prostate cancer. Second, unique candidate genes specific to an oestrogenic compound or dose may allow us to formulate specific epigenomic signatures that could serve as useful molecular markers for specific developmental exposures.

Prostatic PDE4D4 expression is methylation-regulated by oestradiol and bisphenol A exposure

We have initiated studies to determine whether altered DNA methylation due to neonatal oestrogenic exposures results in altered gene expression. PDE4D4 was chosen for further characterization because the differentially methylated DNA fragment identified by methylation sensitive restriction fingerprinting corresponded to the 5'-flanking region, the PDE4D4 fragment was consistently hypomethylated by all neonatal oestrogenic exposures and the changes were

identified as early as day 10 of life. PDE4D4 is an intracellular enzyme that specifically degrades cAMP [50]. Downstream cAMP signalling pathways include PKA activation and phosphorylation of cAMP-responsive element binding protein that regulates transcription of genes involved in cell growth and differentiation [51]. Thus, persistent activation of cAMP pathways may contribute to neoplastic transformation. In this regard, recent studies have shown a tight association between PDE4D4 expression and cancer cell proliferation, including gliomas [52], osteosarcomas [53] and chronic lymphocytic leukaemia [54].

As previously detailed [38], PDE4D4 contains a 700-bp CpG island with 60 CpG sites in the 5'-regulatory region that encompasses the gene transcription and translation start sites. Methylation site mapping was performed by bisulfite genomic sequencing and a cluster was noted between 49–56 CG sites that became increasingly methylated in the normal control rat prostates with ageing, reaching 100% methylation by 7 months of age. In contrast, these 49–56 CG sites remained hypomethylated in ageing prostates exposed neonatally to high- or low-dose oestrogen or BPA. Importantly, these differential methylation patterns were inversely correlated to PDE4D4 gene expression as determined by real-time RT-PCR. Thus, while normal aged rats contained low prostatic expression of PDE4D4, this gene was expressed at high levels in rats exposed to oestradiol or bisphenol A during development. Importantly, this differential gene expression pattern was observed prior to adult exposure to oestradiol that indicates that molecular changes had occurred in the prostates of neonatal bisphenol A-exposed rats that may have contributed to its increased predisposition to hormonal carcinogenesis as an adult. This later observation suggests that PDE4D4 methylation and/or gene expression may be a useful early marker of adult-onset disease initiated by developmental oestrogen exposures in the prostate gland.

Conclusions

In summary, we have shown that a range of oestrogenic exposures during the early period of prostate development, from low-dose oestradiol and environmentally relevant doses of bisphenol A to pharmacological doses of oestrogens, results in an increased susceptibility to pre-neoplastic lesions of the prostate gland with ageing. Based on these findings, we propose that oestrogenic exposures during critical developmental periods may provide a foetal basis for adult prostatic diseases. Furthermore, we have obtained evidence that early exposures to oestradiol or bisphenol A can alter DNA methylation in a gene-specific manner that implicates epigenetic alterations as an underlying mechanism of action in developmental oestrogenization. Because several of these genes are interconnected through similar signalling pathways, we predict that oestrogen-induced alterations may produce complex changes within the prostatic cell that ultimately predispose the gland to carcinogenesis as the animal ages.

Acknowledgement

This study was supported by the NIH ES12281 (G.S.P. and S.M.H.) and Department of Defence award W81XWH-06-1-0373 (W.Y.T.).

References

- 1 Jemal A, Siegel R, Ward E et al. Cancer statistics. *Ca Cancer J Clin* 2006;**56**:106–30.
- 2 Zondek LH, Zondek T. Congenital malformations of the male accessory sex glands in the fetus and neonate. In: Spring-Mills E, Hafez ESE (eds). *Male Accessory Sex Glands*. Elsevier/North-Holland Biomedical Press, New York, 1980;17–37.
- 3 Driscoll SG, Taylor SH. Effects of prenatal maternal estrogen on the male urogenital system. *Obstet Gynecol* 1980;**56**:537–42.
- 4 Zondek T, Zondek LH. The fetal and neonatal prostate. In: Goland M (ed.). *Normal and Abnormal Growth of the Prostate*. Charles Thomas, Springfield, IL, 1975;5–28.
- 5 Rajfer J, Coffey DS. Sex steroid imprinting of the immature prostate. *Invest Urol* 1978;**16**:186–90.
- 6 Santti R, Newbold RR, Makela S, Pylkanen L, McLachlan JA. Developmental estrogenization and prostatic neoplasia. *Prostate* 1994;**24**:67–78.
- 7 Yonemura CY, Cunha GR, Sugimura Y, Mee SL. Temporal and spatial factors in diethylstilbestrol-induced squamous metaplasia in the developing human prostate. II. Persistent changes after removal of diethylstilbestrol. *Acta Anat* 1995;**153**:1–11.
- 8 Ekblom A, Wu J, Adami HO et al. Duration of gestation and prostate cancer risk in offspring. *Cancer Epidemiol Biomarkers Prev* 2000;**9**:221–3.
- 9 Ekblom A, Hsieh CC, Lipworth L et al. Perinatal characteristics in relation to incidence of and mortality from prostate cancer. *Br Med J* 1996;**313**:337–41.
- 10 Henderson BE, Bernstein L, Ross RK, Depue RH, Judd HL. The early *in utero* oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. *Br J Cancer* 1988;**57**:216–8.
- 11 Platz EA, Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. *J Steroid Biochem Mol Biol* 2004;**92**:237–53.
- 12 Hayashi N, Sugimura Y, Kawamura J, Donjacour AA, Cunha GR. Morphological and functional heterogeneity in the rat prostatic gland. *Biol Reprod* 1991;**45**:308–21.
- 13 Prins GS, Birch L, Habermann H et al. Influence of neonatal estrogens on rat prostate development. *Reprod Fertil Dev* 2001;**13**:241–52.
- 14 Huang L, Pu Y, Alam S, Birch L, Prins GS. Estrogenic regulation of signaling pathways and homeobox genes during rat prostate development. *J Androl* 2004;**25**:330–7.
- 15 Prins GS. Developmental estrogenization of the prostate gland. In: Naz RK (ed.). *Prostate: Basic and Clinical Aspects*. C. R. C. Press, Boca Raton, FL, 1997;247–65.
- 16 McLachlan JA. Environmental signaling: what embryos and evolution teach us about endocrine disrupting chemicals. *Endocr Rev* 2001;**22**:319–41.
- 17 Colborn T. Environmental estrogens: health implications for humans and wildlife. *Environ Health Perspect* 1995;**103**:135–6.
- 18 Dodds EC, Lawson W. Synthetic oestrogenic agents without phenanthrene nucleus. *Nature* 1936;**137**:996–7.
- 19 Sajiki J, Yonekubo J. Leaching of bisphenol A (BPA) to seawater from polycarbonate plastic and its degradation by reactive oxygen species. *Chemosphere* 2003;**51**:55–62.
- 20 Kawahata H, Ohta H, Inoue M, Suzuki A. Endocrine disrupter nonylphenol and bisphenol A contamination in Okinawa and Ishigaki Islands, Japan – within coral reefs and adjacent river mouths. *Chemosphere* 2004;**55**:1519–27.

- 21 Inoue K, Kato K, Yoshimura Y, Makino T, Nakazawa H. Determination of bisphenol A in human serum by high-performance liquid chromatography with multi-electrode electrochemical detection. *J Chromatogr B Biomed Sci Appl* 2000;**749**:17–23.
- 22 Hiroi H, Tsutsumi O, Takeuchi T et al. Differences in serum bisphenol A concentrations in premenopausal normal women and women with endometrial hyperplasia. *Endocr J* 2004;**51**:595–600.
- 23 Yamada H, Furuta I, Kato EH et al. Maternal serum and amniotic fluid bisphenol A concentrations in the early second trimester. *Reprod Toxicol* 2002;**16**:735–9.
- 24 Ikezuki Y, Tsutsumi O, Takai Y, Kamiei Y, Taketani Y. Determination of bisphenol A concentrations in human biological fluids reveals significant early prenatal exposure. *Hum Reprod* 2002;**17**:2839–14.
- 25 Schonfelder G, Wittfoht W, Hopp H, Talsness CE, Paul M, Chahoud I. Parent bisphenol A accumulation in the human maternal-fetal-placental unit. *Environ Health Perspect* 2002;**110**:A703–7.
- 26 Krishnan AV, Stathis P, Permuth SF, Tokes L, Feldman D. Bisphenol-A: an estrogenic substance is released from polycarbonate flasks during autoclaving. *Endocrinology* 1993;**132**:2279–86.
- 27 Quesada I, Fuentes E, Viso-Leon MC, Ripoll C, Nadal A. Low doses of the endocrine disruptor bisphenol-A and the native hormone 17 β -estradiol rapidly activate the transcription factor CREB. *FASEB J* 2002;**16**:1671–3.
- 28 Howdeshell KL, Hotchkiss AK, Thayer KA, Vandenberg JG, vom Saal FS. Environmental toxins: exposure to bisphenol A advances puberty. *Nature* 1999;**401**:763–4.
- 29 Timms BG, Howdeshell KL, Barton L, Bradley S, Richter CA, vom Saal FS. Estrogenic chemicals in plastic and oral contraceptives disrupt development of the fetal mouse prostate and urethra. *Proc Natl Acad Sci USA* 2005;**102**:7014–9.
- 30 Munoz-de-Toro M, Markey CM, Wadia PR et al. Perinatal exposure to bisphenol-A alters peripubertal mammary gland development in mice. *Endocrinology* 2005;**146**:4138–47.
- 31 Markey CM, Wadia PR, Rubin BS, Sonnenschein C, Soto AM. Long-term effects of fetal exposure to low doses of the xenoestrogen bisphenol-A in the female mouse genital tract. *Biol Reprod* 2005;**72**:1344–51.
- 32 Leav I, Ho S, Ofner P, Merk F, Kwan P, Damassa D. Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. *J Natl Cancer Inst* 1988;**80**:1045–53.
- 33 Modugno F, Weissfeld JL, Trump DL et al. Allelic variants of aromatase and androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. *Clin Cancer Res* 2001;**7**:3092–6.
- 34 Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. *Endocr Rev* 2005;**26**:833–76.
- 35 Bosland MC, Ford H, Horton L. Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 β or diethylstilbestrol. *Carcinogenesis* 1995;**16**:1311–7.
- 36 Matsumoto J, Yokota H, Yuasa A. Developmental increases in rat hepatic microsomal UDP-glucuronosyltransferase activities toward xenoestrogens and decreases during pregnancy. *Environ Health Perspect* 2002;**110**:193–6.
- 37 Domoradzki JY, Thornton CM, Pottenger LH et al. Age and dose dependency of the pharmacokinetics and metabolism of bisphenol A in neonatal Sprague-Dawley rats following oral administration. *Toxicol Sci* 2004;**77**:230–42.
- 38 Ho SM, Wang WY, Belmonte J, Prins GS. Developmental exposure estradiol and bisphenol A (BPA) increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant (PDE4D4) in the rat prostate. *Cancer Res* 2006;**66**:5624–32.
- 39 Prins GS, Birch L, Yang WY, Ho SM. Developmental estrogen exposures predispose to prostate carcinogenesis with aging. *Reprod Toxicol* 2007;**23**:374–82.
- 40 Shappell S, Thomas D, Roberts R et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor Meeting of the mouse models of human cancer consortium prostate pathology committee. *Cancer Res* 2004;**64**:2270–305.
- 41 Hsieh C-L. Dynamics of DNA methylation pattern. *Curr Opin Genet Dev* 2000;**10**:224–8.
- 42 Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. *Annu Rev Pharmacol Toxicol* 2005;**45**:629–56.
- 43 Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. *Nat Rev* 2006;**7**:21–33.
- 44 Yegnasubramanian S, Kowalski J, Gonzalgo ML et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. *Cancer Res* 2004;**64**:1975–86.
- 45 Enokida H, Shiina H, Urakami S et al. Multigene methylation analysis for detection and staging of prostate cancer. *Clin Cancer Res* 2005;**11**:6582–8.
- 46 Li S, Washburn KA, Moore R et al. Developmental exposure to diethylstilbestrol elicits demethylation of estrogen-responsive lactoferrin gene in mouse uterus. *Cancer Res* 1997;**57**:4356–9.
- 47 Alworth LC, Howdeshell KL, Ruhlen RL et al. Uterine responsiveness to estradiol and DNA methylation are altered by fetal exposure to diethylstilbestrol and methoxychlor in CD-1 mice: effects of low versus high doses. *Toxicol Appl Pharmacol* 2002;**183**:10–22.
- 48 Anway MD, Cupp AS, Uzumcu M, Skinner MK. Epigenetic transgenerational actions of endocrine disruptors and male fertility. *Science* 2005;**308**:1466–9.
- 49 Gonzalgo M, Liang G, Spruck Cr, Zingg J, Rideout Wr, Jones P. Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR. *Cancer Res* 1997;**57**:594–9.
- 50 Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. *J Biol Chem* 2003;**278**:5493–6.
- 51 Fimia GM, Sassorne-Corsi P. Cyclic AMP signalling. *J Cell Sci* 2001;**114**:1971–2.
- 52 Chen TC, Wadsten P, Su S et al. The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells. *Cancer Biol Ther* 2002;**1**:268–76.
- 53 Narita M, Murata T, Shimizu K et al. Phosphodiesterase 4 in osteoblastic osteosarcoma cells as a potential target for growth inhibition. *Anticancer Drugs* 2003;**14**:377–81.
- 54 Lerner A, Kim DH, Lee R. The cAMP signaling pathway as a therapeutic target in lymphoid malignancies. *Leuk Lymphoma* 2000;**37**:39–51.

Epigenetic reprogramming and imprinting in origins of disease

Wan-ye Tang · Shuk-mei Ho

Published online: 20 July 2007
© Springer Science + Business Media, LLC 2007

Abstract The traditional view that gene and environment interactions control disease susceptibility can now be expanded to include epigenetic reprogramming as a key determinant of origins of human disease. Currently, epigenetics is defined as heritable changes in gene expression that do not alter DNA sequence but are mitotically and transgenerationally inheritable. Epigenetic reprogramming is the process by which an organism's genotype interacts with the environment to produce its phenotype and provides a framework for explaining individual variations and the uniqueness of cells, tissues, or organs despite identical genetic information. The main epigenetic mediators are histone modification, DNA methylation, and non-coding RNAs. They regulate crucial cellular functions such as genome stability, X-chromosome inactivation, gene imprinting, and reprogramming of non-imprinting genes, and work on developmental plasticity such that exposures to endogenous or exogenous factors during critical periods permanently alter the structure or function of specific organ systems. Developmental epigenetics is believed to establish "adaptive" phenotypes to meet the demands of the later-life environment. Resulting phenotypes that match predicted later-life demands will promote health, while a high degree of mismatch will impede adaptability to later-life challenges and elevate disease risk. The rapid introduction of synthetic

chemicals, medical interventions, environmental pollutants, and lifestyle choices, may result in conflict with the programmed adaptive changes made during early development, and explain the alarming increases in some diseases. The recent identification of a significant number of epigenetically regulated genes in various model systems has prepared the field to take on the challenge of characterizing distinct epigenomes related to various diseases. Improvements in human health could then be redirected from curative care to personalized, preventive medicine based, in part, on epigenetic markings etched in the "margins" of one's genetic make-up.

Keywords DNA methylation · Histone modification · Chromatin remodeling · Nongenomic heritage · Developmental plasticity · Relaxation of imprinting

1 Epigenetics meets genetics in disease susceptibility

In the past, susceptibility of disease was believed to be determined solely by inheritable information carried on the primary sequence of the DNA. Individuals are endowed with different genotypes that dictate how they respond to endogenous factors such as development cues, hormones, and cytokines or to exogenous influences, including nutrient availability, infection, physical activities, social behavior, and other environmental factors. Over time, these responses form the basis of genetic variability to disease susceptibility. Aberrant changes in linear DNA sequence result in mutations, deletions, gene fusion, tandem duplications, or gene amplifications causing dysregulation of gene expression that underlies the genesis of disease [1–7]. Recently, however, it has become clear that epigenetic disruption of gene expression plays an equally important

W.-y. Tang
Department of Environmental Health, College of Medicine,
University of Cincinnati,
Cincinnati, OH, USA
e-mail: tangwy@uc.edu

S.-m. Ho (✉)
Department of Environmental Health and Cancer Center,
College of Medicine, University of Cincinnati,
Cincinnati, OH, USA
e-mail: shuk-mei.ho@uc.edu

role in the development of disease [8–10] and, arguably, that this process is more susceptible than the former to environmental modulation.

The term epigenetics means outside conventional genetics [11] and was coined by the developmental biologist Conrad H. Waddington (1905–1975) [12]. Waddington treated *Drosophila* pupae with heat and observed altered wing-vein patterns [13]. The altered phenotype persisted in the population long after the stimulus was removed, suggesting that exposure to an environmental factor during a critical developmental window could produce a phenotype-change that lasted a lifetime and was manifested in subsequent generations. He referred to this phenomenon as “genetic assimilation,” or “epigenetics” in modern terminology. According to this paradigm, epigenetics is the process by which the genotype of an organism interacts with the environment to produce its phenotype. It provides a framework to explain the source of variations in individual organisms [14] and also explains what makes cells, tissues, and organs different albeit the identical nature of the genetic information in every cell in the body, since different sets of genes are expressed in different cells in a distinct temporal sequence. The concept has thus expanded the “gene-centric” view of inheritance biology by introducing the possibility of “nongenomic inheritance” as an adaptive mechanism for coping with environmental changes [8, 11].

Currently, epigenetics is defined as heritable changes in gene expression that occur without alterations in DNA sequence. Epigenetic modifications are mitotically and transgenerationally inheritable [15–17]. Three distinct and intertwined mechanisms are now known to regulate the “epigenome”: small-interfering RNAs, DNA methylation, and histone modifications [18–20]. These processes affect transcript stability, DNA folding, nucleosome positioning, chromatin compaction, and ultimately nuclear organization. Synergistically and cooperatively they determine whether a gene is silenced or activated and when and in what tissue it will be expressed. Thus, epigenetics has greatly expanded our understanding of the context of gene expression, which previously was believed to be dictated by the primary nucleotide sequence of a gene. Disruption of the epigenome or induction of “epimutations” [21] certainly underlies disease development [8–10]. Therefore, disease susceptibility is clearly a result of a complex interplay between one’s genetic endowment and epigenetic marks “imprinted” on one’s genome by endogenous or exogenous factors [11].

2 Developmental plasticity, adaptive developmental reprogramming, and early origins of human diseases

Epidemiologic studies now support an early origin of adult human diseases. Classic examples include association

between low birth weight and a greater risk of coronary heart disease, hypertension, stroke, depression, type 2 diabetes, and osteoporosis in later life [8, 10, 22–27]. The paradigm of early origins of adult disease is rooted in the process of developmental plasticity [8, 28, 29]. Most human organ systems begin to develop early in gestation and do not become fully mature until weeks, months, or years after birth. A relatively long gestation and a period of postnatal and perhaps prepubertal maturation allow for prolonged interactions with the environment. These include episodes of hypoxia; hypo- or hypernourishment; infection; and hormonal, drug, or toxin exposures. Developmental plasticity occurs when such exposures, during critical periods of maturation, result in permanent alterations in the structure or function of specific organ systems. This process, commonly referred to as “developmental reprogramming or imprinting” [8, 23, 24], is a so-called adaptive trait since it is an attempt to establish phenotypes that meet the demands of later-life environment [8, 10, 11, 28, 29]. When the resulting phenotypes match the predicted later-life demands, the individual will remain healthy. When there is a high degree of mismatch, however, one’s adaptability to adult life challenges will be impeded and disease risk will be elevated. The latter scenario is more frequent today than in past decades since contemporary human life is greatly influenced by lifestyle choices, which often are in conflict with the programmed adaptive changes made during early development. In addition, synthetic chemicals that mimic internal cues and artificial reproductive technologies are introduced into daily life at alarming rates. These can induce developmental reprogramming with no apparent late-life adaptive values. Collectively, these factors have increased the odds of a mismatch between early developmental programming and later-life demands that have caused various human diseases in recent decades.

Mechanistically, epigenetics underpins developmental reprogramming or imprinting. Thus, understanding how environmental factors influence various epigenetic processes during developmental reprogramming should provide new insights into early diagnosis, prevention, and treatment of these diseases.

3 Epigenetics as a mechanism of developmental reprogramming

The two most studied epigenetic mechanisms recognized as having a role in adaptive developmental programming are histone modifications [30] and DNA methylation [31, 32]. In simple terms, histone modifications refer to post-translational modifications of histone tails and DNA methylation involves the methylation of cytosine at the carbon-5 position in CpG dinucleotides. These processes work together to affect chro-

matin packaging, which in turn determines which gene or gene set is transcribed. Changes mediated by either process are heritable; not only are they transmittable to the daughter cells but to subsequent generations. More recently, the roles of small/micro antisense RNA transcripts in gene regulation have come under intense scrutiny [33, 34]. Disruption of gene expression, via one or more of these mechanisms, likely underpins early origins of adult diseases.

DNA methylation refers to the covalent addition of a methyl group derived from *S*-adenosyl-L-methionine to the fifth carbon of the cytosine ring to form the fifth base, 5-methyl cytosine (5meC) [31, 32, 35]. The reaction is catalyzed by DNA methyltransferases and accessory proteins (Dnmt1, Dnmt3a, Dnmt 3b, Dnmt2, and Dnmt 3L). Across eukaryotic species, methylation occurs predominantly in cytosines located 5' of guanines, known as CpG dinucleotides (CpGs). In the mammalian genome, the distribution of CpG dinucleotides is nonrandom [36]. CpG dinucleotides are greatly underrepresented in the genome because of evolutionary loss of 5meCs through deamination to thymine. However, clusters of CpGs known as CpG islands (CGIs) are preserved in 1–2% of the genome. Typically, they range in length from 200 bp to 5 kb. Most are unmethylated (in which occur near the transcription start sites) under normal circumstances except those associated with imprinted genes, genes subjected to X-chromosome inactivation, and transposable elements [31, 32, 35, 36]. In this regard, DNA methylation is thought to repress inappropriate expression of endogenous transposons that may disrupt the genome and are involved in parental-specific silencing of one allele of imprinted genes [31, 35, 37]. In addition, about 70% of CGIs are associated with DNA sequences 200 bp to 2 kb long located in the promoter, the first and second exons, and the first intron regions of all genes (5' CGIs), suggesting that CGIs are important for gene regulation [31, 35, 36]. There is usually an inverse relationship between the extent of methylation of a regulatory CGI and gene transcription. Two mechanisms have been proposed to explain how cytosine methylation leads to repression of gene transcription [31]. First, the methyl group of the 5meC extends into the major groove of DNA and inhibits binding of transcription factors (TFs) to their CpG-containing recognition sites. Second, a class of proteins known as methyl cytosine binding proteins (MeCPs) specifically binds methylated CGIs and create steric hindrance to the access by TFs to their regulatory elements. Both mechanisms will suppress gene transcription. Furthermore, upon binding to methylated CGIs, MeCPs recruit histone deacetylases (HDACs) and histone methyltransferases (HMTs). These enzymes mediate complex histone modifications (discussed below) and result in the establishment of repressive chromatin structures that permanently silent gene transcription [31, 35].

DNA methylation patterns are established through defined phases during the development of an organism. With the exception of imprinted genes, gamete methylation patterns are erased by a genome-wide demethylation at around the eight-cell stage of blastocyst formation. During the implantation stage, methylation patterns are established via *de novo* methylation. During adulthood, the amount and pattern of methylation are tissue- and cell-type-specific. Disruption of these preset patterns of DNA methylation in adult life has been linked to aging and disease development [38–40]. Furthermore, dysregulation of developmental programming by maternal factors or environmental mimics is now believed to induce abnormal DNA methylation of specific genes that permit them to undergo inappropriate expression in adult life, leading to disease development. Recent evidence strongly supports DNA methylation is a key mechanism of the developmental basis of adult diseases. Contemporary methodologies needed to identify these target genes have been reviewed [41].

Linear DNA is wrapped by an octameric complex composed of two molecules of each of the four histones H2A, H2B, H3, and H4 to form an array of nucleosomes. The amino termini of histones contain a diversity of post-translational modifications [42]. Among them, acetylation and methylation of lysine residues in the amino termini of histones H3 and H4 are most highly correlated with transcriptional activities. Histone acetylation is usually associated with transcriptional activation due to the lower affinity of the acetylated histone for DNA, therefore allowing relaxation of the chromatin. Conversely, deacetylation of histone correlates with transcriptional silencing and the heterochromatic state. In addition to histone acetylation, methylation of histone H3 lysine 9 (H3 Lys9) correlates with a repressed state and heterochromatin assembly. Each lysine residue may be methylated in the form of mono-, di-, or trimethylation, adding to the complexity of the “histone code” [42]. Methylation of the histone tails increases the basicity and hydrophobicity of the histones, as well as its affinity for anionic molecules such as DNA. Thus, histones with methylated tails are found in heterochromatin harboring transcriptionally inactive genes. Acetylation is catalyzed by histone acetyltransferases (HATs) and is removed by opposing histone deacetylases (HDACs). Methyl substitution is catalyzed by the histone methyltransferases (HMTs) and may be removed by yet-unidentified histone demethylases (HDMs). It is now known that histone modifications work hand in hand with DNA methylation to regulate chromatin structure and gene expression. However, it remains tenuous whether early life or environmental factors influence the “histone code” in a manner similar to their influence on DNA methylation.

Evidence is rapidly emerging of a role of noncoding RNA transcripts (ncRNAs) in gene regulation [33, 34].

These ncRNAs have been shown to modulate stability and translation of mRNAs by modulating polysome functions and chromatin structure. However, little to no information is available on whether early life and/or environmental factors could have an impact on these molecules. This will be a very fertile field of future investigation.

4 Early life and environmental factors in epigenetic reprogramming

Table 1 lists the studies demonstrating the epigenetic modifications induced by early-life and environment factors and their associated diseases/disorders. We choose to focus heavily on experimental models that provide more-mechanistic insights, while highlighting relevant epidemiologic studies. Several reviews have provided extensive accounts on this topic [8, 43–47].

4.1 Dietary factors

Maternal nutritional status and dietary factors are important developmental cues for fetal reprogramming that impact

adult diseases. In animal studies we can pinpoint the exact developmental stages of exposure and the mechanism of reprogramming. However, population-based studies often provide only correlation data for extrapolations.

4.1.1 Dietary methyl donors and cofactors

Folate, methionine, choline, and vitamin B₁₂ are dietary methyl donors and cofactors involved in *S*-adenosylmethione (SAM)-substrated methylation. Waterland and Jirtle first demonstrated that supplementation of the diets of female mice with methyl donors before and after pregnancy permanently increased DNA methylation at the viable yellow agouti (*A^{vy}*) metastable epiallele in their offspring [48]. These investigators further showed epigenetic plasticity to methyl-donor diets at another metastable epiallele, axin fused (*Axin^{Fu}*). The window of susceptibility was not restricted to early embryos but extended to mid-gestation [49]. Several population studies have demonstrated a strong correlation between folate status and coronary artery disease. Patients with the atherosclerotic vascular disease often exhibit higher homocysteine and *S*-adenosylhomocysteine (SAHC) and lower genomic DNA methylation status [50]. However,

Table 1 Epigenetic effects of diet and environment in endocrine and metabolic disorders

Dietary Factors	Epigenetic Effects Found in endocrine and metabolic disorders	References
Dietary Methyl Donors and Cofactors	N/A	[48], [49], [50], [51]
Fat intake	Mammary glands tumor	[52]
Glucose intake	Type 2 Diabetes	[53], [54]
Phytoestrogens		
Coumestrol	Hypermethylation of oncogen, <i>c-H-ras</i> in rat pancreas	[58]
Genistein	Prostate disease, obesity, female reproductive tract disorders	[59], [60], [61]
(-)-epigallocatechin-3-O-gallate (EGCG)	N/A	[62], [63]
Environmental Factors		
Heavy Metal		
Chromium	Sperm cells development	[64], [65]
Cadmium	N/A	[66], [67]
Arsenic	Ovarian, adrenal glands tumor, cardiovascular disease	[68], [69]
Lead	N/A	[71]
Nickel	N/A	[72], [73]
Xenochemicals		
Diethylstilbestrol (DES)	Uterine cancer, testicular cancer	[75], [76], [77], [78], [79], [80], [81]
Bisphenol A (BPA)	Prostate cancer, mammary cancer	[82], [83], [84]
Vinclozolin and methoxychlor	Infertility; abnormalities in prostate, testis, mammary gland; and mate preference	[17], [85], [86]
2,3,7,8-tetrachlorodibenzo- <i>p</i> -dioxin (TCDD)	N/A	[87], [88]
Phthalate esters	N/A	[90]
Polychlorinated biphenyls (PCBs)	Reproductive system disruption	[91], [92]
Chlorine disinfection by-products (DBPs)	N/A	[93]

N/A represents that particular factor that shows epigenetic effect on the genome but not directly associates with endocrine and metabolic disorders.

no specific genes have been identified as the target of reduced methylation in these patients. Another intriguing example of disease susceptibility related to methyl donor diet was illustrated in a population study reporting an association between folate status and a mutation in the gene encoding methylenetetrahydrofolate reductase, a key enzyme in determining genomic DNA methylation. This study suggests an interplay between nutritional epigenetics and genetic susceptibility in the modulation of gene expression [51]. Collectively, these findings offer valuable insights into the pathophysiology of diseases associated with nutritional epigenetics. This knowledge may also inspire novel prevention strategies by modifying the nutritional status of at-risk populations.

4.1.2 High fat or glucose intake

Typical western diets are high in fat and refined sugar (glucose). It is now known that a high-fat diet during pregnancy is associated with an elevated fetal estrogenic environment and a higher incidence of mammary cancer in the offspring. In Sprague–Dawley rats, during normal aging, mammary estrogen receptor (ER) undergoes progressive hypermethylation-mediated transcriptional silencing, which may offer a protective mechanism against cell growth and tumorigenesis. However, *in utero* exposure to a high-fat diet resulted in hypomethylation of the receptor's promoter and overexpression of ER in rat mammary glands, which is associated with a higher incidence of tumorigenesis in the exposed offspring [52]. Thus, early exposure to a high-fat diet has permanently disrupted a natural developmental program that might afford protection against mammary tumorigenesis.

Prenatal glucose levels influence the risk of developing type 2 diabetes in later life, suggesting the presence of epigenetic memory that may persist in insulin/glucose target tissues [53]. Furthermore, the development of obesity or type 2 diabetes is associated with glucose-induced, persistent changes in gene expression. Among the affected genes is glucose transporter 4 (GLUT4), which is the major glucose transporter in adipose tissue, and skeletal and cardiac muscles. With 3T3-L1 used as a cell model, it was shown that both methylation of specific CpG sites and a methylation-sensitive transcription factor contribute to *GLUT4* gene regulation during preadipocytes to adipocytes differentiation [53]. Additionally, differential DNA methylation was observed in promoters of genes involved in glucose metabolism. These include the facilitative glucose transporter 4 [54] and the uncoupling protein 2 [55]. Both are major targets involved in the development of type 2 diabetes.

4.1.3 Bioflavonoids and Tea catechins

Recently, there have been grave concerns about the health impacts of the isoflavones, a class of phytoestrogens readily

found in the diet, particularly in soy products. They are biologically active and can signal via ER- and non-ER-mediated pathways [56, 57]. Moreover, early developmental exposure to the phytoestrogens equol and coumestrol induced hypermethylation of the *c-H-ras* promoter and gene silencing in the rat pancreas [58]. Adult dietary supplement with genistein, a major isoflavone in soy, was shown to hypermethylate a set of genes in rat prostate [59]. In contrast, maternal supplementation with genistein was shown to shift the coat color and protect *Avy* mouse offspring from obesity by modifying the fetal epigenome [60]. Additionally, genistein treatment of neonatal mice caused significant abnormalities in the reproductive systems of the female mice [61]. Collectively, these animal studies raise concerns about the safety of developmental exposure to genistein. Questions related to the susceptibility of developmental plasticity to phytoestrogens and long-term epigenetic memories remain unanswered. Beside bioflavonoids, the tea polyphenol (-)-epigallocatechin-3-O-gallate (EGCG), is another natural compounds found to have modulating effects on DNA methylation [62]. EGCG was found to inhibit DNA methyltransferases and reactivate specific methylation-silenced genes in human colon and prostate cancer cell lines [63].

4.2 Environmental factors

4.2.1 Heavy metals

The adverse health effects of occupational or environmental exposure to heavy metals can be mediated by epigenetic mechanisms. Heavy metals such as chromium (Cr), cadmium (Cd), arsenic (As), lead (Pb), and nickel (Ni) have been reported to exert epigenetic effects on the genome. Paternal exposure to Cr(III) was shown to modify the epigenome/genome and to induce transgenerational carcinogenesis [64]. Paternal exposure to Cr(III) increases tumor risk in offspring. One allele of the 45S rRNA spacer promoter was found to be hypomethylated in sperm germ cells after exposure to the heavy metal, leading to speculation that this epimutation may increase tumor risk in the offspring [65]. Short-term exposure of rat liver cells to cadmium inhibited DNA methyltransferase activity, but prolonged exposure to this metal ion caused neoplastic transformation and attended increases in DNA methylation and DNA methyltransferase activity [66]. The pathologies of heavy metal (Ni, As, and Cd) toxicity in rodents resemble those seen in animals fed a methyl-deficient diet (lacking choline and folate) [67]. The metal ions, as well as the diet, significantly inhibited DNA methyltransferase activity, perhaps leading to hypomethylation of disease-causing genes. Epidemiologic data corroborate experimental findings and consistently show a broad range of

disorders associated with arsenic exposure in humans. These include cancer, atherosclerosis, neurologic disturbance, and cardiovascular diseases [68]. Moreover, exposure to arsenic *in utero* induces cancer of the liver, lungs, urinary bladder, and kidneys [69]. In this regard, arsenic is classified as a "complete" transplacental carcinogen in mice. In addition to its potent mutagenic action, arsenic can act through epigenetic mechanisms that modify DNA methylation patterns. The metal ion has been shown to deplete SAM and repress DNMT1 and DNMT3A [70]. Other metals, such as lead and nickel, have also been reported to have relevance in transplacental exposures and later carcinogenic effects by acting through epigenetic mechanisms [71, 72]. More recent studies have also reported heavy metal-associated histone modifications and chromatin organization [72, 73]. Specifically, nickel ions induce the silencing of the gpt transgene in G12 Chinese hamster cells by increasing histone H3K9 dimethylation via inhibition of H3K9 demethylation [73].

4.2.2 Xenochemicals and endocrine disruptors

The link between *in utero* exposure to the synthetic estrogen diethylstilbestrol (DES) and increased incidence of reproductive tract cancers in "DES daughters" has been a difficult lesson learned by the health-care community [74]. DES was prescribed during 1938 to 1971 to women to prevent miscarriages. It is a long-acting estrogen and hence a potent endocrine disruptor. In humans and experimental animals, exposure to DES during critical windows in early development disrupts the differentiation of the reproductive tract and results in a high incidence of structural and functional abnormalities, as well as of cancers in hormone-sensitive organs. Neonatal exposure of mice to DES induced demethylation of a single CpG site in the promoter of the *lactoferrin* gene [75] and exon-4 demethylation in the *c-fos* gene [76] in the uteri of the exposed animals. Prenatal exposure of mice to this xenoestrogen increased both liver weight and ribosomal DNA hypermethylation [77]. Recently, with the use of restriction landmark genomic scanning (RLGS), which can analyze genome-wide DNA methylation, seven loci of the genomic DNA were found to be demethylated and one locus methylated in the epididymis of fetal and neonatal DES-treated mice [78]. In collaboration with Newbold and associates, we recently reported that neonatal treatment of mice with DES or genistein prevents the ovarian steroid-induced silencing of *NSBP1* gene in the uteri of intact mice after the onset of puberty, via DNA hypermethylation [79]. The developmentally reprogrammable gene was identified by methylation-sensitive restriction fingerprinting (MSRF) [41]. In this model, neonatal exposure to DES or genistein induces high incidences of endometrial cancer in intact mice approaching

18 months of age. Therefore, we hypothesize that the normal silencing of *NSBP1* by ovarian steroids is disrupted by neonatal estrogen exposure. In this regard, epigenetic reprogramming by ovarian steroids during adult life may serve as a protective mechanism against endometrial cancer development. Early life disruption of this program could be the culprit of DES/genistein-induced endometrial cancer. Most important, it has been proposed that the adverse effects of DES can be transmitted across generations [80, 81]. The molecular targets that mediate this process are yet to be discovered.

Bisphenol A (BPA) was first synthesized as an estrogen mimic. At present, it is commonly used in the manufacture of polycarbonate plastics and epoxy resins. Developmental exposure to BPA results in morphologic and functional alterations of the male and female genital tracts and mammary glands and subsequently in an increase in susceptibility to infertility and the development of malignancies of the breast and prostate [82, 83]. In collaboration with Prins and associates, we first reported that neonatal exposure to environmentally relevant doses of BPA alters the prostate epigenome [84]. Using MSRF as an unbiased screening platform, we identified prostate phosphodiesterase type 4 variant 4 (*PDE4D4*) to be a target of epigenetic reprogramming (Fig. 1). *PDE4D4* is destined to undergo age-dependent transcriptional silencing via progressive hypermethylation of its promoter. However, neonatal exposure of mice to BPA or estrogen disrupts this developmental program and leaves the promoter of *PDE4D4* resistance to a predetermined "shut-off" program. This aberration allows persistent overexpression of the gene throughout adult life. Since we recently found that *PDE4D4* promotes prostate cell growth (Tang, unpublished data), we therefore hypothesize that chronic aberrant overexpression of *PDE4D4* leads to unscheduled growth of the prostate that may predispose it to neoplastic transformation. Indeed, our data [84] showed an increased incidence of precancerous lesions in the prostates of mice neonatally treated with estrogen/BPA.

Anway, Skinner, and co-workers [17, 85, 86] have provided the first evidence that *in utero* exposure of male mice to vinclozolin, a pesticide and an antiandrogen, induced epigenetic changes that could be transmitted across four generations. The epigenetic modification in specific DNA sequences is associated with adult phenotypes such as decreased spermatogenic capacity and increased incidence of infertility [17]; abnormalities in the prostate, breast, kidney, testis, and immune system [85]; and aberrant mating behavior [86]. The latter phenotype has significant ramifications in evolutionary biology as it suggests that epigenetic transgenerational inheritance of endocrine disruptor action impacts sexual selection and natural selection. In this regard, epigenetics could play a determinant role in evolution and natural selection of species [86].

**Estrogens or Xenoestrogens “reprogram” the male reproductive system
at early life via DNA methylation**




Fig. 1 Schematic diagram of our hypothesis on how neonatal estrogen (E2) and bisphenol A (BPA) alter the prostate genome via DNA methylation and histone modifications with phosphodiesterase type 4 variant 4 (PDE4D4) used as an example. Without exposure to E2 and BPA, *PDE4D4* is silenced with aging. A group of enzymes, including histone deacetylases (HDACs), DNA methyltransferases (DNMTs), and methylated DNA-binding protein (MeCP2), may be involved in gene silencing. Nevertheless, after exposure to E2 and BPA, *PDE4D4*

fails to “shut-off” and is actively transcribed throughout life. We propose that chromatin structure is remodeled by opening the chromatin in the presence of histone acetyltransferase (HAT), methylation binding domains (MBDs) and other unknown factors and that this remodeling further prevents HDACs, DNMTs, and MeCP2 from binding to silence the gene. Persistent elevation of *PDE4D4* expression is associated with the increase in incidence of prostate cancer later in life

2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD) is an environmental contaminant that has been reported to disrupt the normal development of experimental animals [87]. Exposure of mouse pre-implantation embryos to TCDD inhibited fetal growth, a response strongly associated with the changes in the methylation status of the imprinted genes *H19* and *IGF2* [88]. TCDD also induced histone modifications in normal human mammary epithelial cells [89]. Other environmental contaminants such as phthalate esters [90], polychlorinated biphenyls [91, 92], and chlorine disinfection by-products [93] also affect the reproductive system or induce tumor development by altering DNA methylation and/or steroid hormone metabolism and signaling.

5 Conclusions

Although this review has focused heavily on the interaction between environmental factors and epigenetics, early origins of disease can easily be determined by endogenous factors such as steroid hormones. In particular, estrogens and androgens play crucial roles in development, as well as in the genesis of diseases and cancer. They are now known

to have profound epigenetic influences by acting upon developmental plasticity [17, 41, 85], although their traditional actions are still mediated via classical nuclear receptor signaling pathways. The fact that the epigenetic “memory” can be transmitted to daughter cells and across several generations, influence sexual behavior, and thus impact Darwinian evolution makes this a field of investigation that should be highly valuable for generating new insights into the basis of disease development. The pioneer research examining a few epigenetic targets at a time are the proof-of-principle studies (McLachan [75, 76], Newbold [61, 80], Prins [94], Ho [41, 79], Soto [82], Skinner [17, 85] and Hilakivi-Clarke [46, 52]). To attain the next level of excellence, research in this area should focus on high-throughput comprehensive characterization of an entire epigenome susceptible to specific or multifaceted developmental reprogramming. Large-scale projects such as those defining an estrogen-sensitive epigenome are in order. Yet these investigations can progress only with adequate support from high-throughput modern technology platforms such as promoter tiling arrays, pyrosequencing, mass spectrometry, and bioinformatics analyses. The relatively long duration of developmental plasticity in humans (months

to years) will allow the environment to have a significant impact on reprogramming. Furthermore, some of the phenotypes will take many years to be manifested. The challenges to fully understand the basis of a disease could thus be overwhelming. Optimistically, however, since the epigenetic processes are long term and potentially reversible, once the origin of the disease is understood, intervention and prevention strategies could be devised and applied to reverse the course. These may include dietary interventions, life-style changes, and drug treatment. Future clinical practices to improve human health thus should shift from curative/palliative care to personalized preventive medicine which could be based, in part, on the epigenetic marks engraved along the “book-margins” of one’s genetic make-up.

6 Key unanswered questions

- Q1: How long or how many generations does it take to reverse an epigenetic imprint? How plastic is the system for reversal? What are the therapeutic or life-style opportunities? Are there non-invasive remedies?
- Q2: Does each class of environmental factor work on a unique set of reprogrammable genes? How much overlap between two unrelated environmental factors? Can one identify a distinct set of epigenetic marks for each stimulus and could these be developed into early predictors of diseases?
- Q3: What are the mechanisms responsible for integrating the various epigenomic changes induced by the vast number of environmental stimuli?
- Q4: What are the critical windows for epigenetic reprogramming? How long will it take for the ultimate phenotype to emerge? Could surrogate markers be used for prediction of disease and prescription of intervention?

Acknowledgments Grant support: NIH grants to S-M Ho: ES12281, ES13071, ES15905, and ES15584 and the Department of Defense award to W-Y Tang: DAMD W81XWH-06-1-0373 (W-Y Tang).

References

- Liu Y, Freedman BI. Genetics of progressive renal failure in diabetic kidney disease. *Kidney Int* 2005;Suppl S94–7.
- Kroll TG. Molecular events in follicular thyroid tumors. *Cancer Treat Res* 2004;122:85–105.
- Moore MA. Converging pathways in leukemogenesis and stem cell self-renewal. *Exp Hematol* 2005;33:719–37.
- Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. *J Clin Oncol* 2005;23:8253–61.
- Tusie Luna MT. Genes and type 2 diabetes mellitus. *Arch Med Res* 2005;36:210–22.
- Soussi T, Ishioka C, Claustres M, Beroud C. Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. *Nat Rev Cancer* 2006;6:83–90.
- Garg V. Insights into the genetic basis of congenital heart disease. *Cell Mol Life Sci* 2006;63:1141–8.
- Godfrey KM, Lillycrop KA, Burdge GC, Gluckman PD, Hanson MA. Epigenetic mechanisms and the mismatch concept of the developmental origins of health and disease. *Pediatr Res* 2007;61:5R–10R.
- Jiang YH, Bressler J, Beaudet AL. Epigenetics and human disease. *Annu Rev Genomics Hum Genet* 2004;5:479–510.
- Dolinoy DC, Weidman JR, Jirtle RL. Epigenetic gene regulation: linking early developmental environment to adult disease. *Reprod Toxicol* 2007;23:297–307.
- Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. *Nat Genet* 2003;33 Suppl:245–54.
- Van Speybroeck L. From epigenesis to epigenetics: the case of C. H. Waddington. *Ann NY Acad Sci* 2002;981:61–81.
- Waddington CH. The strategy of the genes: a discussion of some aspects of theoretical biology. New York: Macmillan;1957.
- Akhtar A, Cavalli G. The epigenome network of excellence. *PLoS Biol* 2005;3:e177.
- Rakyan VK, Blewitt ME, Druker R, Preis JJ, Whitelaw E. Metastable epialleles in mammals. *Trends Genet* 2002;18:348–51.
- Rakyan VK, Chong S, Champ ME, Cuthbert PC, Morgan HD, Luu KV, Whitelaw E. Transgenerational inheritance of epigenetic states at the murine Axin(Fu) allele occurs after maternal and paternal transmission. *Proc Natl Acad Sci USA* 2003;100:2538–43.
- Anway MD, Cupp AS, Uzumcu M, Skinner MK. Epigenetic transgenerational actions of endocrine disruptors and male fertility. *Science* 2005;308:1466–9.
- Morris KV. siRNA-mediated transcriptional gene silencing: the potential mechanism and a possible role in the histone code. *Cell Mol Life Sci* 2005;62:3057–66.
- Cheung P, Lau P. Epigenetic regulation by histone methylation and histone variants. *Mol Endocrinol* 2005;19:563–73.
- Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. *Annu Rev Pharmacol Toxicol* 2005;45:629–56.
- Holliday R. Mutations and epimutations in mammalian cells. *Mutat Res* 1991;250:351–63.
- Fernandez-Twinn DS, Ozanne SE. Mechanisms by which poor early growth programs type-2 diabetes, obesity and the metabolic syndrome. *Physiol Behav* 2006;88:234–43.
- Barker DJ, Osmond C, Simmonds SJ, Wield GA. The relation of small head circumference and thinness at birth to death from cardiovascular disease in adult life. *BMJ* 1993;306:422–6.
- Gluckman PD, Hanson MA. The developmental origins of the metabolic syndrome. *Trends Endocrinol Metab* 2004;15:183–7.
- Ravelli AC, Van Der Meulen JH, Michels RP, Osmond C, Barker DJ, Hales CN, Bleker OP. Glucose tolerance in adults after prenatal exposure to famine. *Lancet* 1998;351:173–7.
- Dennison EM, Arden NK, Keen RW, Syddall H, Day IN, Spector TD, Cooper C. Birthweight, vitamin D receptor genotype and the programming of osteoporosis. *Paediatr Perinat Epidemiol* 2001;15:211–9.
- Thompson C, Syddall H, Rodin I, Osmond C, Barker DJ. Birth weight and the risk of depressive disorder in late life. *Br J Psychiatry* 2001;179:450–5.
- Bateson P, Barker D, Clutton-Brock T, Deb D, D’Udine B, Foley RA, Gluckman P, Godfrey K, Kirkwood T, Lahr MM, McNamara J, Metcalfe NB, Monaghan P, Spencer HG, Sultan SE. Developmental plasticity and human health. *Nature* 2004;430:419–21.
- Gluckman PD, Hanson MA. Living with the past: evolution, development, and patterns of disease. *Science* 2004;305:1733–6.

30. Saha A, Wittmeyer J, Cairns BR. Chromatin remodelling: the industrial revolution of DNA around histones. *Nat Rev Mol Cell Biol* 2006;7:437–47.
31. Singal R, Ginder GD. DNA methylation. *Blood* 1999;93:4059–70.
32. Dolinoy DC, Das R, Weidman JR, Jirtle RL. Metastable epialleles, imprinting, and the fetal origins of adult diseases. *Pediatr Res* 2007;61:30R–7R.
33. Verdel A, Jia S, Gerber S, Sugiyama T, Gygi S, Grewal SI, Moazed D. RNAi-mediated targeting of heterochromatin by the RITS complex. *Science* 2004;303:672–6.
34. Matzke MA, Birchler JA. RNAi-mediated pathways in the nucleus. *Nat Rev Genet* 2005;6:24–35.
35. Costello JF, Plass C. Methylation matters. *J Med Genet* 2001;38:285–303.
36. Antequera F, Bird A. Number of CpG islands and genes in human and mouse. *Proc Natl Acad Sci USA* 1993;90:11995–9.
37. Murphy SK, Jirtle RL. Imprinted genes as potential genetic and epigenetic toxicologic targets. *Environ Health Perspect* 2000;108 Suppl 1:5–11.
38. Monk M, Boubelik M, Lehnert S. Temporal and regional changes in DNA methylation in the embryonic, extraembryonic and germ cell lineages during mouse embryo development. *Development* 1987;99:371–82.
39. Kafri T, Ariel M, Brandeis M, Shemer R, Urven L, McCarrey J, Cedar H, Razin A. Developmental pattern of gene-specific DNA methylation in the mouse embryo and germ line. *Genes Dev* 1992;6:705–14.
40. Issa JP. CpG-island methylation in aging and cancer. *Curr Top Microbiol Immunol* 2000;249:101–18.
41. Ho SM, Tang WY. Techniques used in studies of epigenome dysregulation due to aberrant DNA methylation: an emphasis on fetal-based adult diseases. *Reprod Toxicol* 2007;23:267–82.
42. Jenuwein T, Allis CD. Translating the histone code. *Science* 2001;293:1074–80.
43. Crews D, McLachlan JA. Epigenetics, evolution, endocrine disruption, health, and disease. *Endocrinology* 2006;147:S4–10.
44. Gatz M, Prescott CA, Pedersen NL. Lifestyle risk and delaying factors. *Alzheimer Dis Assoc Disord* 2006;20:S84–8.
45. Heindel JJ. Role of exposure to environmental chemicals in the developmental basis of reproductive disease and dysfunction. *Semin Reprod Med* 2006;24:168–77.
46. Hilakivi-Clarke L, De Assis S. Fetal origins of breast cancer. *Trends Endocrinol Metab* 2006;17:340–48.
47. Phillips DI. Programming of the stress response: a fundamental mechanism underlying the long-term effects of the fetal environment? *J Intern Med* 2007;261:453–60.
48. Waterland RA, Jirtle RL. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. *Mol Cell Biol* 2003;23:5293–300.
49. Waterland RA, Dolinoy DC, Lin JR, Smith CA, Shi X, Tahiliani KG. Maternal methyl supplements increase offspring DNA methylation at Axin Fused. *Genesis* 2006;44:401–6.
50. Castro R, Rivera I, Struys EA, Jansen EE, Ravasco P, Camilo ME, Blom HJ, Jakobs C, Tavares dA I. Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. *Clin Chem* 2003;49:1292–6.
51. Friso S, Choi SW, Dolnikowski GG, Selhub J. A method to assess genomic DNA methylation using high-performance liquid chromatography/electrospray ionization mass spectrometry. *Anal Chem* 2002;74:4526–31.
52. Yenbutr P, Hilakivi-Clarke L, Passaniti A. Hypomethylation of an exon I estrogen receptor CpG island in spontaneous and carcinogen-induced mammary tumorigenesis in the rat. *Mech Ageing Dev* 1998;106:93–102.
53. Dabelea D, Hanson RL, Lindsay RS, Pettitt DJ, Imperatore G, Gabir MM, Roumain J, Bennett PH, Knowler WC. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. *Diabetes* 2000;49:2208–11.
54. Yokomori N, Tawata M, Onaya T. DNA demethylation during the differentiation of 3T3-L1 cells affects the expression of the mouse GLUT4 gene. *Diabetes* 1999;48:685–90.
55. Carretero MV, Torres L, Latasa U, Garcia-Trevijano ER, Prieto J, Mato JM, Avila MA. Transformed but not normal hepatocytes express UCP2. *FEBS Lett* 1998;439:55–8.
56. Lamartiniere CA, Cotroneo MS, Fritz WA, Wang J, Mentor-Marcel R, Elgavish A. Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. *J Nutr* 2002;132:552S–8S.
57. Valachovicova T, Slivova V, Bergman H, Shuherk J, Sliva D. Soy isoflavones suppress invasiveness of breast cancer cells by the inhibition of NF-kappaB/AP-1-dependent and -independent pathways. *Int J Oncol* 2004;25:1389–95.
58. Lyn-Cook BD, Blann E, Payne PW, Bo J, Sheehan D, Medlock K. Methylation profile and amplification of proto-oncogenes in rat pancreas induced with phytoestrogens. *Proc Soc Exp Biol Med* 1995;208:116–9.
59. Day JK, Bauer AM, DesBordes C, Zhuang Y, Kim BE, Newton LG, Nehra V, Forsee KM, MacDonald RS, Besch-Williford C, Huang TH, Lubahn DB. Genistein alters methylation patterns in mice. *J Nutr* 2002;132:2419S–23S.
60. Dolinoy DC, Weidman JR, Waterland RA, Jirtle RL. Maternal genistein alters coat color and protects Avy mouse offspring from obesity by modifying the fetal epigenome. *Environ Health Perspect* 2006;114:567–72.
61. Jefferson WN, Padilla-Banks E, Newbold RR. Disruption of the female reproductive system by the phytoestrogen genistein. *Reprod Toxicol* 2007;23:308–16.
62. Lee WJ, Shim JY, Zhu BT. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. *Mol Pharmacol* 2005;68:1018–30.
63. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, Welsh W, Yang CS. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. *Cancer Res* 2003;63:7563–70.
64. Cheng RY, Hockman T, Crawford E, Anderson LM, Shiao YH. Epigenetic and gene expression changes related to transgenerational carcinogenesis. *Mol Carcinog* 2004;40:1–11.
65. Shiao YH, Crawford EB, Anderson LM, Patel P, Ko K. Allele-specific germ cell epimutation in the spacer promoter of the 45S ribosomal RNA gene after Cr(III) exposure. *Toxicol Appl Pharmacol* 2005;205:290–96.
66. Takiguchi M, Achanzar WE, Qu W, Li G, Waalkes MP. Effects of cadmium on DNA-(Cytosine-5) methyltransferase activity and DNA methylation status during cadmium-induced cellular transformation. *Exp Cell Res* 2003;286:355–65.
67. Poirier LA, Vlasova TI. The prospective role of abnormal methyl metabolism in cadmium toxicity. *Environ Health Perspect* 2002;110 Suppl 5:793–5.
68. Waalkes MP, Liu J, Ward JM, Diwan BA. Mechanisms underlying arsenic carcinogenesis: hypersensitivity of mice exposed to inorganic arsenic during gestation. *Toxicology* 2004;198:31–8.
69. Waalkes MP, Ward JM, Diwan BA. Induction of tumors of the liver, lung, ovary and adrenal in adult mice after brief maternal gestational exposure to inorganic arsenic: promotional effects of postnatal phorbol ester exposure on hepatic and pulmonary, but not dermal cancers. *Carcinogenesis* 2004;25:133–41.
70. Reichard JF, Schnekenburger M, Puga A. Long term low-dose arsenic exposure induces loss of DNA methylation. *Biochem Biophys Res Commun* 2007;352:188–92.
71. Silbergeld EK, Waalkes M, Rice JM. Lead as a carcinogen: experimental evidence and mechanisms of action. *Am J Ind Med* 2000;38:316–23.

72. Salnikow K, Costa M. Epigenetic mechanisms of nickel carcinogenesis. *J Environ Pathol Toxicol Oncol* 2000;19:307–18.
73. Chen H, Ke Q, Kluz T, Yan Y, Costa M. Nickel ions increase histone H3 lysine 9 dimethylation and induce transgene silencing. *Mol Cell Biol* 2006;26:3728–37.
74. Veurink M, Koster M, Berg LT. The history of DES, lessons to be learned. *Pharm World Sci* 2005;27:139–43.
75. Li S, Washburn KA, Moore R, Uno T, Teng C, Newbold RR, McLachlan JA, Negishi M. Developmental exposure to diethylstilbestrol elicits demethylation of estrogen-responsive lactoferrin gene in mouse uterus. *Cancer Res* 1997;57:4356–9.
76. Li S, Hansman R, Newbold R, Davis B, McLachlan JA, Barrett JC. Neonatal diethylstilbestrol exposure induces persistent elevation of c-fos expression and hypomethylation in its exon-4 in mouse uterus. *Mol Carcinog* 2003;38:78–84.
77. Alworth LC, Howdeshell KL, Ruhlen RL, Day JK, Lubahn DB, Huang TH, Besch-Williford CL, vom Saal FS. Uterine responsiveness to estradiol and DNA methylation are altered by fetal exposure to diethylstilbestrol and methoxychlor in CD-1 mice: effects of low versus high doses. *Toxicol Appl Pharmacol* 2002;183:10–22.
78. Sato K, Fukata H, Kogo Y, Ohgane J, Shiota K, Mori C. Neonatal exposure to diethylstilbestrol alters the expression of DNA methyltransferases and methylation of genomic DNA in the epididymis of mice. *Endocr J* 2006;53:331–7.
79. Tang W, Barker J, Jefferson WN, Newbold RR, Ho S. Early exposure to diethylstilbestrol or genistein and uterine cancer risk: investigating nucleosomal binding protein 1 (Nsbp1) as a gene susceptible to estrogen reprogramming in the mouse uterus. *Endocrine Society's 89th Annual Meeting Proceeding*. p95, 2007.
80. Newbold RR, Padilla-Banks E, Jefferson WN. Adverse effects of the model environmental estrogen diethylstilbestrol are transmitted to subsequent generations. *Endocrinology* 2006;147: S11–7.
81. Ruden DM, Xiao L, Garfinkel MD, Lu X. Hsp90 and environmental impacts on epigenetic states: a model for the trans-generational effects of diethylstilbestrol on uterine development and cancer. *Hum Mol Genet* 2005;14 Spec No. 1:R149–55.
82. Maffini MV, Rubin BS, Sonnenschein C, Soto AM. Endocrine disruptors and reproductive health: the case of bisphenol-A. *Mol Cell Endocrinol* 2006;254–255:179–86.
83. Welshons WV, Nagel SC, vom Saal FS. Large effects from small exposures. III. Endocrine mechanisms mediating effects of bisphenol A at levels of human exposure. *Endocrinology* 2006;147:S56–69.
84. Ho SM, Tang WY, Belmonte dF, Prins GS. Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. *Cancer Res* 2006;66:5624–32.
85. Anway MD, Leathers C, Skinner MK. Endocrine disruptor vinclozolin induced epigenetic transgenerational adult onset disease. *Endocrinology* 2006;147:5515–23.
86. Crews D, Gore AC, Hsu TS, Dangleben NL, Spinetta M, Schallert T, Anway MD, Skinner MK. Transgenerational epigenetic imprints on mate preference. *Proc Natl Acad Sci USA* 2007;104:5942–6.
87. Couture LA, Abbott BD, Birnbaum LS. A critical review of the developmental toxicity and teratogenicity of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin: recent advances toward understanding the mechanism. *Teratology* 1990;42:619–27.
88. Wu Q, Ohsako S, Ishimura R, Suzuki JS, Tohyama C. Exposure of mouse preimplantation embryos to 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) alters the methylation status of imprinted genes H19 and Igf2. *Biol Reprod* 2004;70:1790–7.
89. Bradley C, vanderMR, Roodi N, Yan H, Chandrasekharan MB, Sun ZW, Mernaugh RL, Parlf F. Carcinogen-induced histone alteration in normal human mammary epithelial cells carcinogenesis, 2007.
90. Foster PM. Disruption of reproductive development in male rat offspring following in utero exposure to phthalate esters. *Int J Androl* 2006;29:140–7.
91. Desaulniers D, Xiao GH, Leingartner K, Chu I, Musicki B, Tsang BK. Comparisons of brain, uterus, and liver mRNA expression for cytochrome p450s, DNA methyltransferase-1, and catechol-o-methyltransferase in prepubertal female Sprague–Dawley rats exposed to a mixture of aryl hydrocarbon receptor agonists. *Toxicol Sci* 2005;86:175–84.
92. McLachlan JA, Simpson E, Martin M. Endocrine disruptors and female reproductive health. *Best Pract Res Clin Endocrinol Metab* 2006;20:63–75.
93. Tao L, Wang W, Li L, Kramer PK, Pereira MA. DNA hypomethylation induced by drinking water disinfection by-products in mouse and rat kidney. *Toxicol Sci* 2005;87:344–52.
94. Prins GS, Birch L, Tang WY, Ho SM. Developmental estrogen exposures predispose to prostate carcinogenesis with aging. *Reprod Toxicol* 2007;23:374–82.



Developmental estrogen exposures predispose to prostate carcinogenesis with aging[☆]

Gail S. Prins^{a,*}, Lynn Birch^a, Wan-Yee Tang^b, Shuk-Mei Ho^b

^a Department of Urology, University of Illinois at Chicago, 820 South Wood Street, MC 955, Chicago, IL 60612, United States

^b Department of Environmental Health, University of Cincinnati, 3223 Eden Avenue, Cincinnati, OH 45267-0056, United States

Received 11 July 2006; received in revised form 7 October 2006; accepted 10 October 2006

Abstract

Prostate morphogenesis occurs *in utero* in humans and during the perinatal period in rodents. While largely driven by androgens, there is compelling evidence for a permanent influence of estrogens on prostatic development. If estrogenic exposures are abnormally high during the critical developmental period, permanent alterations in prostate morphology and function are observed, a process referred to as developmental estrogenization. Using the neonatal rodent as an animal model, it has been shown that early exposure to high doses of estradiol results in an increased incidence of prostatic lesions with aging which include hyperplasia, inflammatory cell infiltration and prostatic intraepithelial neoplasia or PIN, believed to be the precursor lesion for prostatic adenocarcinoma. The present review summarizes research performed in our laboratory to characterize developmental estrogenization and identify the molecular pathways involved in mediating this response. Furthermore, recent studies performed with low-dose estradiol exposures during development as well as exposures to environmentally relevant doses of the endocrine disruptor bisphenol A show increased susceptibility to PIN lesions with aging following additional adult exposure to estradiol. Gene methylation analysis revealed a potential epigenetic basis for the estrogen imprinting of the prostate gland. Taken together, our results suggest that a full range of estrogenic exposures during the postnatal critical period – from environmentally relevant bisphenol A exposure to low-dose and pharmacologic estradiol exposures – results in an increased incidence and susceptibility to neoplastic transformation of the prostate gland in the aging male which may provide a fetal basis for this adult disease.

© 2006 Elsevier Inc. All rights reserved.

Keywords: Prostate; Carcinogenesis; Estradiol; Estrogens bisphenol A; Development; Steroid receptor; Epigenetics; Methylation

1. Introduction

The prostate is a male accessory sex gland that receives a great deal of interest not because of its physiologic role, but rather due to the high incidence of abnormal growth and tumor formation with aging in humans. Currently, prostate cancer is the most common non-skin cancer in males and is the second leading cause of cancer deaths in American men [1]. According to the American Cancer Society, prostate cancer rates have been on the rise since 1975. With the 1987 introduction of PSA testing, the newly enhanced ability to diagnose the disease caused incidence to spike to 240 age-adjusted cases

per 100,000 men by 1992. After this “catch-up” period, rates dropped for 3 years, but have been rising again since 1998. Additionally, benign prostatic hyperplasia (BPH) is the most common benign neoplasm, occurring in ~50% of all men by the age of 60. Despite extensive research in the field, the basis for these high rates of abnormal prostatic growth is not well understood. It is recognized, however, that steroid hormones play a role in the initiation and progression of prostate cancer which is the basis for hormonal treatment strategies. Eunuchs with low levels of circulating testosterone do not develop prostatic carcinoma [2] and cancer regression can be initially achieved by castration and androgen blockade [3]. Although primarily under androgenic control, the prostate gland is also an estrogen target organ. Furthermore, estrogen involvement in the etiology of BPH and prostatic cancer has been postulated [4–6] and the use of antiestrogens has been recently recognized to have a therapeutic role in prostate cancer management [7,8].

[☆] Supported by NIH grants DK40890 (GSP), ES12281 (GSP and SMH) and Department of Defense awards DAMD W81XWH-04-1-0165 (SMH) and W81XWH-06-0373 (WYT).

* Corresponding author. Tel.: +1 312 413 9766; fax: +1 312 996 1291.

E-mail address: gprins@uic.edu (G.S. Prins).

It has long been speculated that early developmental events which are regulated by steroids in the prostate gland may be linked to its predisposition to high rates of disease in adult men [9]. Thus, it is noteworthy that relative to adult estrogenic responses, the prostate gland is particularly sensitive to estrogen exposures during the critical developmental period. In this context, the present review will focus on the potential role of fetal or perinatal estrogens in permanently imprinting the prostate gland during development which in turn sets the stage for increased susceptibility to prostate carcinogenesis with aging.

2. Prostate gland development

Unlike other male accessory sex glands which develop embryologically from the mesodermal Wolffian ducts, the prostate gland originates from the urogenital sinus (UGS) and is endodermal in origin. It has been suggested for decades that the high rates of prostate cancer in men compared to the paucity of carcinoma in the seminal vesicles, vas deferens or epididymis may have a basis in this unique embryologic origin for an accessory sex gland. Prostate development commences *in utero* as UGS epithelial cells form outgrowths or buds that penetrate into the surrounding UGS mesenchyme in the ventral, dorsal and lateral directions posterior to the bladder. In humans, prostate morphogenesis occurs during the second and third trimester and is complete at the time of birth [10,11]. This contrasts with the rodent prostate gland where bud initiation commences in late fetal life and at the time of birth, a rudimentary structure is present consisting of a few main epithelial ducts. Extensive branching morphogenesis and cellular differentiation subsequently take place during the first 15 days of life [12]. Thus, the neonatal rodent prostate gland has emerged as a useful model for fetal prostate development in humans.

The initiation of prostatic development is dependent upon androgens produced by the fetal testes [9] and studies with 5α reductase inhibitors have shown that dihydrotestosterone (DHT) is the active androgen required for prostate formation [13]. Normal development, differentiation and onset of secretory activity requires the presence of androgens throughout the developmental process [14]. Androgen receptors (AR) are highly expressed in the UGS mesenchyme prior to and during prostate morphogenesis [15,16] and evidence by Cunha et al. [17] using mice has demonstrated that androgen-stimulated mesenchymal factors drive the morphogenetic process. Since AR are induced in rat prostate epithelium by postnatal days 1–3, it is possible that androgen-driven epithelial signals also contribute to morphogenesis and differentiation of the prostate [15].

The developing prostate gland also expresses other members of the steroid receptor superfamily including estrogen receptors $ER\alpha$ and $ER\beta$ and retinoic acid receptors $RAR\alpha$, β and γ which are liganded by all-trans or 9-*cis* retinoic acid as well as $RXR\alpha$, β and γ which are activated by 9-*cis* retinoic acid alone. Studies in rodent prostate glands have shown relatively high stromal cell $ER\alpha$ expression during perinatal morphogenesis of the gland which significantly declines thereafter suggesting a specific role for $ER\alpha$ in prostate development [16,18,19]. In the rat and murine prostate, $ER\beta$ is primarily localized to differen-

tiated luminal epithelial cells [20–22]. $ER\beta$ expression is low at birth, increases as epithelial cells cytodifferentiate and reaches maximal expression with onset of secretory capacity at puberty which suggests a role for $ER\beta$ in the differentiated function of the prostate [20]. In humans, $ER\alpha$ is also consistently observed in stromal cells during fetal development [23]. It is noteworthy, however, that the developmental pattern for $ER\beta$ in the human prostate differs markedly from the rodent. As early as fetal week 7, $ER\beta$ is expressed throughout the urogenital sinus epithelium and stroma [23]. This strong expression is maintained in most epithelial and stromal cells throughout gestation, particularly in the active phase of branching morphogenesis during the second trimester suggesting the involvement of $ER\beta$ and estrogens in this process [16,23]. While this pattern is maintained postnatally for several months, $ER\beta$ expression declines thereafter with a noticeable decrease in adluminal cells at puberty [16] again suggesting a specific developmental role for estrogens.

3. Estrogen imprinting of the developing prostate: fetal basis for adult disease

Similar to androgens, circulating levels of estradiol are high during the fetal and early neonatal life in both humans and rodent models [24] and there is compelling evidence that the developing prostate gland is particularly sensitive to these estrogens. During the third trimester of *in utero* development in humans, rising maternal estradiol levels and declining fetal androgen production result in an increased estrogen/testosterone (E/T) ratio. This relative increase in estradiol has been shown to directly stimulate extensive squamous metaplasia within the developing prostatic epithelium which regresses rapidly after birth when estrogen levels drop precipitously [25–27]. Although the natural role for estrogens during prostatic development is unclear, it has been proposed that excessive estrogenization during prostatic development may contribute to the high incidence of BPH and prostatic carcinoma currently observed in the aging male population [28,29]. African-American men have a two-fold increased risk of prostatic carcinoma as compared to their Caucasian counterparts and it has been postulated that this is related, in part, to elevated levels of maternal estrogens during early gestation in this population [30,31]. Indicators of pregnancy estrogen levels such as length of gestation, pre-eclampsia and jaundice indicate a significant correlation between elevated estrogen levels and prostate cancer risk [32,33]. Further, maternal exposure to diethylstilbestrol (DES) during pregnancy was found to result in more extensive prostatic squamous metaplasia in male offspring than observed with maternal estradiol alone [34]. While prostatic metaplasia eventually resolved following DES withdrawal, ectasia and persistent distortion of ductal architecture remained [35]. This has led to the postulation that men exposed prenatally to DES may be at increased risk for prostatic disease later in life although this has not been borne out in the limited population studies conducted to date [36]. However, extensive studies with rodent models predict marked abnormalities in the adult prostate including increased susceptibility to adult-onset carcinogenesis following early estrogenic exposures [28,37–39]. Although use of DES during pregnancy was discontinued in the early 1970s,

the recent realization that certain environmental chemicals have potent estrogenic activities [40] has led to a renewed interest in the effects of exogenous estrogens during prostatic development [41].

4. Rat model of developmental estrogenization

To carefully examine and elucidate a potential role for early-life estrogen exposures in adult prostate disease, we have made extensive use of the rat model for developmental estrogenization. The initial model used in our laboratory is the Sprague–Dawley rat given injections of 25 μ g estradiol benzoate on neonatal days 1, 3 and 5 of life (Fig. 1). It is important to mention that while this is considered “high-dose”, the majority of neonatally administered estradiol is bound to α -fetoprotein which circulates at high levels in neonatal rat serum [42]. Consequently, neonatal estradiol is 75-fold less potent than an equivalent dose of DES [43] or, put another way, 25 μ g estradiol/pup is equivalent to 0.33 μ g DES/pup. As observed in earlier studies with mice and rats following early DES exposure [44,45], neonatal estradiol exposure consistently led to prominent pathology of the rat prostate gland. Histologic analysis of the young adult (day 90) ventral prostates of neonatally estrogenized prostates revealed disorganization of the epithelium with loss of basal/apical orientation, epithelial hyperplasia, inflammatory cell infiltrates and a relative increase in stromal elements [46–48]. Of significant interest, the pathologic lesions of the epithelium progress with aging such that by 18–22 months of age, ventral and dorsal lobes exhibited extensive hyperplasia (epithelial piling and cribriform patterning within the lumens), adenoma formation and moderate-to-high grade prostatic intraepithelial neoplasia (PIN) lesions characterized by nuclear enlargement, anisokaryosis and hyperchromasia [49]. Since neonatal estrogen exposure also results in decreased circulating testosterone (T) levels, a group of aged estrogenized rats were given 2 cm T implants for the last 6 months of life which restored T levels to normal. This treatment resulted in a 100% incidence of high-grade PIN throughout the ventral lobes by 18 months of age. Aged male rats exposed neonatally to DES have also been shown to develop profound squamous metaplasia in the dorsolateral prostate and development of solid tumors with highly invasive squamous cell carcinoma in some animals [44]. Similar results have been observed in neonatal DES-exposed mice [37,45]. Together these findings support the hypothesis

that early high-dose estrogen imprinting may be a predisposing factor to malignant transformation of the prostate gland in the aging male.

To better understand the processes by which high-dose neonatal estrogens drive hyperplasia and PIN lesions within the adult prostate gland, we further characterized the estrogenized phenotype at the anatomic and cellular level. Brief neonatal estrogen exposure permanently retards growth and development of the prostate gland such that all lobes are hypomorphic, reaching only 20–50% of normal adult prostate size [48]. In the dorsal and lateral lobes, not only is growth reduced but severe branching deficiencies exist such that elongating ducts fail to develop secondary and tertiary branch points and complex morphology [50]. While reduced growth is in part a function of reduced circulating T levels following neonatal estrogen exposure [48], organ culture studies also demonstrated a direct effect of estrogens in growth retardation as well as altering prostate differentiation [51,52].

Following neonatal exposure to high-dose estradiol, both epithelial and stromal cell proliferation and differentiation are markedly disturbed leading to defects that persist throughout the lifespan of the animal [15,53–56]. For epithelial cells, cytodifferentiation during development is perturbed or, for some end-points, permanently blocked by neonatal estrogens as determined by alterations in basal and luminal cell markers (p63, cytokeratins 5/15 and 8/18) and decreased production of secretory proteins (PBP, DLP proteins, urokinase, 26 kDa protease) [15,22,53]. Furthermore, alterations in the expression of e-cadherin and the gap junction proteins connexins 32 and 43 in the adult prostate epithelial cells result in impaired cell–cell adhesion and defective cell–cell communication [56]. In this regard, it is noteworthy that the epithelial cell differentiation defects are most prominent in the ventral prostate which also has the highest incidence of aging-associated PIN lesions [49].

Stromal-epithelial communication is also perturbed in the estrogen-exposed prostate through increased proliferation of periductal fibroblasts immediately adjacent to the outgrowing ducts during early development [53]. Direct cross-talk between epithelial cells and adjacent smooth muscle cells via secreted growth factors and extracellular matrix components is essential for normal prostate development [57]. The immediate proliferation and differentiation of mesenchymal cells into a multicellular fibroblast layer between the epithelial and smooth muscle cells




Fig. 1. Schematic representation of rat animal model for developmental estrogenization of the prostate gland. Day of birth (DOB) is considered day 0. Newborn male pups were given s.c. injections of high dose estradiol benzoate (25 μ g) or oil as controls on days 1, 3 and 5. Rats are weaned on day 25. In young adulthood, significant differentiation defects and dysplasia are observed in the prostate gland as described in the text.

effectively blocks this critical stromal–epithelial cell interaction and interrupts growth factor communication as has been shown specifically for transforming growth factor $\beta 1$ (*Tgfb1*) [53]. Altogether, the above findings indicate that neonatal estrogen exposure interrupts intercellular communication and blocks certain epithelial cells within the rat prostate from entering a normal differentiation pathway. These persistent alterations in differentiation and gene expression may be a key mechanism through which changes towards a dysplastic state are mediated.

5. Molecular pathways for developmental estrogenization of the prostate

We next sought to determine the molecular pathways which mediate permanent alterations in prostate growth and function long after the hormone is withdrawn. It was observed in early studies that the activational response to androgens during adulthood is permanently blunted in estrogenized rats [46] and we determined that this effect is mediated, in part, through an immediate and permanent reduction in prostatic AR expression [15,48,58,59]. Furthermore, the temporal expression patterns and quantitative levels of several other members of the steroid receptor superfamily are dysregulated by early exposure to high doses of estradiol. Thus, ER α and progesterone receptor (PR) are transiently up-regulated in stromal cells [18,38], ER β is permanently down-regulated in luminal epithelial cells [20], RAR β is up-regulated in basal cells while RAR α is up-regulated in both epithelial and stromal cells [60]. This has led us to propose that early estrogen exposure effectively switches the developing prostate gland from an androgen-AR dominated tissue to one that is primarily regulated by estrogens and retinoids. We further hypothesize that this irretrievably alters the prostate by changing organizational signals that determine prostate behavior throughout life.

Developmental genes that dictate normal prostate gland morphogenesis were next examined as potential direct targets of the altered steroid signaling *milieu*. Specific perturbations in expression of key homeobox transcription factors as well as secreted morphoregulatory genes were observed which serves to explain some of the common and lobe-specific estrogenized phenotypes. As this has been the subject of two recent reviews [39,61], the findings will be briefly summarized here. In the prostate gland, the posterior *Hox13* genes are involved in positional identity and differentiation. Of these, *Hoxb13* is expressed in the epithelium where it plays a specific role in differentiation [62,63]. In the rat prostate, *Hoxb13* epithelial expression increased postnatally and was expressed at the highest levels in the ventral lobe [38]. Following neonatal exposure to high-dose estrogen, *Hoxb13* expression was immediately and permanently suppressed in all prostate lobes with the most significant reduction (80%) observed in the ventral prostate gland. Another critical homeobox gene, the androgen-regulated *Nkx3.1*, is normally expressed in UGS-derived prostate epithelium where it plays a role in differentiation and growth [64,65]. In control rats, a marked peak in *Nkx3.1* expression was observed postnatally between days 6 and 15 of life which subsequently declined to steady-state levels thereafter. While adult levels were not

disturbed, the transient postnatal *Nkx3.1* peak was completely abolished following high-dose neonatal estrogen exposure [61]. We propose that estrogen-initiated loss of prostatic epithelial *Hoxb13* and *Nkx3.1* genes may play a critical role in mediating the differentiation defects observed in the developmentally estrogenized prostate gland.

In addition to developmental regulation by homeobox genes, branching morphogenesis occurs as a complex interplay between epithelial and mesenchymal cells through secreted morphoregulatory genes [66]. We have recently examined the ontogeny and localization of bone morphogenic protein 4 (*Bmp4*), sonic hedgehog (*Shh*) and fibroblast growth factor-10 (*Fgf10*) in the normal developing rat prostate lobes and those exposed neonatally to estradiol to determine if alterations in their signaling pathways are involved in mediating specific aspects of the estrogenized phenotype. *Bmp4* has been implicated as a negative regulator of prostate growth [67] and levels in the rat prostate lobes rapidly decline postnatally. Following estrogen exposure however, *Bmp4* expression remained high through postnatal day 30 and we propose that this contributes to hypomorphic growth throughout the prostatic complex [61]. Our recent studies on epithelial *Shh* [50] and mesenchymal *Fgf10* [68] demonstrated a critical role for these two genes in regulating branching morphogenesis of the prostate gland. Interestingly, early estrogen exposure led to a lobe-specific reduction in *Shh* and *Fgf10* signaling in the dorsolateral prostate which is the site of severe branching deficiencies in response to estrogenization. Furthermore, the data suggest that reduced *Fgf10* expression in the stromal cells by estrogens is the proximate cause of *Shh* reductions and branching deficiencies [68]. Since a precise temporal expression pattern of these and other morphoregulatory genes is normally required for appropriate growth and differentiation of the prostatic epithelium and stroma, the estrogen-initiated disruption in this pattern would lead to permanent growth, branching and differentiation defects of the prostate gland. In summary, we propose that these and other yet unidentified molecular defects as a result of developmental estrogenization initiate permanent disturbances in prostate homeostasis which contributes to the development of prostatic neoplasia, PIN lesions and carcinoma as the animals age.

6. Neonatal exposure to low-dose estradiol and bisphenol A

The above effects of developmental estrogen exposures were in response to pharmacologic levels of estrogens as a model for early maternal exposures to agents such as DES or continued contraceptive use of ethinyl estradiol during pregnancy. A separate yet equally important issue is whether lower estrogenic exposures during development, such as elevated maternal estrogens or environmental estrogenic exposures, produce permanent prostatic abnormalities. Initial studies by vom Saal and colleagues to address the low-dose estrogen effects on the prostate gland found that in contrast to high-dose exposures, low-doses of estradiol or bisphenol A (BPA) during fetal life increased prostatic bud number, cell proliferation and adult prostate size in mice [69,70]. However, no histopathologic abnormalities were

observed in young adulthood. Furthermore, the low-dose estrogenic response in the prostate gland has not been consistently reported [71], due in part to species/strain differences, background estrogen levels and other experimental variables, and is a matter of considerable debate [72,73]. To examine this issue in the neonatal rat model, we administered estradiol over a 7-log range of doses on neonatal days 1, 3 and 5 in both Sprague-Dawley rats and the more estrogen-sensitive Fischer 344 rats [74]. We observed that only high-dose neonatal estradiol produced consistent prostatic pathology at 3 months whereas exposure to lower estradiol levels produced no permanent prostatic weight change or pathologic alterations [74] despite the advancement of puberty [75].

Although low-dose estrogens by themselves did not appear to drive prostate pathology in early adulthood, we asked whether low-dose exposures during development might shift the sensitivity of the prostate gland to adult estrogenic exposures as has been recently observed for some female reproductive endpoints [76,77]. This question is biologically relevant since circulating estradiol levels and the serum estrogen:testosterone ratio increase in aging men partly due to increased body fat content and aromatase activity, at a time when prostate cancer incidence rises [78]. Furthermore, prolonged adult exposure to estradiol at levels within a physiologic range is capable of driving prostatic carcinogenesis in the Noble rat model [4]. To address this possibility, we established a “second-hit” model as schematized in Fig. 2. Briefly, newborn male rats were exposed to either high-dose estradiol (2.5 mg/kg BW), low-dose estradiol (0.1 µg/kg BW), an environmentally relevant dose of BPA (10 µg/kg BW) or oil as controls on neonatal days 1, 3 and 5 as a “first hit”. At day 90 of life, a “second hit” of estradiol (E) was given by implanting T + E (or empty) capsules for 16 weeks. The T capsules result in 3 ng/ml serum T levels [79] and were necessary to maintain prostate homeostasis since E treatment alone results in feedback inhibition of endogenous T secretion with resultant prostatic involution. The E capsules produce serum levels of ~75 pg/ml in rats which, although elevated for males, is not considered pharmacologic [79]. These T + E capsule for 16 weeks produce PIN in the dorsolateral prostates at 100% incidence in Noble rats [4] but only 33% incidence in Sprague–Dawley rats [80]. At 28 weeks of age, the prostates were examined for hyperplasia, inflammation and PIN, the presumed precursor lesion of prostate cancer.

PIN scores, based on grade and frequency, and PIN incidence showed marked differences across treatment groups [81]. Neonatal exposure to either high-dose estradiol or to low-dose estradiol alone resulted in elevated PIN scores and incidence with aging (66% and 55%, respectively) while BPA alone had no effect on prostate pathology. As expected, prolonged adult T + E exposure increased PIN incidence to 40% in control rats given oil neonatally. This was further increased to a 100% incidence with significantly elevated PIN scores by initial early exposure to high-dose estradiol. Neonatal low-dose estradiol prior to adult hormones, however, did not augment PIN lesions further than that seen with neonatal low-dose estradiol alone. In contrast, neonatal exposure to an environmentally relevant dose of BPA produced a significant augmentation of PIN lesions to 100% incidence when followed by adult T + E exposure. The overall PIN score was significantly higher than both oil-treated rats ($P < 0.05$) and those given BPA alone ($P < 0.01$) and was equivalent to the PIN score observed following high-dose estradiol exposure. Histologically, severe atypia was common with nuclear elongation and irregular size, cellular piling, and adenoma formation. These findings are highly significant since they are the first observation of a link between developmental low-dose BPA exposure and adult prostatic pathologic lesions. Together, this new experimental paradigm suggests that low-dose exposures to estradiol alone increase susceptibility to adult onset prostate dysplasia while environmentally relevant doses of BPA increase the sensitivity of the prostate gland to carcinogenesis following additional adult insults such as elevated circulating estrogens.

7. Epigenetic changes in DNA methylation as a molecular mediator for estrogen imprinting of the prostate gland

While we have identified both transient and permanent alterations in the expression of multiple cell signaling pathways following high-dose estradiol exposure (see above), the molecular basis of these changes has remained elusive. One distinct possibility is through epigenetic modifications of DNA via cytosine methylation or demethylation which would result in aberrant and heritable silencing or activation of genes. Importantly, there is evidence that early hormonal exposures during developmental sensitive periods can permanently alter DNA




Fig. 2. Schematic representation of “two-hit” rat animal model for low-dose exposure to estradiol or bisphenol A (BPA) followed by second exposure to T + E implants on day 90. Newborn rats were injected with oil, high-dose estradiol benzoate (EB, 2500 µg/kg BW), low-dose EB (0.1 µg/kg BW) or BPA (10 µg/kg BW) on days 1, 3 and 5. At day 90, they were implanted with empty capsules or T + E capsules for 16 weeks. Arrowheads indicate times for tissue collection.

methylation of specific genes. McLachlan showed demethylation of CpG/–464 in the lactoferrin promoter of mouse uteri following neonatal high-dose DES exposure which persisted as tumors developed [82]. Similarly, neonatal phytoestrogen exposure was associated with hypermethylation of *c-H-ras* in the rat pancreas [83] while fetal DES and methoxychlor exposure resulted in altered methylation of ribosomal DNA in mouse uteri [84].

To examine whether epigenomic alterations in DNA methylation play a role in prostate imprinting by estrogens, we screened for global methylation changes using methylation sensitive restriction fingerprinting, or MSRF, using prostates exposed neonatally to high-dose estradiol, low-dose estradiol or environmentally relevant doses of BPA without or with adult T + E exposure (see above). As recently described [81], over 50 DNA candidates were identified as potential leads with repeatable methylation alterations across multiple samples and lobes. Of the identified candidates, 16 showed no homology with known rat genes, six were identified one time (PLC β 3, HPCAL1, CARK, GPCR14, PDE4D4 and PDGFR α) and two were identified multiple times (CAR-X1 and SLC12A2) with similar methylation patterns observed each time. It is noteworthy that several candidate genes involve signal transduction pathways: Na–K–Cl cotransport (SLC12A2), serotonin receptor/G-protein coupled receptor (GPCR14), MAPK/ERK pathway (PDGFR α), phosphokinase C pathway (PLC β 3), cAMP pathways (PDE4D4 and HPCAL1) and neural or cardiac development (CARX1, CARK). Furthermore, these signaling pathways are involved in cell cycle and/or apoptosis, suggesting that neonatal estrogen exposures may perturb proliferation/apoptosis equilibrium through epigenetic gene (de)regulation.

We initiated further studies to determine whether altered DNA methylation due to neonatal estrogenic exposures results in altered gene expression. Our initial studies focused on phosphodiesterase type 4, variant 4 (PDE4D4), an intracellular enzyme

that specifically degrades cAMP [85]. This gene was chosen since the differentially methylated DNA fragment identified by MSRF corresponded to the 5'-flanking region of the gene, it was consistently hypomethylated by all neonatal estrogenic exposures and the changes were identified by day 10 of life. Importantly, PDE4D4 controls the intracellular levels of cAMP which activates multiple downstream cell signaling pathways, regulating transcription of genes involved in cell growth and differentiation [86]. Thus, persistent activation of cAMP pathways may contribute to neoplastic transformation. In this regard, recent studies have shown a tight association between PDE4 expression and cancer cell proliferation, including glioma cells [87], osteosarcomas [88] and chronic lymphocytic leukemia [89]. Furthermore, PDE4 is currently being pursued as a possible chemotherapeutic target [90].

The 5'-flanking/promoter region of PDE4D4 was identified with a 700-bp CpG island that encompassed the transcription/translation start site [85]. Using bisulfite genomic sequencing, a specific methylation cluster was identified in the 5'-flanking region of this PDE4D4 CpG island that was gradually hypermethylated with aging in the normal prostates. It is significant that this age-related PDE4D4 hypermethylation was directly associated with loss of gene expression as determined by real-time RT-PCR. In contrast to normal prostates, the PDE4D4 CpG island became hypomethylated with aging in all prostates exposed neonatally to high or low-dose estradiol or to BPA. Furthermore, this was directly associated with continued elevated PDE4D4 expression throughout life. Cell line studies confirmed that site-specific methylation is involved in transcriptional silencing of the PDE4D4 gene and showed hypomethylation of this gene in the prostate cancer cells. Importantly, PDE4D4 hypomethylation with increased gene expression was distinguishable in all neonatally estrogen/BPA-exposed prostates as early as day 90 of age before any secondary exposure to estrogens had commenced. This raises the pos-




Fig. 3. Proposed model for epigenetic mechanism of developmental estrogenization of the prostate gland by exposures to estradiol, E₂ or environmental disruptors such as BPA. See text for description.

sibility that PDE4D4 could be used as a molecular marker for prostate cancer risk assessment as a result of endocrine disruptors.

8. Summary and conclusions

In summary, we have shown that a full range of estrogenic exposures during the developmental critical period – from environmentally relevant BPA exposure to low-dose and pharmacologic estradiol exposures – results in an increased incidence and susceptibility to neoplastic transformation of the prostate gland in the aging male which may provide a fetal basis for this adult disease. Our working hypothesis is that abnormal estrogenic exposures during developmental critical periods initiate permanent molecular and cellular changes early in life which predispose the prostate to neoplasia in adulthood. Further, our recent findings provides evidence that developmental exposures to environmental endocrine disruptors (such as BPA), pharmacologic and natural estrogens (E_2) impact the prostate epigenome during early life which suggests an epigenomic basis for estrogen imprinting of the prostate gland. Based upon these findings, we propose a model for prostate cancer susceptibility due to developmental estrogen exposures in Fig. 3. As depicted on the time-line, prostate development normally proceeds from fetal initiation and prostatic budding of progenitor cells, to neonatal morphogenesis and cytodifferentiation to pubertal growth and maturation with functional secretions which continue into adulthood. Developmental exposure to estrogens {high-dose pharmacologic exposure, low-dose exposures such as elevated maternal E_2 , or environmentally relevant xenoestrogens (e.g. BPA exposure)} lead to epigenetic changes (altered DNA methylation) which are heritable through subsequent cell divisions. This initially results in the expansion of progenitor cells with differentiation defects as the prostate develops. Subsequent adult insults such as rising E_2 with aging (or injury, inflammation or other mutation-generating events) are then required to promote these initial alterations leading to prostatic dysplasia and tumor-formation with aging.

References

- [1] Jemal A, Siegel R, Ward E, et al. Cancer statistics. *Ca Cancer J Clin* 2006;56(106–130).
- [2] Moore RA. *Endocrinology of neoplastic disease*. New York: Oxford University Press; 1947. p. 194.
- [3] Huggins C, Hodges CF. Studies on prostatic cancer. I. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. *Can Res* 1941;1:293–7.
- [4] Leav I, Ho S, Ofner P, Merk F, Kwan P, Damassa D. Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. *J Natl Cancer Inst* 1988;80(13):1045–53.
- [5] Thomas JA, Keenan EJ. Effects of estrogen on the prostate. *J Androl* 1994;15(2):97–9.
- [6] Modugno FJLW, Trump DL, et al. Allelic variants of aromatase and androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. *Cl Cancer Res* 2001;7:3092–6.
- [7] Raghow S, Hooshdraran MZ, Katiyar S, Steiner MS. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. *Cancer Res* 2002;62:1370–6.
- [8] Steiner MS, Pound CR. Phase IIA clinical trials to test the efficacy and safety of toremifene in men with high-grade prostatic intraepithelial neoplasia. *Clin Prostate Cancer* 2003;2(1):32–3.
- [9] Price D. Comparative aspects of development and structure in the prostate. In: Vollmer EP, editor. *Biology of the prostate and related tissues*. Washington, DC: National Cancer Institute; 1963. p. 1–27.
- [10] Lowsley OS. The development of the human prostate gland with reference to the development of other structures at the neck of the urinary bladder. *Am J Anat* 1912;13:299–348.
- [11] Prins GS. Development of the prostate. In: Haseltine F, Paulsen C, Wang C, editors. *Reproductive issues and the aging male*. New York: Embryonic, Inc.; 1993. p. 101–12.
- [12] Hayashi N, Sugimura Y, Kawamura J, Donjacour AA, Cunha GR. Morphological and functional heterogeneity in the rat prostatic gland. *Biol Reprod* 1991;45:308–21.
- [13] Siiteri PK, Wilson JD. Testosterone formation and metabolism during male sexual differentiation in the human embryo. *JCEM* 1974;38(1):113–25.
- [14] Donjacour AA, Cunha GR. Assessment of prostatic protein secretion in tissue recombinants made of urogenital sinus mesenchyme and urothelium from normal or androgen-insensitive mice. *Endocrinology* 1993;132(6):2342–50.
- [15] Prins GS, Birch L. The developmental pattern of androgen receptor expression in rat prostate lobes is altered after neonatal exposure to estrogen. *Endocrinology* 1995;136(3):1303–14.
- [16] Adams JY, Leav I, Lau KM, Ho SM, Pflueger SM. Expression of estrogen receptor beta in the fetal, neonatal, and prepubertal human prostate. *Prostate* 2002;52(1):69–81.
- [17] Cunha GR, Donjacour AA, Cooke PS, et al. The endocrinology and developmental biology of the prostate. *Endocr Rev* 1987;8(3):338–63.
- [18] Prins GS, Birch L. Neonatal estrogen exposure up-regulates estrogen receptor expression in the developing and adult rat prostate lobes. *Endocrinology* 1997;138(5):1801–9.
- [19] Tilley WD, Horsfall DJ, Skinner JM, Henderson DW, Marshall VR. Effect of pubertal development on estrogen receptor levels and stromal morphology in the guinea pig prostate. *Prostate* 1989;15:195–210.
- [20] Prins GS, Marmer M, Woodham C, et al. Estrogen receptor-b messenger ribonucleic acid ontogeny in the prostate of normal and neonatally estrogenized rats. *Endocrinology* 1998;139(3):874–83.
- [21] Makela S, Strauss L, Kuiper G, et al. Differential expression of estrogen receptors alpha and beta in adult rat accessory sex glands and lower urinary tract. *Mol Cell Endocrinol* 2000;164:109–16.
- [22] Prins GS, Birch L, Couse JF, Choi I, Katzenellenbogen B, Korach KS. Estrogen imprinting of the developing prostate gland in mediated through stromal estrogen receptor α : studies with α ERKO and β ERKO mice. *Cancer Res* 2001;61:6089–97.
- [23] Shapiro E, Huang H, Masch RJ, McFadden DE, Wilson EL, Wu XR. Immunolocalization of estrogen receptor alpha and beta in human fetal prostate. *J Urol* 2005;174(5):2051–3.
- [24] Dohler KD, Wuttke W. Changes with age in levels of serum gonadotropins, prolactin, and gonadal steroids in prepubertal male and female rats. *Endocrine* 1975;97(4):898–907.
- [25] Zondek T, Zondek LH. The fetal and neonatal prostate. In: Goland M, editor. *Normal and abnormal growth of the prostate*. Springfield, IL: Thomas C. Thomas; 1975. p. 5–28.
- [26] Zondek T, Mansfield MD, Attree SL, Zondek LH. Hormone levels in the fetal and neonatal prostate. *Acta Endocr* 1986;112:447–56.
- [27] Wernet N, Kern L, Heitz PH, et al. Morphological and immunohistochemical investigations of the utriculus prostaticus from the fetal period up to adulthood. *Prostate* 1990;17:19–30.
- [28] Rajfer J, Coffey DS. Sex steroid imprinting of the immature prostate. *Invest Urol* 1978;16(3):186–90.
- [29] Santti R, Newbold RR, Makela S, Pytkkanen L, McLachlan JA. Developmental estrogenization and prostatic neoplasia. *Prostate* 1994;24:67–78.
- [30] Henderson BE, Bernstein L, Ross RK, Depue RH, Judd HL. The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. *Br J Cancer* 1988;57(2):216–8.

- [31] Platz EA, Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. *J Steroid Biochem Mol Biol* 2004;92:237–53.
- [32] Ekblom A, Wu J, Adami HO, et al. Duration of gestation and prostate cancer risk in offspring. *Cancer Epidemiol Biomark Prev* 2000;9(2):221–3.
- [33] Ekblom A, Hsieh CC, Lipworth L, et al. Perinatal characteristics in relation to incidence of and mortality from prostate cancer. *Br Med J* 1996;313:337–41.
- [34] Driscoll SG, Taylor SH. Effects of prenatal maternal estrogen on the male urogenital system. *Obstet Gynecol* 1980;56(5):537–42.
- [35] Yonemura CY, Cunha GR, Sugimura Y, Mee SL. Temporal and spatial factors in diethylstilbestrol-induced squamous metaplasia in the developing human prostate. II. Persistent changes after removal of diethylstilbestrol. *Acta Anat* 1995;153:1–11.
- [36] Giusti RM, Iwamoto K, Hatch EE. Diethylstilbestrol revisited: a review of the long-term health effects. *Ann Int Med* 1995;122(10):778–88.
- [37] Arai Y, Mori T, Suzuki Y, Bern HA. Long-term effects of perinatal exposure to sex steroids and diethylstilbestrol on the reproductive system of male mammals. In: Bourne GHAD JF, editor. *International review of cytology*. New York, NY: Academic Press Inc.; 1983. p. 235–68.
- [38] Prins GS, Birch L, Habermann H, et al. Influence of neonatal estrogens on rat prostate development. *Reprod Fertil Dev* 2001;13:241–52.
- [39] Huang L, Pu Y, Alam S, Birch L, Prins GS. Estrogenic regulation of signaling pathways and homeobox genes during rat prostate development. *J Androl* 2004;25(3):330–7.
- [40] McLachlan JA. Environmental signaling: what embryos and evolution teach us about endocrine disrupting chemicals. *Endocr Rev* 2001;22(3):319–41.
- [41] Ho SM, Wang WY, Belmonte J, Prins GS. Developmental exposure to low-dose estradiol or bisphenol A (BPA) increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant (PDE4D4) in the rat prostate. *Cancer Res* 2006;66(11):5624–32.
- [42] Sheehan DM, Young M. Diethylstilbestrol and estradiol binding to serum albumin and pregnancy plasma of rat and human. *Endocrinology* 1979;104(5):1442–6.
- [43] Sheehan DM, Branham WS. Dissociation of estrogen-induced uterine growth and ornithine decarboxylase activity in the postnatal rat. *Teratogen Carcinogen Mutagen* 1987;7(4):411–22.
- [44] Arai Y, Chen CY, Nishizuka Y. Cancer development in male reproductive tract in rats given diethylstilbestrol at neonatal age. *Gann* 1978;69:861–2.
- [45] Pylkkanen L, Makela S, Valve E, Harkonen P, Toikkanen S, Santti R. Prostatic dysplasia associated with increased expression of C-MYC in neonatally estrogenized mice. *J Urol* 1993;149:1593–601.
- [46] Rajfer J, Coffey DS. Effects of neonatal steroids on male sex tissues. *Invest Urol* 1979;17(1):3–8.
- [47] Naslund MJ, Coffey DS. The differential effects of neonatal androgen, estrogen and progesterone on adult rat prostate growth. *J Urol* 1986;136:1136–40.
- [48] Prins GS. Neonatal estrogen exposure induces lobe-specific alterations in adult rat prostate androgen receptor expression. *Endocrinology* 1992;130(6):3703–14.
- [49] Prins GS. Developmental estrogenization of the prostate gland. In: Naz RK, editor. *Prostate: basic and clinical aspects*. Boca Raton: CRC Press; 1997. p. 247–65 [Chapter 10].
- [50] Pu Y, Huang L, Prins GS. Sonic Hedgehog-patched-Gli signaling in the developing rat prostate gland: lobe-specific suppression by neonatal estrogens reduces ductal growth and branching. *Dev Biol* 2004;273:257–75.
- [51] Jarred R, Cancilla B, Prins GS, Thayer K, Cunha GR, Risbridger G. Evidence that estrogens directly alter androgen-regulated prostate development. *Endocrinology* 2000;141(9):3471–7.
- [52] Putz O, Prins GS. Prostate gland development and estrogenic imprinting. In: Burnstein KL, editor. *Steroid hormones and cell cycle regulation*. Boston, MA: Kluwer Academic Publishers; 2002. p. 73–89.
- [53] Chang WY, Wilson MJ, Birch L, Prins GS. Neonatal estrogen stimulates proliferation of periductal fibroblasts and alters the extracellular matrix composition in the rat prostate. *Endocrinology* 1999;140(1):405–15.
- [54] Birch L, Prins GS. Neonatal estrogens induce epithelial apoptosis in the developing rat prostate through inhibition of the PI3K-Akt pathway. In: The endocrine society's 85th annual meeting, vol. 405. Philadelphia, PA: The Endocrine Society Press; 2003 [Abstract # P2–6].
- [55] Chang WY, Birch L, Woodham C, Gold LJ, Prins GS. Neonatal estrogen exposure alters the transforming growth factor- β signaling system in the developing rat prostate and blocks the transient p21^{cip1/waf1} expression associated with epithelial differentiation. *Endocrinology* 1999;140(6):2801–13.
- [56] Habermann H, Chang WY, Birch L, Parmender M, Prins GS. Developmental exposure to estrogens alters epithelial cell adhesion and gap junction proteins in the adult rat prostate. *Endocrinology* 2001;142:359–69.
- [57] Hayward S, Rosen M, Cunha G. Stromal–epithelial interactions in the normal and neoplastic prostate. *Br J Urol* 1997;79(Suppl 2):18–26.
- [58] Prins GS, Woodham C, Lepinske M, Birch L. Effects of neonatal estrogen exposure on prostatic secretory genes and their correlation with androgen receptor expression in the separate prostate lobes of the adult rat. *Endocrinology* 1993;132(6):2387–98.
- [59] Woodham C, Birch L, Prins GS. Neonatal estrogens down regulate prostatic androgen receptor levels through a proteasome-mediated protein degradation pathway. *Endocrinology* 2003;144(11):4841–50.
- [60] Prins GS, Chang WY, Wang Y, van Breemen RB. Retinoic acid receptors and retinoids are up-regulated in the developing and adult rat prostate by neonatal estrogen exposure. *Endocrinology* 2002;143(9):3628–40.
- [61] Prins GS, Huang L, Birch L, Pu Y. The role of estrogens in normal and abnormal development of the prostate gland. *Ann NY Acad Sci* 2006;1089(December), in press.
- [62] Sreenath T, Orosz A, Fujita K, Bieberich CJ. Androgen-independent expression of hoxb-13 in the mouse prostate. *Prostate* 1999;41(3):203–7.
- [63] Economides KD, Capecchi MR. *Hoxb13* is required for normal differentiation and secretory function of the ventral prostate. *Development* 2003;130:2061–9.
- [64] Bieberich CJ, Fujita K, He WW, Jay G. Prostate-specific and androgen-dependent expression of a novel homeobox gene. *J Biol Chem* 1996;271(50):31779–82.
- [65] Schiavolino PJ, Abrams EW, Yang L, Austenberg LP, Shen MM, Abate-Shen C. Tissue-specific expression of murine Nkx3.1 in the male urogenital system. *Dev Dyn* 1997;209:127–38.
- [66] Hogan BLM. Morphogenesis. *Cell* 1999;96:225–33.
- [67] Podlasek J, Clemens JQ, Lee J, Bushman W. Bone morphogenetic protein-4 is a negative regulator of prostate ductal branching. *J Urol* 1999;161(4):125.
- [68] Huang L, Pu Y, Alam S, Birch L, Prins GS. The role of Fgf10 signaling in branching morphogenesis and gene expression in the rat prostate gland: lobe-specific suppression by neonatal estrogens. *Dev Biol* 2005;278:396–414.
- [69] vom Saal FS, Timms BG, Montano MM, et al. Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. *Proc Natl Acad Sci USA* 1997;94:2056–61.
- [70] Timms BG, Howdeshell KL, Barton L, Bradley S, Richter CA, vom Saal FS. Estrogenic chemicals in plastic and oral contraceptives disrupt development of the fetal mouse prostate and urethra. *Proc Natl Acad Sci* 2005;102(19):7014–9.
- [71] Ashby J, Tinwell H, Haseman J. Lack of effects for low dose levels of bisphenol A and diethylstilbestrol on the prostate gland of CF-1 mice exposed in utero. *Regul Toxicol Pharmacol* 1999;30:156–66.
- [72] Melnick R, Lucier G, Wolfe M, et al. Summary of the National Toxicology Program's Report on the endocrine disruptors low-dose peer review. *Environ Health Perspect* 2002;110(4):427–31.
- [73] vom Saal FS, Hughes C. An extensive new literature concerning low-dose effects of bisphenol A shows the need for a new risk assessment. *Environ Health Perspect* 2005;113(8):926–33.
- [74] Putz O, Schwartz CB, Kim S, LeBlanc GA, Cooper RL, Prins GS. Neonatal low- and high-dose exposure to estradiol benzoate in the male rat. I. Effects on the prostate gland. *Biol Reprod* 2001;65:1496–505.
- [75] Putz O, Schwartz CB, LeBlanc GA, Cooper RL, Prins GS. Neonatal low- and high-dose exposure to estradiol benzoate in the male rat. II. Effects on male puberty and the reproductive tract. *Biol Reprod* 2001;65:1506–17.
- [76] Newbold RR, Jefferson WN, Padilla-Banks E, Haseman J. Developmental exposure to diethylstilbestrol (DES) alters uterine response to estrogens in prepubescent mice: low versus high dose effects. *Reprod Toxicol* 2004;18(3):399–406.

- [77] Munoz-de-Toro M, Markey CM, Wadia PR, et al. Perinatal exposure to bisphenol-A alters peripubertal mammary gland development in mice. *Endocrinology* 2005;146(9):4138–47.
- [78] Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. *Endocr Rev* 2005;26(6):833–76.
- [79] Lee C, Prins GS, Henneberry MO, Grayhack JT. Effect of estradiol on the rat prostate in the presence and absence of testosterone and pituitary. *J Androl* 1981;2(6):293–9.
- [80] Bosland MC, Ford H, Horton L. Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague–Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 β or diethylstilbestrol. *Carcinogenesis* 1995;16(6):1311–7.
- [81] Prins GS, Tang W, Belmonte de Frausto J, Ho SM. Developmental exposure to estradiol or bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase 4. *Cancer Res* 2006;66(11):5624–32.
- [82] Li S, Washburn KA, Moore R, et al. Developmental exposure to diethylstilbestrol elicits demethylation of estrogen-responsive lactoferrin gene in mouse uterus. *Cancer Res* 1997;57(19):4356–9.
- [83] Lyn-Cook BD, Blann E, Payne PW, Bo J, Sheehan D, Medlock K. Methylation profile and amplification of proto-oncogenes in rat pancreas induced with phytoestrogens. *Proc Soc Exp Biol Med* 1995;208(1):116–9.
- [84] Alworth LC, Howdeshell KL, Ruhlen RL, et al. Uterine responsiveness to estradiol and DNA methylation are altered by fetal exposure to diethylstilbestrol and methoxychlor in CD-1 mice: effects of low versus high doses. *Toxicol Appl Pharmacol* 2002;183(1):10–22.
- [85] Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. *J Biol Chem* 2003;278(8):5493–6.
- [86] Fimia GM, Sassorne-Corsi P. Cyclic AMP signalling. *J Cell Sci* 2001;114:1971–2.
- [87] Chen TC, Wadsten P, Su S, et al. The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells. *Cancer Biol Ther* 2002;1(3):268–76.
- [88] Narita M, Murata T, Shimizu K, et al. Phosphodiesterase 4 in osteoblastic osteosarcoma cells as a potential target for growth inhibition. *Anticancer Drugs* 2003;14(5):377–81.
- [89] Lerner A, Kim DH, Lee R. The cAMP signaling pathway as a therapeutic target in lymphoid malignancies. *Leuk Lymph* 2000;37(1/2):39–51.
- [90] Hirsh L, Dantes A, Suh B-S, et al. Phosphodiesterase inhibitors as anti-cancer drugs. *Biochem Pharmacol* 2004;68:981–8.

Review

Techniques used in studies of epigenome dysregulation due to aberrant DNA methylation: An emphasis on fetal-based adult diseases

Shuk-mei Ho^{a,b,*}, Wan-ye Tang^a

^a Department of Environmental Health, College of Medicine, University of Cincinnati, Cincinnati, OH, USA

^b Cancer Center, College of Medicine, University of Cincinnati, Cincinnati, OH, USA

Received 2 September 2006; received in revised form 4 January 2007; accepted 8 January 2007

Available online 19 January 2007

Abstract

Epigenetic changes are heritable modifications that do not involve alterations in the primary DNA sequence. They regulate crucial cellular functions such as genome stability, X-chromosome inactivation, and gene imprinting. Epidemiological and experimental observations now suggest that such changes may also explain the fetal basis of adult diseases such as cancer, obesity, diabetes, cardiovascular disorders, neurological diseases, and behavioral modifications. The main molecular events known to initiate and sustain epigenetic modifications are histone modification and DNA methylation. This review specifically focuses on existing and emerging technologies used in studying DNA methylation, which occurs primarily at CpG dinucleotides in the genome. These include standard exploratory tools used for global profiling of DNA methylation and targeted gene investigation: methylation sensitive restriction fingerprinting (MSRF), restriction landmark genomic scanning (RLGS), methylation CpG island amplification-representational difference analysis (MCA-RDA), differential methylation hybridization (DMH), and cDNA microarrays combined with treatment with demethylating agents and inhibitors of histone deacetylase. The basic operating principals, resource requirements, applications, and benefits and limitations of each methodology are discussed. Validation methodologies and functional assays needed to establish the role of a CpG-rich sequence in regulating the expression of a target or candidate gene are outlined. These include *in silico* database searches, methylation status studies (bisulfite genomic sequencing, COBRA, MS-PCR, MS-SSCP), gene expression studies, and promoter activity analyses. Our intention is to give readers a starting point for choosing methodologies and to suggest a workflow to follow during their investigations. We believe studies of epigenetic changes such as DNA methylation hold great promise in understanding the early origins of adult diseases and in advancing their diagnosis, prevention, and treatment.

© 2007 Elsevier Inc. All rights reserved.

Keywords: Cytosine methylation; Chromatin remodeling; Fetal-based adult disease; Epigenetics; Genome-wide methylation profiling; Methylation sensitive restriction fingerprinting; Restriction landmark genomic scanning (RLGS)

Contents

1. DNA methylation as an epigenetic mechanism of fetal-based adult diseases	268
1.1. Epigenetic modulation of fetal programming	268
1.2. DNA methylation: chemistry, developmental dynamics, and proposed functions	269
1.3. DNA methylation in fetal basis of adult disease	270
2. Techniques and methods	270
2.1. Methods for identification of candidates	271
2.1.1. Methylation sensitive restriction fingerprinting (MSRF)	271
2.1.2. Restriction landmark genomic scanning (RLGS)	272
2.1.3. Methylation CpG island amplification-representational difference analysis (MCA-RDA)	272

* Corresponding author. Tel.: +1 513 558 5701; fax: +1 513 558 0071.

E-mail address: shuk-mei.ho@uc.edu (S.-m. Ho).

2.1.4.	Differential methylation hybridization (DMH) using CGI arrays	273
2.1.5.	Bisulfite sequencing	274
2.1.6.	Methylation-specific oligonucleotide (MSO)/methylation target microarrays	274
2.1.7.	Transcriptional profiling of genes reactivated by demethylating agents or inhibitors of histone deacetylation	275
2.1.8.	Genome-wide methylation array/promoter arrays	275
2.1.9.	Chromatin immunoprecipitation (ChIP) on DNA microarray (ChIP-chip)	275
2.1.10.	Luminometric methylation assay (LUMA) using pyrosequencing	276
2.1.11.	Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS)/high-performance liquid chromatography (HPLC)	276
2.2.	Characterization of a target or candidate sequence and validation of its involvement in gene regulation	277
2.2.1.	<i>In silico</i> database analysis	277
2.2.2.	Validation assays of gene of interest	278
3.	Discussion	278
	Acknowledgments	279
	References	279

1. DNA methylation as an epigenetic mechanism of fetal-based adult diseases

1.1. Epigenetic modulation of fetal programming

Past research has identified mutations, deletions, gene fusion, tandem duplications, and gene amplifications as key mechanisms that dysregulate expression of disease-predisposing or disease-determining genes at the linear DNA level [1–7]. However, it has become clear that disruption of epigenetic regulation of gene expression plays an equally important role in the development of diseases [8–10].

The term *epigenetic* means *outside conventional genetics* [11]. Epigenetic changes are reversible, heritable modifications that do not involve alterations in the primary DNA sequence. Three distinct and intertwined mechanisms are now known to initiate and sustain epigenetic modifications: small-interfering RNAs, DNA methylation, and histone modification [12–14]. These processes affect transcript stability, DNA folding, nucleosome positioning, chromatin compaction, and ultimately nuclear organization. Singularly or conjointly, they determine whether a gene is silenced or activated. Dysregulation of these processes certainly is the possible mechanism underpinning the epigenetic basis of disease development [8,9]. Disease susceptibility, therefore, is a result of a complex interplay between one's genetic endowment and epigenetic modulations induced by endogenous or exogenous environmental cues.

Epigenetic modifications of disease risk could begin as early as during fetal development and be transmitted transgenerationally [15–20]. The paradigm of fetal basis of adult disease first emerged from large-cohort epidemiological studies linking poor growth *in utero* with adult diseases [16,21,22]. During pregnancy, maternal conditions such as nutritional deficits, infection, hypertension, diabetes, or hypoxia expose the fetus to hormonal and metabolic cues that induce “fetal programming.” It alters the courses of cellular and organ differentiation *in utero* and permanently affects the functional capacity of adult organs in later stages of life [15,22]. From an evolutionary perspective, fetal programming is an “adaptive” trait since it allows the fetus to make anticipatory responses to the external environment to

gain advantages for later life challenges. However, contemporary human life is greatly influenced by lifestyle choices that are in conflict with the programmed adaptive changes made during fetal development. In addition, synthetic agents that mimic internal cues can alter the course of fetal programming adversely. Both could cause insufferable consequences in later life, leading to heightened disease susceptibility. Classical examples include the association of lower birth weight with a greater risk for adult onset of cardiovascular disease [23], Type 2 diabetes mellitus [24], osteoporosis [25], and depression [26]. The link between exposure to the synthetic estrogen diethylstilbestrol (DES) *in utero* and increased incidence of reproductive tract cancers in “DES daughters” has been a difficult lesson learned by the health care community [27]. Genetic factors, such as telomere attrition [28] and polymorphisms in mitochondrial DNA [29], may in part mediate fetal programming. However, epigenetic dysregulation of gene expression is currently a widely accepted mechanism of fetal-based adult disease [15–20].

The two main epigenetic mechanisms currently recognized as playing a role in the fetal basis of adult disease are histone modification and DNA methylation [15–20]. A comprehensive review of how these processes affect gene transcription is beyond the scope of this review. In simple terms, the histone modification refers to post-translational modifications of histone tails, while DNA modification involves methylation of cytosine at the carbon-5 position in CpG dinucleotides. The two processes work together to affect chromatin packaging of DNA, which, in turn, determines which gene or gene set is transcribable. Changes mediated by either process are heritable, not only transmittable to the daughter cells, but to subsequent generations [19,30]. Thus, interest in the field of epigenetic control of fetal-based disease has increased dramatically within the last few years. Our intention with this review is to give readers a starting point for choosing methodologies and a workflow to follow during their investigations. The past decade has witnessed an exponential increase in novel approaches to the conduct of epigenetic analysis [31]. Methodologies applicable for the investigation of histone modifications have recently been reviewed [13]. This review will focus primarily on contemporary methods designed

to elucidate DNA methylation—regulated gene expression as a mechanism of early origins of adult diseases.

1.2. DNA methylation: chemistry, developmental dynamics, and proposed functions

DNA methylation refers to the covalent addition of a methyl group derived from *S*-adenosyl-L-methionine to the fifth carbon of the cytosine ring to form the fifth base, 5-methyl cytosine (5mC; Fig. 1) [32,33]. The reaction is catalyzed by DNA methyltransferases and accessory proteins (Dnmt1, Dnmt3a, Dnmt3b, Dnmt2, and Dnmt3L). Across eukaryotic species, methylation occurs predominantly in cytosines located 5' of guanines, known as CpG dinucleotides (CpGs), although methylation also takes place in non-CpGs such as CpNpG and nonsymmetrical CpA and CpT at a lower frequency.

In the mammalian genome, the distribution of CpG sequences is nonrandom [34]. Because of the high susceptibility of 5mC to undergo spontaneous deamination to yield thymine (Fig. 1), the mammalian genome has become progressively depleted of CpGs through the course of evolution. CpGs are normally under-represented, appearing at a low frequency of 1 per 80 dinucleotides in 98% of the mammalian genome. In contrast, CpGs are found as clusters known as CpG islands (CGIs) in 1–2% of the genome. Typically, a CGI ranges in length from 200 bp to 5 kb, has a high percentage of CG (>60%), and a ratio of CpG to GpC of at least 0.6. CGIs are normally unmethylated and presumably protected from spontaneous deamination. Important exceptions to the unmethylated status of CGIs include those that are associated with imprinted genes, genes subject to X-chromosome inactivation, and transposable elements [33,35]. About 70% of CGIs are associated with DNA sequences 1- to 2-kb long located in the promoter, the first and second exons, and the first intron regions of all genes (5' CGIs) [36]. Most 5' CGIs are found overlapping with the transcription start site, suggesting that they are important for gene regulation.

It has been proposed that over half of the 5' CGIs participate in the regulation of gene transcription [33,35], although, it is important to note, not all CGIs are involved in gene regulation. An inverse relationship usually exists between the extent of methylation of a regulatory CGI and gene transcription [35]. Two mechanisms have been proposed to explain how cytosine methylation leads to repression of gene transcription [33]. First, the methyl group of the 5mC extends into the major groove of DNA and inhibits binding of transcription factors (TFs) to their CpG-containing recognition sites. Second, a class of proteins known as methyl-binding proteins (MBDs) specifically bind methylated CGIs and create steric hindrance to access by TFs to their regulatory elements. Both scenarios will suppress gene transcription. Furthermore, upon binding to methylated CGIs, MBDs recruit histone deacetylases (HDACs) and histone methyltransferases (HMTs). These enzymes mediate complex histone modifications and result in the establishment of repressive chromatin structures that permanently silent gene transcription [35,37].

DNA methylation is viewed, at the global level, as a generalized repression system in more complex genomes [38]. It is thought to repress inappropriate expression of endogenous transposons that may disrupt the organization and integrity of the genome and to be the key mechanism responsible for X-chromosome inactivation and genomic imprinting [33,35]. Recent evidence suggests that DNA methylation plays a crucial role in the establishment and/or maintenance of cell- or tissue-specific gene expression in adult somatic tissues.

DNA methylation pattern is established through defined phases during the development of an organism. Gamete methylation patterns are erased by a genome-wide demethylation at around the eight-cell stage of blastocyst formation. During the implantation stage, methylation patterns are established via *de novo* methylation. In adulthood, the amount and pattern of methylation are tissue- and cell-type specific. Disruption of these preset patterns of DNA methylation in adult life has been linked to aging and disease development [39–41]. Furthermore, dereg-




Fig. 1. DNA methylation machinery and transcriptional repression. (A) Diagrams showing the biochemical pathways for cytosine methylation, demethylation, and mutagenesis of cytosine and 5-metC [33]. DNA methylation by addition of a methyl group to carbon 5 position of the cytosine ring is catalyzed by DNA methyltransferases (DNMTs), and demethylation is catalyzed by demethylase. 5-Methyl cytosine (5mC) undergoes hydrolytic deamination to thymidine. Mutation at CpG occurs because 5mC is more susceptible than cytosine to deamination and because some of the T-G mismatches produced by deamination are poorly repaired. (B) Methylation at cytosine of DNA blocks transcription. Singal and Ginder have proposed three mechanisms of how methylation inhibits gene transcription [33]. Details are in the text.

ulation of fetal programming by suboptimal maternal factors or environmental mimics is now believed to involve abnormal DNA methylation of specific genes that permit them to undergo either inappropriate or untimely expression in adult life, leading to disease development. Recent and limited evidence supports this as a key mechanism of the fetal basis of adult disease (see below).

1.3. DNA methylation in fetal basis of adult disease

Several lines of direct and indirect evidence support the hypothesis that DNA methylation is a key mechanism mediating fetal-based adult disease development. Fetal exposure of agouti mice to methyl donors (folic acid, choline, and betaine), which is expected to induce global DNA methylation changes, causes shifts in the coat color from yellow to brown and reduces the risk of obesity, diabetes, and cancer [42]. Global gene profiling identified altered expression of 27 genes with regulatory 5' CGIs in mice born to mothers on a choline-deficient diet [43]. These mice also exhibited abnormal hippocampal development and loss of memory function in adult life.

McLachlan and associates [44] provided the first evidence in support of the effects of early-life exposure on DNA methylation of specific genes that may show dysregulated expression in disease target organs later in life. These investigators found a high incidence of uterine cancer and elevated expression of *c-fos* and *lactoferrin* genes in mice exposed neonatally to diethylstilbestrol (DES) [45]. In concordance with epigenetic regulation of gene expression as a underpinning the early origin of adult disease, these investigators reported demethylation of a single CpG site in the lactoferrin promoter and hypomethylation of the promoter and intron-1 regions of *c-fos* in the uterus of adult mice exposed neonatally to DES [46]. In a multi-generations study, Skinner and associates [19,47] demonstrated induction of 15 imprinted-like genes/DNA sequences with altered methylation patterns in sperm obtained from mice exposed developmentally to vinclozolin. Importantly, the altered methylation patterns in these sequences persist in sperm of subsequent non-exposed generations. Although these findings did not provide a direct link between changes in methylation status of the susceptible genes and disruption of their expression in later life, they are highly suggestive that such a relationship exists. More direct evidence linking epigenetic re-programming via DNA methylation and aberrant gene expression in adult tissues and altered disease susceptibility was provided by a recent study showing increased prostate cancer risk in rats exposed neonatally to bisphenol A or estradiol [20]. In this study, the investigators demonstrated concomitant, aberrant overexpression of *phosphodiesterase 4 variant 4 (PDE4D4)* and hypomethylation in a 5' CGI of *PDE4D4* in the prostate of rats exposed early in life to the estrogen and its mimic. Additional cell-culture experiments further substantiated the claim for this interrelationship.

Since the fetal basis of adult disease is a rapidly growing field, it would be timely to provide a comprehensive review of methods and techniques available to interested investigators. It is our intention to provide readers with a starting point in their choice of methodologies and a workflow to follow during

their investigations. The basic operating principals, resource requirements, applications, and benefits and limitations of each methodology are discussed below. Validation methodologies and functional assays necessary to establishing the role of a CpG-rich sequence in regulating the expression of a target or candidate gene are briefly outlined. We recognize that this is a rapidly growing field, with many innovative methodologies and approaches emerging daily, and thus that it will be impossible for us to cover this topic exhaustively.

2. Techniques and methods

In this review, we will outline methodologies that would allow investigators to globally discover CpGs or CGIs that are differentially methylated in different tissues/cells or under different experimental conditions. Many of the methods are also applicable to investigations in which researchers already have target genes in mind. In the course of describing methodologies, we will first introduce the operating principals, then give examples of applications, and finally discuss the benefits and limitations for each technique. Table 1 summarizes some of the key features of each methodology and their advantages and limitations for easy reading and for facilitating decision-making regarding the choice of a methodology for a particular study.

To identify candidates under methylation regulation and to determine whether a newly identified CGI is involved in gene regulation, one needs undertake a comprehensive and vigorous investigative approach (Fig. 2). The typical experimental workflow for a discovery platform involves: (1) identification of candidates through genome-wide screening methods, (2) in




Fig. 2. The work-flow chart outlines how to discover the methylated genes in a step-by-step manner. First, one of the methylation profiling techniques is used to pool out several candidate clones showing differential methylation patterns. After subcloning and sequencing, candidate clones are identified by aligning sequences into BLAST (from NCBI) or BLAT (from UCSC) database. Next, *in silico* database analysis, such as promoter and CpG island search on the candidate clones, is done to characterize the gene structure and design primers for subsequent data validation assays. Several methods, such as RT-PCR, Western blotting analysis, bisulfite sequencing (BS), methylation-specific PCR (MS-PCR), combined bisulfite restriction analysis (COBRA), methylation-specific single strand conformation polymorphism (MS-SSCP), and MethyLight, are used to validate the methylation level and gene expression of the target genes. If target genes are ready the methylation studies, it is not necessary to start from the first step. Methylation studies start from any step, depending on the researcher's needs.

Table 1
Advantages and limitations of different approaches to methylation profiling

Methods	Global/gene specific	Sample amount	Advantages	Limitations	Examples
MSRF	Global	100 ng–1 µg	Simple set-up Screen for novel genes	Small scale	[20,49]
RLGS	Global	1–5 µg	High-throughput	Landmark site only Special gel electrophoresis set-up Software is not available for every species	[59–61]
MCA-RDA	Gene specific Global (RDA)	5 µg	High-throughput CpG islands specific	Need of prior knowledge of sequences (except RDA)	[63–65]
DMH/MSO	Gene specific	2 µg	High-throughput CpG islands specific	Need of prior knowledge of sequences	[71,81]
CGI/ChIP-chip Promoter array	Global	1–10 µg	High-throughput	High cost Platform specific Not popular	[79] [106,107]
LUMA	Global/gene specific	200–500 ng	High-throughput	Relative high cost Platform specific Limited length of sequence	[108,112,113]
MALDI-TOF/HPLC	Gene specific	10 ng–1 µg	High-throughput	Relative high cost Platform specific Still in stage of optimization of the protocol Mostly on specific target gene	[123,130] [131,132]

silico database analyses to shortlist candidates that contain 5' CGIs or CpGs, (3) confirmation of changes in methylation status in the candidate CpGs under the expected experimental conditions, (4) establishment of a causal or correlative relationship between increased cytosine methylation and gene silencing, and (5) other supportive functional assays to uncover the functionality of the cognate genes. However, if a target gene is to be studied, the entry point could begin at step (2). All the subsequent steps are applicable for target-gene studies.

2.1. Methods for identification of candidates

Currently, there is a wide range of approaches to obtaining quantitative and qualitative information on changes in genomic DNA methylation. Several standard exploratory tools, including methylation sensitive restriction fingerprinting (MSRF), restriction landmark genomic scanning (RLGS), methylation CpG island amplification-representational difference analysis (MCA-RDA), differential methylation hybridization (DMH), methylation-specific oligonucleotide microarrays (MSO), methylation target array (MTA), and cDNA microarrays combined with treatment of demethylating agents, are routinely used to identify putative regulatory CGIs at the genome-wide level, as well as to analyze methylation status of specific CGIs of known genes in large sample sets. Other

advanced techniques, such as chromatin immunoprecipitation (ChIP)-on chips, polymerase extension assay by pyrosequencing, mass spectrometry, and HPLC, have emerged as high-throughput methods for obtaining information of CpG methylation outside/inside CGIs. These techniques also have the potential for being used in a whole-genome screen.

2.1.1. Methylation sensitive restriction fingerprinting (MSRF)

MSRF (Fig. 3) is a sensitive PCR-based method that allows one to screen for novel CpG-rich sequences that exhibit differential changes in cytosine methylation under different physiological or pathological conditions [48]. Multiple samples can be compared simultaneously. Genomic DNA isolated from tissues is subjected to *MseI* restriction digestion. Since the restriction site of *MseI* is TTAA, which is rarely found in CG-rich regions, cellular DNA is digested into small fragments, leaving most of the CG-rich region intact. The *MseI*-digested DNA is then divided into two aliquots with one aliquot left unmodified and the other subjected to digestion with *BstUI*, a methylation-sensitive restriction enzyme. *BstUI* cuts at CGCG, a sequence that occurs in more than 80% of CGIs, and therefore will cut most CG-rich regions unless they are protected by methylation. Short DNA sequences with methylated *BstUI* sites are left uncut and can subsequently be amplified by PCRs, whereas sequences with




Fig. 3. Principle of methylation sensitive restriction fingerprinting (MSRF). (A) Methylated cellular DNA that will be digested by enzymes *MseI* and *BstUI* and DNA with an intact methyl group can be amplified in PCR. (B) A schematic diagram depicting expected results. In this comparison, the methylation status was defined by comparing samples A and B. If there is no difference in methylation status, no difference in methylation status will be observed for both cases. If that candidate is being methylated in sample A, none of the *BstUI* sites in the CpG-rich sequence will be digested and they can be amplified in PCR. If vice versa, DNA fragments will be absent in the lane of sample A (*MseI/BstUI*) if this candidate is unmethylated in sample A.

unmethylated *Bst*UI sites are cut and will not yield any PCR products. Aliquots of the single (*Mse*I)- or double (*Mse*I and *Bst*UI)-digested DNA are then subjected to PCR amplification using different pairs of short arbitrary primers (10mer with at least one CG site in the primer) [48] in the presence of radiolabeled [³²P]-dNTPs. Labeled PCR products are size-fractionated on 6% polyacrylamide gels. “Candidates” with differentially methylated patterns among different samples are visualized with autoradiography, which is used to guide excision of “candidates” from the dried sequencing gels. Amplification and sequencing of the candidates followed by sequence database analyses reveal the identities of the candidates and possibly their innate genes.

We have successfully used MSRF to globally profile the prostate epigenome for genes whose promoter/5′ CGIs undergo aberrant cytosine methylation following neonatal exposure to estrogens or bisphenol A [20]. Among the initial 50 candidate sequences identified, three were confirmed to be part of the promoter regions of genes regulated by methylation. One of the genes, phosphodiesterase 4D4, was further characterized for its functional role in modulating prostate cancer risk in adulthood [20]. In an earlier study [49], using a similar approach, we identified hypermethylation of peroxisome membrane protein 24 as a marker/modifier for the transition of prostate cancer cells from an androgen-dependent to an androgen-independent state. Others have used this method to identify genes whose promoters are aberrantly methylated in breast cancers [48], nasopharyngeal carcinoma [50], and hepatocellular carcinoma [51]. This method has also been used to identify novel epigenetically modified candidates during stem cell differentiation [52].

With radiolabeling of PCR products, only a small amount of genomic DNA from each sample is required (100 ng–1 μg) (Table 1). Therefore, this method is highly applicable to studies using laser-capture microdissected samples or for developmental studies in which tissue availability is a key concern. Usually products from 4–8 sets of arbitrary primers are run on each gel and only a limited number of candidates (30–40) can be identified in one autoradiograph. The ease of setting up MSRF for methylation profiling of multiple samples is definitely an advantage of this methodology, since it only requires the use of a simple sequencing gel set-up, standard PCR protocols, and routine amplification and sequencing techniques. By increasing the number of arbitrary primers used in MSRF, one can increase the coverage of the genome and the number of candidate sequences identified. For example, in two of the experiments we have conducted [20,49], both using 4 primers and 6 permutations of primer pairs, we identified approximately 50 candidate sequences. However, if 9 primers were to be used, a total of 40 [$n \times (n - 1)/2$; n is the number of primers] permutations for arbitrary PCRs could be achieved, likely yielding over 1400 candidates.

2.1.2. Restriction landmark genomic scanning (RLGS)

The RLGS approach was first developed to identify imprinting genes [53] and later adapted for genome-wide screening of methylation changes in CGIs (Fig. 4). It can evaluate the methylation status of thousands of CG-rich sequences and simultaneously obtain information on copy number of their cognate genes [53–56]. Methylation detection in RLGS profiles depends on the methylation sensitivity of the restriction enzymes used to cut the genomic DNA. *Not*I, which recognizes GC-rich sequences, is most commonly used to generate thousands of landmark sites on the gel. Differences in digestion are assessed by radiolabeling the DNA at cleaved *Not*I sites. Following further endonuclease digestion, two-dimensional electrophoretic separation, and autoradiography, the intensity of a DNA fragment on the resulting RLGS profile quantitatively reflects the copy number and methylation status of the *Not*I fragment (Fig. 4). Early applications of RLGS for identification of novel differentially methylated genes were hampered by the tedious task of having to obtain sequence information on the identified sequences. With the completion of several commonly used genome databases (human and mouse), development of interactive informatics tools, and tailored software programs, it is now possible to conduct automated RLGS fragment prediction and to download corresponding sequences for mouse [57] and human studies [58]. Users can directly upload or query RLGS databases at <http://genome.gsc.riken.go.jp/RLGS/RLGSHome.html> or <http://dot.ped.med.umich.edu:2000/VGS/index.html>.

RLGS has been used to analyze epigenetic changes due to aberrant DNA methylation for breast cancer [59], ovarian cancer [60], and hepatocellular carcinoma [61]. Recently, Sato and co-workers applied this method to illustrate the aberrant methylation of genomic DNA in the epididymis of mice neonatally exposed to DES [62]. Seven loci of the genomic DNA were found to be




Fig. 4. Diagram showing the procedures of restriction landmark genomic scanning (RLGS). Methylation detection in the RLGS profile depends on the methylation sensitivity of *Not*I. *Not*I, which recognizes CG-rich regions and cannot cleave DNA sequences when 5-cytosine is methylated, acts as the landmark in the profiles. Three types of methylation status are expected, depending on which allele is methylated. m*Not*I represents the methylated site of the enzymes. Following further endonuclease digestion of *Eco*RV (1D gel electrophoresis) and *Hin*fI (2D gel electrophoresis), the RLGS profile will result in a change in spot intensity that quantitatively reflects the copy number and methylation status of the *Not*I fragment.

aberrantly demethylated, and one locus in the epididymis of DES-treated mice was found to be methylated. Among these putative candidates, four were confirmed to have promoter or 5′ CGIs. However, additional experiments necessary to establish the regulatory role of these CGIs on their cognate gene expression were not included in this study. This omission of validation experiments has prevented the authors from drawing definitive conclusions on the significance of DNA methylation changes in these CG-rich sequences or their cognate genes in mediating DES-induced abnormalities in this organ.

An obvious advantage of RLGS is its ability to identify thousands of loci/landmark fragments in a single run (Table 1). With continued improvements on the various RLGS sequence databases, sequence identification of the loci should no longer be a limitation of this methodology. At least for human and mouse studies, the current automated RLGS fragment prediction programs and sequence databases are quite adequate, yet challenges still exist for studies using samples from other species. Furthermore, since the methodology requires at least a few micrograms of DNA, sample availability may be a limitation for some investigations. Other demands for successful utilization of RLGS are the requirements for a fairly elaborate gel electrophoresis set-up and a powerful image analysis system. Finally, limited library coverage is another constraint for this approach unless new advanced genome sequence-based tools are developed in the future.

2.1.3. Methylation CpG island amplification-representational difference analysis (MCA-RDA)

Methylated CGI amplification (MCA) coupled with representational difference analyses (RDA) [63,64] provides a powerful approach [65] for simultaneous identification and cloning of novel differentially methylated sequences between two samples (Fig. 5). The fundamental principle of MCA involves amplification of DNA sequences with closely spaced (<1 kb)




Fig. 5. Schematic diagram for methylation CpG island amplification (MCA) coupled with representational difference analysis (RDA). CpG sites are labeled as 1 to 4. In the comparison of the methylation status of sample A and sample B, CpG site 2 is methylated in both cases whereas CpG site 4 is methylated only in sample A. For MCA, unmethylated CpGs are digested by methylation-sensitive restriction enzyme (*SmaI*), resulting in the formation of the blunt end fragments. Those methylated CpGs are then digested with *XmaI* and generate sticky end fragments. Following ligation into linker and PCR amplification, amplicons of short sequences can then be directly hybridized to enable study of the methylation status of the gene of interest for which a probe is available. As shown in the figure, differential methylation of CpG sites 2 and 4 between samples A and B can be found in dot-blot analysis. Besides, MCA amplicons (i.e., fragments containing CpG site 4) showing differential methylation status in sample A can be cloned by RDA to identify any novel candidates.

methylated *SmaI* (CCCGGG) sites, which are commonly found in CGIs. Since only short fragments (400–600 bp) flanked by two *SmaI* sites are amplified, MCA ensures enrichment of CGIs [65]. A pair of enzymes, *SmaI* (methylation-sensitive) and *XmaI* (methylation insensitive), that cut the same recognition sequence CCCGGG are used in the protocol (Fig. 5). The two DNA samples under investigation are first subjected to *SmaI* digestion to remove unmethylated *SmaI* sites, generating only blunt end fragments in DNA regions that with no methylated *SmaI* sites; i.e., hypomethylated CGI regions. These blunt end sequences will not be amplified by subsequent steps of the protocol and thus are eliminated from the DNA pools. The samples are then digested with the *SmaI* isoschizomer *XmaI*, which cuts at methylated *SmaI* sites, generating fragments with a four-base overhang. Adaptors are ligated to this overhang before the fragments are amplified by PCR using primers complementary to the adaptors. Southern or dot blotting analysis is employed to determine if a candidate CGI is differentially methylated among samples.

To identify novel CGIs that are differentially methylated in two different samples, RDA, a subtraction technique developed to clone small differences between genomes [63], is used following MCA, a technique referred to as MCA-RDA. The RDA technique is based on subtraction of “tester” sequences from the “driver” pool of sequences, followed by PCR amplification of the tester sequences left un-hybridized. Differentially present clones, after the subtraction, are identified by subcloning and sequencing.

MCA-RDA was first used to identify novel hypermethylated CGIs in colorectal cancer [65]. More recently, several groups have used this method to identify genomic clones that are hypermethylated in microsatellite instability-positive sporadic colorectal cancers [66], hypermethylated DNA fragments as putative biomarkers of prostate cancer [67], and hypermethylated sequences uniquely expressed in pancreatic carcinoma but not in normal pancreatic cells [68].

The MCA assay can be adapted for medium-throughput determination of the methylation status of a large number of target genes through the utilization of “printed” membranes or highly reproducible dot-blot [69]. The costs and

efforts for these set-ups will depend largely on the numbers of samples and genes under investigation. Similarly, the combined MCA-RDA approach has proven to be highly effective in identifying hundreds of CGIs containing genomic fragments between two samples. However, its limitation resides in the inability to compare more than two samples in a single subtraction experiment. Furthermore, the method is not conducive to the identification of aberrantly hypomethylated sequences.

2.1.4. Differential methylation hybridization (DMH) using CGI arrays

An affinity column that contained the methyl-CpG binding domain of the rat MeCP2 protein was constructed to isolate CGIs from human genomic DNA [70]. Using this CGI library (close to 8000 CGIs), Huang et al. developed a novel array-based method called DMH that allows for a genome-wide screening for differentially methylated CGIs between two different samples [71]. The method has been widely used in the identification of aberrantly methylated gene promoters that are differentially expressed in various cancers [71–75]. In addition to its use in cancer research, DMH has been used to uncover specific CGIs that are altered in the prostates of mice fed genistein-rich diets [76]. Details of the methodology have been reviewed [77] and here we have illustrated only key steps and general principles underlying the procedures (Fig. 6). Genomic DNA isolated from two different samples is first digested with *MseI* to generate small DNA fragments (100–200 bp), leaving most CGIs intact. The cut ends of the DNA fragments are ligated to linkers. Repetitive sequences are removed from the digests using Cot-1 subtractive hybridization [78]. The remaining DNA fragments are then subjected to methylation-sensitive endonuclease *BstUI* digestion. Following *BstUI* digestion, DNA fragments in the two samples are amplified and labeled with cyanine (Cy) 3 or Cy5. The fluorescently-labeled amplicons, representing differentially methylated DNA fragments between the two samples, are co-hybridized to a high-density CGI microarray with approximately 8000 thousand probes. Cy3 and Cy5 fluorescence on each probe is detected in a two-channel scanner. Differences in methylation of a particular CGI between two samples are reflected in fluorescence intensities detected from the Cy3- and Cy5-labeled targets hybridized on the corresponding CGI probe in the microarray.




Fig. 6. Schematic diagram for differential methylation hybridization (DMH). In brief, genomic DNA is first digested with *MseI* and ligated to linkers and then digested with methylation-sensitive *BstUI*. Both *MseI* or *MseI/BstUI* digestion products are amplified to generate probes for hybridization to a microarray that is prescreened by their CGI library array. The hybridization output is the measured intensities of the two fluorescence reporters with red (sample B) and green (sample A). Yellow spots indicate equal amounts of bound DNA from each amplicon (i.e., amplicon a), signifying no methylation differences between sample A and B genomes. Spots hybridized predominantly with sample B amplicon but not with sample A amplicon would appear red (i.e., amplicon b), which is indicative of the presence of hypermethylated CpG island loci in the tumor genome. Methylation level of each CG clone can be analyzed.

Although the “first-generation” CGI arrays contain approximately 8000 probes, most published reports [71–75] found that only 0.5–1.5% (40–120 candidates) of the probes on the arrays were differentially methylated in the two samples under comparison. Following additional *post hoc* conformational analyses, most studies identified only a handful (8–15) of genes with promoter CGIs that play a role in gene regulation. The original DMH utilized CGIs dotted on nylon membranes, which have high background signal, thus creating problems with a high noise-to-signal ratio. The fabrication of current arrays on glass slides has minimized this problem. Recently, the availability of new high-density human and mouse CGI arrays have greatly expanded the power of using DMH for a whole-genome screen of differential methylation [79].

In summary, DMH is a useful tool for the discovery of differentially methylated CGIs in two samples. When combined with bioinformatic tools for analyzing expression microarray data, DMH can readily be used to classify samples into biologically or clinically relevant groups on the basis of their methylation profiles (see above references). However, the method does present some limitations for individual investigators if their institutional microarray core facility is not set up to run the arrays. On the technical side, since most genes are single-copy genes, the differences in Cy3 and Cy5 signal intensities for most loci (spots) may not be as strong and readily discernable as those in transcriptional profiling arrays in which fold changes for many probes could be more significant. Furthermore, problems arising from dye bias (Cy5 versus Cy3) would affect DMH more than transcriptional profiling. Furthermore, since the method requires approximately 2–5 μ g of high-quality genomic DNA as starting materials, it may put constraints on experiments in which sample availability is an issue (e.g., microdissected samples). Finally, only two samples can be compared at a time. If multiple samples or treatment groups (several experimental groups over multiple time points) were to be compared, high-order bioinformatic analysis tools would be needed to facilitate these comparisons.

2.1.5. Bisulfite sequencing

Bisulfite sequencing is a “gold-standard” method used to determine the methylation status of each cytosine over an amplified region of a given gene, a method now used routinely for studies of CGIs [80]. The underlying principle is based on the ability of sodium bisulfite to deaminate cytosine (C) residues into uracil (U) in genomic DNA, whereas the methylation cytosine residues are resistant to this modification. After PCR amplification, the Us are amplified as thymines (Ts). Cloning and subsequent sequencing of the DNA fragments containing the CGIs then provide information on the methylation status of each C within the island (Figs. 2 and 11).

The method is used routinely in analyzing the methylation status of any target or candidate DNA sequence containing CpGs. It has the advantage of revealing the methylation status of each CpG dinucleotide within the sequence and also the interrelationship between the methylation status of multiple CpG sites. However, it is more labor intensive than other shot-gun approaches, such as methylation-sensitive PCR (see below). Its successful application also depends on whether nested PCR primers could be designed to amplify the fragment of interest. Furthermore, DNA integrity that is less than optimal, as is the case of DNA isolated from microdissected samples or paraffin-embedded tissues, presents significant challenges for this application.

2.1.6. Methylation-specific oligonucleotide (MSO)/methylation target microarrays

As an alternative to bisulfite sequencing, methylation-sensitive oligonucleotide (MOS) array was initially designed to provide a high-throughput method for fine mapping of CpG sites in a known CGI using a hybridization-based microarray protocol [81–83] (Fig. 7). Subsequently, the methodology was adapted to interrogate simultaneously the methylation status of multiple CGIs [84]. Test DNA is restricted with *KpnI* and *NdeI*, bisulfite modified and amplified, and labeled with Cy5, resulting in a pool of labeled targets with altered nucleotide sequences due to their differential methylation status. Sets of short oligonucleotides (~21–25-mers), corresponding to the methylated and unmethylated versions of the CGI, are designed to provide coverage of the entire region. These pair of oligonucleotides are synthesized and immobilized in triplicates as probes on glass slides. After hybridization of the targets to the probes, hybridization signals are captured, quantified, and analyzed. The percentage of methylation for each short CG-rich fragment (2–4 CpG sites) is




Fig. 7. Diagram illustrating how to analyze DNA methylation by methylation-specific oligonucleotide (MSO). Genomic DNA is first modified with sodium bisulfite before the assay. The probes on the MSO array are a set of short oligonucleotides (~20-mers) designed for specific methylated CG or unmethylated C/TG sites to test all the CpG sites within the CGI of a known gene. Both methylated and unmethylated DNA can be amplified, labeled with Cy5 dye, and then hybridized to oligonucleotide probes attached to the glass plate/membrane. Signals from MSO arrays can be recorded with a fluorescence scanner, and signal intensities between the pair of probes are compared to arrive at the percentage of methylation of the CpG within the short region represented by the oligonucleotides, usually 2–3 CpG sites [81].

determined by comparison of signal intensities between the paired “methylated” and “unmethylated” oligonucleotide probes.

Gitan et al. were successful in using this method to compare the methylation status of the estrogen receptor α CGI in breast cancer cell lines, normal fibroblasts, breast cancers, and control tissues [81]. Yang et al. used this method to examine the androgen receptor gene promoter in 76 cases of non-Hodgkin lymphoma [83]. Hou et al. also used MSO arrays to study the methylation status of *p16* in gastric carcinomas [84]. Yu and associates identified a subset of aberrantly methylated genes/ESTs (25/105) in prostate cancer using MSO arrays printed with probes for 105 CGIs [85]. Similarly, MSO arrays were used to examine 156 loci involving 38 genes to identify those with DNA methylation patterns that differentiate between three types of small B-cell lymphomas [86].

To increase the throughput for screening of methylation changes in the promoter of a given gene among multiple samples simultaneously, Zhou and co-workers have described two versions of methylation target arrays (MTAs) [87]. In their investigation of the promoter region of *IGFBP7* gene in ten cases of breast cancer tissues and six cases of responding normal breast tissues, the investigators have fabricated two arrays, a bisulfite PCR product array and a bisulfite genomic DNA array, and compared the sensitivity and reliability of these two arrays to detect methylation changes in this promoter. They found that the bisulfite genomic DNA array is less suitable than the bisulfite PCR product array for analyzing methylation changes using tissue samples. Hence, the latter methods warrant future development for high-throughput analysis of target genes.

Undoubtedly, MSO array hybridization is a versatile and high-throughput method for comparing the methylation status of known CGIs among multiple samples. Approximately 2–3 μ g of genomic DNA is needed as starting material [85]. However, reproducibility of results could be drastically affected by the performance of the bisulfite treatment, which would impact the quality of the targets. Furthermore, since only a few samples could be processed with a single hybridization, the method is insufficient for effective analyses of hundreds of clinical samples. The efficiency of the various hybridizations may vary significantly. The success of the methodology also depends on the specificity of the methylated/unmethylated oligonucleotides.

2.1.7. Transcriptional profiling of genes reactivated by demethylating agents or inhibitors of histone deacetylation

DNA methylation and histone deacetylation are two major mechanisms resulting in epigenetic silencing of genes through direct and indirect methylation of CGIs. Hence, several investigators have taken the approach of using DNA demethylating agents or inhibitors of histone deacetylation to reactivate epigenetically silenced genes and then using transcription profiling [88] to identify the reactivated genes. This approach allows a pool of candidates to be identified, i.e., those genes that are reactivated after the treatment. *Post hoc* validation methods (see below) are then used to identify among these candidates which promoters play a regulatory role in transcription through cytosine methylation [89–91].

This approach was proven successfully in identifying dysregulated genes caused by aberrant cytosine methylation in colorectal cancer and gastric cancer [89]. A recent study [91] compared the gene sets reactivated by 5-aza-2'-deoxycytosine (5-AZA), a DNA demethylating agent, and trichostatin (TSA), an inhibitor of histone deacetylation, in HepG2 cells. They found distinct and common gene sets that are reactivated by the individual agents and their combination, respectively, suggesting that the two epigenetic mechanisms may regulate different sets of genes. In contrast, Li and associates used an integrated “triple” microarray system to elucidate the “epigenetic hierarchies” on gene regulation. Analyses of data with established statistical models demonstrate that genes reactivated by DNA demethylation and histone hyperacetylation are highly correlative [92]. A comparable approach was recently applied to study the effects of maternal care, an early-life experience, in stable epigenetic programming of gene expression in the hippocampus that mediates stress responsivity. Adult offspring exhibiting anxiety behavior due to maternal care were centrally infused with TSA or methionine. Global transcriptional profiling identified over 900 genes that were reactivated by these two reagents, and these genes are likely as candidates mediating adult anxiety disorder caused by early life experience.

5-AZA is a commonly used DNA demethylating agent [93]; it causes cytosine demethylation by covalently binding to the maintenance DNA methyltransferase (DNMT1) and inhibiting its “proofreading” ability during DNA replication. In this manner, the hemimethylated DNA can escape methylation and thereby become fully unmethylated after one further round of DNA replication. Treatment of cells with 5-AZA has repeatedly been demonstrated to reactivate genes silenced by DNA methylation. However, a few precautionary notes are noteworthy regarding its use in the aforementioned approaches: (1) 5-AZA could cause a low frequency of mutations that affect patterns of gene expression; (2) the agent has a short half-life and must be freshly prepared and added to the cell cultures repeatedly; (3) 5-AZA works best when cells are replicating rapidly; and (4) a period of recovery after treatment is necessary for the new DNA methylation patterns to be established.

Trichostatin A (TSA) belongs to the hydroxamic acid type of histone deacetylase (HDAC) inhibitors with very high potency [94]. TSA is widely used in many experimental settings due to its potency and wide coverage, i.e., it inhibits both class I and II HDAC isoforms. Treatment of cells with TSA has been shown to reactivate about 10% of genes but also to cause silencing of close to an equal number of expressed genes in melanoma cell lines [95]. Most HDAC inhibitors are able to induce expression of genes related to the cell cycle and apoptosis, and therefore genes reactivated by HDAC inhibitors are not necessarily related to epigenetic regulation. Hence, similar to the use of DNA demethylating agents in expression array studies, *post hoc* experiments are needed to verify that the candidates identified are directly regulated by cytosine methylation of their promoter CGIs.

Finally, since the promoters of many genes and ESTs remain unknown, the use of transcriptional profiling to identify DNA methylation-regulated genes still faces significant challenges since confirmation of a regulatory CGI for a given gene is possible only if its promoter region is published or in public databases. The use of genome walking techniques to find the 5' upstream sequence of a gene of interest could be tedious.

2.1.8. Genome-wide methylation array/promoter arrays

The initial CGI library was first produced by Cross and co-workers by isolating CG-rich DNA fragments with methyl-CpG binding protein affinity columns (see above). Subsets of these CG-rich clones (9-k set or 12-k set) were used in the construction of several arrays for the detection of differentially methylated CGIs [70,71]. However, not all the CG-rich clones correspond to CGIs and not all

CGIs are in the promoter regions. Promoter arrays have recently become readily available through the University Health Network Microarray Center (UHNMC) in Toronto (www.microarray.ca). More than 20K CG-rich sequence clones can be assessed and used to distinguish promoter methylation status of human and mouse genome. The UHNMC's human CpG island array contains 12,192 spotted clones, while the mouse array contains 7296 probes. These probe sets cover a large percentage of CGIs found in the human and mouse genomes. Moreover, the UHNMC provides a web interface for users to download the corresponding sequences of the clones. These arrays clearly provide a high-throughput, genome-wide screen of promoters with CGIs undergoing methylation changes due to experimental or pathological conditions. Since these arrays have become commercially available, an increasing number of studies using this approach have been published and yield insightful data on epigenetic gene regulation [75,79,96–98]. A new approach that combines methylation-sensitive enzyme digestion with the comparative genomic hybridization (CGH) technique was developed to screen the entire genome for changes in methylation pattern [99].

The above technology remains most suitable for running by a core facility, where inter-array variations could be minimized and high-throughput could be achieved. The expenditure for setting-up routine hybridization is relatively high since it requires hybridization stations, equipment for quality controls of the targets (e.g., Nanodrop), and a scanner for capturing signals. In addition, because of the large volume of data generated in one experiment, pre- and post-experimental consultations on experimental design and data mining are critical elements for this kind of study. Specific software packages provided by the vendors and others developed in-house are required to generate meaningful results.

Custom designed or small-scale promoter methylation arrays have recently become commercial available that simultaneously profile the methylation status of the gene of interests from one sample (NimbleGen System; Panomics). This is a high-throughput analysis of promoter methylation that costs less than the genome-wide CGI array.

2.1.9. Chromatin immunoprecipitation (ChIP) on DNA microarray (ChIP-chip)

Chromatin immunoprecipitation (ChIP) was developed to identify and characterize the interactions of specific genomic DNA sequences associated with a target protein such as a transcriptional factor in the context of intact cells [100]. An antibody specific to the target protein is used to immunoprecipitate the protein–DNA complexes. After the crosslink between the two is reversed, the identities of the DNA sequences are then uncovered by amplification and sequencing. Recently, with the advent of bioinformatics on promoter/transcription start site [101] and DNA microarrays, it has become possible to use the DNA fragments isolated from a ChIP assay as targets to probe a microarray in a protocol known as the ChIP-chip [102–106] (Fig. 8). The logical approach to applying the ChIP-chip methodology to study the effects of DNA methylation/chromatin structure on gene expression is to use groups of antibodies specific for histone deacetylase/methylases to pull down DNA, followed by DNA array analysis. A human promoter array has recently been developed for ChIP experiments (Affymetrix). It is a single array comprising more than 4.6 million probes tiled through more than 25,500 human promoter regions proximal to transcriptional start sites and probes for approximately 59% CpG islands annotated by UCSC in the NCBI human genome assembly (Build 34).

An example of the use of the ChIP-chip approach for methylation studies is the identification of the “methylome,” which refers to the complete set of DNA sequences susceptible to methylation in a cell [107]. Genomic DNA is sonicated into smaller fragments. Anti-5'-methylcytosine antibody is used to enrich methyl cytosine-rich genomic DNA fragments, a procedure known as methylated DNA immunoprecipitation (MeDIP). The MeDIP-enriched fragments are then labeled with Cy3, while the non-MeDIP DNA (or the input DNA) is labeled with Cy5. The two samples are co-hybridized to a sub-megabase resolution tiling (SMRT) array or a CGI array. Relative signal intensity at each locus (spot) represented on the array indicates methylation status. DNA methylation profiles could be obtained simultaneously at both genome-wide and locus-specific levels.

This approach provides an unbiased, whole-genome view of changes in methylation status that are mapped to chromosomal regions. It is one of the most exciting of the recently developed applications of the ChIP-chip technology for DNA methylation studies. However, the limitations in this technique remain the high cost of setting up the array technology platform and the dependence on the efficiency of the antibody to pull down DNA fragments. The

number of probes on the CGI arrays will continue to grow, hence increasing the coverage.

2.1.10. Luminometric methylation assay (LUMA) using pyrosequencing

The underlying principal of LUMA is based on DNA cleavage by a pair of isoschizomer endonucleases followed by bioluminometric polymerase extension to quantify the extent of restriction cleavage using pyrosequencing [108]. The method is a modern version of one of the earliest method used to detect methylated cytosine in genomic DNA [109] in which *HpaII* (methylation-sensitive) and *MspI* (methylation-insensitive) were used to cut at the recognition site CCGG. *HpaII* is not able to cut if the internal internal cytosine is methylated (C^m CCGG). After the DNA cleavage, the methylation status can be determined by Southern blotting or by PCR analysis [109]. With the advent of pyrosequencing [110], a new sequencing methodology that dispenses labeled primers, labeled nucleotides, and gel-electrophoresis, the extent of methylation at each CpG sites could be determined accurately and rapidly. The LUMA workflow (Fig. 9) started with DNA digestion in parallel reactions using either *MspI* or *HpaII* in combination with *EcoRI*. *MspI* or *HpaII* both leave 5'CG overhangs after DNA cleavage, but in the *HpaII* reaction, C^m CGG sites are protected. As an internal reference, *EcoRI* generates 5'-AATT overhangs. These overhangs are then filled in a polymerase extension assay with stepwise addition of dNTPs (four steps: dATP α S, dGTP + dCTP, dTTP, and dGTP + dCTP). As each dNTP is extended, inorganic pyrophosphate (PPi) is released and converted to ATP by ATP-sulfurylase and adenosine-5-phosphosulfate. This reaction is coupled to the conversion of luciferin to oxyluciferin by luciferase and ATP to generate a proportional amount of visible light, which is quantified by a charge-coupled-device camera in the Pyrosequencer. The signals corresponding to dATP α S and dTTP additions both represent *EcoRI* cleavage and are equal in the two DNA samples (*MspI* + *EcoRI*-treated versus *HpaII* + *EcoRI*-treated). The signal intensities generated by the additions of dCTP and dGTP are added together, and the sum represents an *HpaII* or *MspI* cleavage. The degree of methylation at a CpG site can be derived from the (*HpaII*/*EcoRI*)/(*MspI*/*EcoRI*) ratio.

LUMA can be used to access cytosine methylation level of the whole genome [108]. However, the technology has more commonly applied to stud-

ies of targeted CGIs [111]. LUMA has been used to determine changes in methylation status associated with disease development [112–114] or as diagnostic/prognostic markers of cancers [115–118]. It is limited by the length of the sequence read and thereby the number of CpGs that can be analyzed in one sequencing reaction. In addition, the relatively high cost of the pyrosequencing machine has limited the use of the technology without the support of a core facility.

2.1.11. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS)/high-performance liquid chromatography (HPLC)

Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) [119,120] is a promising and powerful technique for DNA methylation analysis. Various MS approaches have been developed for the measurement of levels of DNA methylation, including rapid screening of single nucleotide polymorphisms (SNPs), and quantitative allele studies. It has been used to monitor nucleotide digestion and DNA sequencing [121,122]. The commonly used approach involves bisulfite conversion of genomic DNA [80] followed by DNA sequencing, resulting in accurate determination of methylation status in genomic DNA.

As an alternative, Schatz et al. introduced RNA-mediated analysis of methylation status of individual CpGs using MALDI-TOF-MS based on *in vitro* transcription of bisulfite PCR product and base-specific cleavage [123]. After treatment with sodium bisulfite, DNA samples are subjected to PCR in which the amplicons are tagged with T7 RNA polymerase promoter as well as with a complementary sequence with low guanosine content. After T7-mediated transcription, these guanosine residues in the newly transcribed RNA are subjected to cleavage by RNase T1 and the methylation fingerprint (RNA fragmentation pattern) is visualized by MALDI-MS (Fig. 10). This approach was applied to the analysis of artificially methylated and unmethylated DNA, mixtures thereof, and colon DNA samples.

Recently, Tos et al. combined the bisulfite conversion genomic DNA method with the GOODs [124,125] assay for accurate quantification of methylation status of CpG dinucleotides using MALDI-MS. They analyzed




Fig. 8. Workflow of chromatin immunoprecipitation (ChIP) on DNA microarray (ChIP-chip) analysis. At first, living cells are fixed by formaldehyde crosslinking. Intact genomic DNA with transcription factors (TF) is then isolated, and the chromatin-protein complex of interest is immunoprecipitated (IP) with a specific antibody to that intact TF. After reverse crosslinking, DNA is extracted and purified before PCR to generate chromatin amplicons. Amplicons from experimental immunoprecipitation are labeled with Cy5, and Cy3 is used to label input reference amplicons. Labeled probes are applied on the CGI array for hybridization. Data can be utilized to study the interaction between particular TFs and specific CpG sites of genes.




Fig. 9. Procedures for analysis global DNA methylation with luminometric methylation assay (LUMA). Genomic DNA is digested with combinations of restriction enzymes, *EcoRI*/*MspI* or *EcoRI*/*HpaII*, to leave the TTAA (*EcoRI*) and CG (*HpaII* [methylation-sensitive] or *MspI* [methylation-insensitive]) overhangs. Next, the extent of the cleavage is determined by a polymerase extension assay based on a four-step pyrosequencing reaction. Inorganic pyrophosphate (PPi) is generated at each nucleotide addition in the polymerase extension assay. Signals are generated based on the utilization of PPi in a luciferase-based reaction. The amount of light generated is directly proportional to the number of overhangs produced by respective restriction enzymes. The A and T peaks represent signals from Steps 1 and 3. The C + G peaks resulting from Step 2 illustrate *HpaII* or *MspI* cleavage. The second C + G peak originating from Step 4 is an internal control for the completion of Step 2. Unmethylated CG is cleaved by *HpaII*, and a CG overhang is left after the cleavage and amplified in polymerase extension. Methylation status can be determined by analyzing the *HpaII*/*MspI* ratio at CG peaks from Step 2. The *HpaII*/*MspI* ratio is close to 1 in the unmethylated sample but close to zero in the methylated sample.

several paraffin-embedded tissue biopsies and found the MS results comparable to those of chip hybridization. Furthermore, Ehrich et al. applied base-specific cleavage of DNA following MALDI-TOF-MS analysis to measure the degree of methylation in normal and neoplastic lung cancer tissue samples, allowing accurate classification of samples according to their histopathology [126]. This method is applicable to methylation studies of target genes.

Another related technology for global profiling involves the use of high-performance liquid chromatograph (HPLC). It is the routine and most widely used separation technique for the measurement of 5-methylcytosine and/or DNA methylation [127–129] involving the digestion of DNA to nucleotides, nucleosides, or bases, followed by high-resolution separation and quantification with UV detection. HPLC has been implicated in the study of p16 methylation status of gastric dysplasia/carcinomas [130,131] and a study of tamoxifen-induced hepatocarcinogenesis in rat [132]. Recently, Song et al. reported a novel method utilizing liquid chromatography-electrospray ionization tandem mass spectrometry to measure 5-methyl-2'-deoxycytidine levels [133]. Tissue-specific differences in DNA methylation in various mammals has been reported by using HPLC analysis [134]. Several other chromatographic and electrophoretic techniques, including gas chromatography, thin layer chromatography, and capillary electrophoresis, have also been used to determine DNA methylation [135–137].

Both MALDI-TOF-MS and HPLC are tools suitable for high-throughput, multi-channel detection with the benefits of high speed, accuracy, and automation. They either can measure the content of methyl-cytosine in the whole genome or can detect methylation patterns of specific target genes. Relatively high cost or the need for standardization of the protocols would be the major pitfalls of applying these techniques to methylation studies.

2.2. Characterization of a target or candidate sequence and validation of its involvement in gene regulation

The various global discovery platforms mentioned above would undoubtedly identify many novel genes that are epigenetically regulated and that might be important in the development of diseases. However, the major challenge remains in designing an efficient strategy for *post hoc* validation of the involvement of the CGI in gene regulation. It has to be re-emphasized that multiple validation approaches need to be conducted before one can lay claim to its role in gene regulation. These include, but are not limited to, database searches and *in silico* analyses, studies of methylation status using bisulfite sequencing (Section 2.1.5), combined bisulfite restriction analysis (COBRA), methylation-sensitive PCR (MS-PCR), methylation-sensitive single strand conformational polymorphism (MS-SSCP), MethylLight analysis, and gene expression studies (Figs. 2 and 11). Some of these techniques are summarized briefly below, and most of them can be used both for target gene studies and for studies of novel candidates identified by discovery platforms.

2.2.1. In silico database analysis

The first step in *post hoc* validation starts at *in silico* analysis of the candidate genes of interest. Detailed searches of public databases such as the National Centre for Biotechnology Information (NCBI) and the University of California Santa Cruz (UCSC) Genome Bioinformatics group are the logical first steps. If the CGI is located in the promoter or 5' region of a gene, it usually has a higher chance of being involved in transcriptional regulation. After promoter/5' sequences of a candidate gene are identified, the next step is to locate the CGI and discern its location relative to the transcriptional start site and to the 5' exons




Fig. 10. Analysis of CpG methylation patterns using RNase T1 cleavage and Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Genomic DNA is modified by sodium bisulfite to convert unmethylated cytosines to uracils followed by PCR amplification with forward primer containing a control tag and reverse primer carrying T7 promoter. RNA transcription generates G-sites at originally methylated C sites and G-specific cleavage with RNase T1 is done. Control tag is used to monitor the successful full-length transcription and followed RNase T1 cleavage. RNA fragments are subjected to MALDI-TOF analysis. By comparison of the profile of *m/z* values of all fragments in the samples, methylation status of genes can be found.




Fig. 11. Different approaches can be chosen to yield the information on the overall characterization of genes showing differential methylation status. Unmethylated DNA is distinguished from methylated DNA with a sodium bisulfite modification of DNA used as a standard procedure prior to validation assays. The underlying principle is based on the ability of sodium bisulfite to deaminate cytosine (C) residues into uracil (U) in genomic DNA, whereas the methylation cytosine residues are resistant to this modification. After PCR amplification, the U residues are amplified as thymines (Ts). Cloning and subsequent sequencing of the DNA fragments containing the CpGs then provide information on the methylation status of each C within the CpGs. Details of methylation-specific PCR (MS-PCR), combined bisulfite restriction analysis (COBRA), methylation-specific single-strand conformation polymorphism (MS-SSCP), and MethyLight are discussed in the text.

and introns. Information generated from these analyses provides clues as to (1) whether a CGI exists in the sequence and (2) if it has a high probability of playing a regulatory role in gene expression. These *in silico* analyses could be laborious, but several open-source tools are now available through the Internet: Met-Primer (<http://www.urogene.org/methprimer/index.html>), Promoter Inspector (<http://www.genomatix.de>), BIMAS (<http://thr.cit.nih.gov/molbio/index.shtml>), and Database of Transcription Start Sites (<http://dbtss.hgc.jp>).

2.2.2. Validation assays of gene of interest

Once a “potential” CGI has been identified in the 5′ region of a gene, physical and functional characterization of the CGI is in order. The first criterion of a regulatory CGI is that an inverse relationship can be established between its degree of methylation and the expression of its cognate gene. Determination of the methylation status of the CGI and its adjacent sequences could be achieved by one or more of the following methods: MS-PCR, COBRA, MS-SSCP, MethyLight, or bisulfite DNA sequencing. For cell-culture experiments, DNA could be extracted from cultures under different conditions or exposed to DNA-demethylating agents or inhibitors of histone deacetylase. By extracting both DNA for methylation studies and RNA for transcript quantification, one can determine if an inverse relationship exists between the extent of methylation in the CGI and gene transcription [20]. Bisulfite genomic sequencing [80] is the preferred method (see Section 2.1.5) of initial characterization because it can reveal the methylation status of individual CpG in the CGI. Detailed mapping of a CGI could uncover important “methylation hotspots” that could be used to design methylation oligonucleotides for use in gene silencing experiments by targeting these hotspot sequences [138].

After initial characterization of the putative CGI, other methods are available for more-rapid or higher-throughput analyses. MS-PCR [139,140] can be used to assess the methylation status of a cluster of CpGs within a CGI by conducting PCRs with primers designed for the methylated or unmethylated version of the sequence of interest. MS-PCR has the advantage of requiring small amounts of DNA, with a sensitivity of detecting 0.1% methylated alleles in a given sample. It can be applied to DNA extracted from paraffin-embedded samples which most of the DNA is fragmented.

One of the limitations of MS-PCR is that it is not highly quantitative. Hence, other more quantitative methods have recently been developed. COBRA is similar to MS-PCR but provides more quantitative information on the degree of methylation of the targeted sequence. Restriction-enzyme digestion is used to reveal methylation-dependent sequence differences in PCR products of sodium

bisulfite-treated DNA as described previously [141]. The method has the advantage of accessing methylation levels of a target sequence in a small amount of DNA samples and provides linear quantification across a wide spectrum of DNA methylation levels. The technique can be reliably applied to DNA obtained from microdissected paraffin-embedded tissue samples. COBRA thus combines the powerful features of ease of use, quantitative accuracy, and compatibility with archival samples. MS-SSCP also provides a fairly quantitative method to access the methylated and unmethylated allele populations. It uses high-resolution gel electrophoresis to generate a specific methylation pattern for determining the percentages of methylation in a targeted sequence. In SSCP, methylated alleles, due to the difference in conformation from the unmethylated alleles, can be separated by MDE-gel electrophoresis and visualized by SYBR-Gold staining or radiolabeling [142,143]. A high-throughput technology, known as MethyLight, has recently been developed for cytosine analysis. It utilizes fluorescence-based real-time PCR Taq-Man technology [144,145] and thus is highly quantitative. MethyLight assays have good precision and linearity. It can be used effectively in a high-throughput manner for analysis of DNA methylation of small amounts of DNA.

After the methylation status of the CGI has been established by the aforementioned methods, it is imperative to determine the expression of its cognate gene. Modern laboratory procedures such as quantitative reverse transcriptase-PCR or real-time PCR are most appropriate for such studies because they provide quantitative data and are adaptable to high-throughput application. If levels of transcripts can not be accessed directly (e.g., if only archival paraffin-embedded samples are available), then immunostaining of sections [138] or *in-situ* hybridization could be attempted to ascertain gene expression. In addition, cell cultures treated with DNA demethylating agents and inhibitors of histone deacetylase can further elucidate the regulatory role of the CGI. More recently, we have used a class of methylation oligonucleotides to induce sequence-specific methylation *in cellulo* that subsequently leads to gene silencing. In this manner, we have provided additional evidence that DNA methylation is involved in the regulation of estrogen receptor β [138].

3. Discussion

In this section, we would like to point out some important issues that should be noted when methylation techniques are employed in epigenetic studies. The above validation assays could be used for whole-tissue analyses [20]. However, a tissue contains multiple cell types and any change in the methylation status and gene expression of that CGI might occur in only one cell type. In this scenario, it would be beneficial to have laser-capture microscope-assisted microdissection to enrich a specific cell population [138]. Alternatively, enzymatic digestion of the tissue followed by isolation of the specific cell population would also enhance the experimental outcome.

Methods including BSPCR, MS-PCR, MS-SSCP, COBRA, or MethyLight depend on whether nested PCR primers could be designed to amplify the fragment of interest. Furthermore, if the integrity of the DNA is less than optimal, as is in the case of DNA isolated from microdissected samples or paraffin-embedded tissues, the amplified fragment would be limited in size. Also, efficiency of bisulfite modification on DNA samples would be another major pitfall affecting the sensitivity and accuracy of the PCR results.

On the other hand, if 5AZA and/or TSA treatments are performed to determine the relationship between the transcription level and methylation status of target genes, dosage of the modifiers and incubation period for the treatment are critical. Optimization of the protocol is necessary. Additional studies such as site-directed mutagenesis and luciferase reporter assay *in vitro* and *in vivo* can be involved to establish the gene regulatory

function of the CGIs. Briefly, deletion constructs at specific CG sites are generated by using a commercial site-directed mutagenesis kit according to the manufacturer's recommendations. Modified promoters are re-subcloned into reporter vector followed by a promoter reporter assay. ChIP or transcription-factors binding assay may also be included to determine which regulatory elements on promoters are associated with the methylation changes.

In summary, multiple methods and technologies are available to determine changes in global and regional methylation of cytosine in genomic DNA; each has advantages, disadvantages, and areas of applicability. Because of variations in sample size, the nature of the samples, the number of samples in the studies, the experience of the investigators, and the resources of the laboratory or the institution, there is no "gold" standard or "standard operation procedure" for conducting a DNA methylation analysis. This review simply attempts to provide an overview of the currently available techniques and to discuss some of the advantages and limitations of each technology. With the rapid growth in interest in understanding the epigenetic regulation of disease development, a variety of new and improved methodologies are certain to emerge in the coming years. These technologies will undoubtedly change the landscape of epigenetic studies and provide valuable new insights into areas such as the developmental basis of disease and reproductive toxicology.

Acknowledgments

Grant support: NIH grants ES12281 (S.-M. Ho) and ES13071 (S.-M. Ho) and the Department of Defense awards DAMD W81XWH-06-1-0373 (W.-Y. Tang).

We thank Dawn Ho for technical contribution to the generation of the artwork. We also thank Suresh Babu, Yuet-kin Leung, and Neville N.C. Tam for discussions in preparation of the manuscript.

References

- [1] Liu Y, Freedman BI. Genetics of progressive renal failure in diabetic kidney disease. *Kidney Int Suppl* 2005;S94–7.
- [2] Kroll TG. Molecular events in follicular thyroid tumors. *Cancer Treat Res* 2004;122:85–105.
- [3] Moore MA. Converging pathways in leukemogenesis and stem cell self-renewal. *Exp Hematol* 2005;33:719–37.
- [4] Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. *J Clin Oncol* 2005;23:8253–61.
- [5] Tusie Luna MT. Genes and type 2 diabetes mellitus. *Arch Med Res* 2005;36:210–22.
- [6] Soussi T, Ishioka C, Claustres M, Beroud C. Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. *Nat Rev Cancer* 2006;6:83–90.
- [7] Garg V. Insights into the genetic basis of congenital heart disease. *Cell Mol Life Sci* 2006;63:1141–8.
- [8] Verschure PJ, Visser AE, Rots MG. Step out of the groove: epigenetic gene control systems and engineered transcription factors. *Adv Genet* 2006;56:163–204.
- [9] Jiang YH, Bressler J, Beaudet AL. Epigenetics and human disease. *Annu Rev Genomics Hum Genet* 2004;5:479–510.
- [10] Rodenhiser D, Mann M. Epigenetics and human disease: translating basic biology into clinical applications. *CMAJ* 2006;174:341–8.
- [11] Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. *Nat Genet* 2003;33(Suppl):245–54.
- [12] Morris KV. siRNA-mediated transcriptional gene silencing: the potential mechanism and a possible role in the histone code. *Cell Mol Life Sci* 2005;62:3057–66.
- [13] Cheung P, Lau P. Epigenetic regulation by histone methylation and histone variants. *Mol Endocrinol* 2005;19:563–73.
- [14] Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. *Annu Rev Pharmacol Toxicol* 2005;45:629–56.
- [15] Gluckman PD, Hanson MA. The developmental origins of the metabolic syndrome. *Trends Endocrinol Metab* 2004;15:183–7.
- [16] Dolinoy DC, Weidman JR, Jirtle RL. Epigenetic gene regulation: linking early developmental environment to adult disease. *Reprod Toxicol* 2007;23:297–307.
- [17] Santos F, Dean W. Epigenetic reprogramming during early development in mammals. *Reproduction* 2004;127:643–51.
- [18] Weidman JR, Maloney KA, Jirtle RL. Comparative phylogenetic analysis reveals multiple non-imprinted isoforms of opossum Dlk1. *Mamm Genome* 2006;17:157–67.
- [19] Anway MD, Cupp AS, Uzumcu M, Skinner MK. Epigenetic trans-generational actions of endocrine disruptors and male fertility. *Science* 2005;308:1466–9.
- [20] Ho SM, Tang WY, Belmonte dF, Prins GS. Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. *Cancer Res* 2006;66:5624–32.
- [21] Dolinoy DC, Weidman JR, Waterland RA, Jirtle RL. Maternal genistein alters coat color and protects Avy mouse offspring from obesity by modifying the fetal epigenome. *Environ Health Perspect* 2006;114:567–72.
- [22] Fernandez-Twinn DS, Ozanne SE. Mechanisms by which poor early growth programs type-2 diabetes, obesity and the metabolic syndrome. *Physiol Behav* 2006;88:234–43.
- [23] Barker DJ, Osmond C, Simmonds SJ, Wield GA. The relation of small head circumference and thinness at birth to death from cardiovascular disease in adult life. *BMJ* 1993;306:422–6.
- [24] Ravelli AC, van der Meulen JH, Michels RP, et al. Glucose tolerance in adults after prenatal exposure to famine. *Lancet* 1998;351:173–7.
- [25] Dennison EM, Arden NK, Keen RW, et al. Birthweight, vitamin D receptor genotype and the programming of osteoporosis. *Paediatr Perinat Epidemiol* 2001;15:211–9.
- [26] Thompson C, Syddall H, Rodin I, et al. Birth weight and the risk of depressive disorder in late life. *Br J Psychiatry* 2001;179:450–5.
- [27] Veurink M, Koster M, Berg LT. The history of DES, lessons to be learned. *Pharm World Sci* 2005;27:139–43.
- [28] Demerath EW, Cameron N, Gillman MW, et al. Telomeres and telomerase in the fetal origins of cardiovascular disease: a review. *Hum Biol* 2004;76:127–46.
- [29] Lee HK, Park KS, Cho YM, et al. Mitochondria-based model for fetal origin of adult disease and insulin resistance. *Ann N Y Acad Sci* 2005;1042:1–18.
- [30] Rakyen VK, Blewitt ME, Druker R, et al. Metastable epialleles in mammals. *Trends Genet* 2002;18:348–51.
- [31] Tollefsbol TO. Methods of epigenetic analysis. *Methods Mol Biol* 2004;287:1–8.
- [32] Chiang PK, Gordon RK, Tal J, et al. S-Adenosylmethionine and methylation. *FASEB J* 1996;10:471–80.
- [33] Singal R, Ginder GD. DNA methylation. *Blood* 1999;93:4059–70.
- [34] Murphy SK, Jirtle RL. Imprinted genes as potential genetic and epigenetic toxicologic targets. *Environ Health Perspect* 2000;108(Suppl 1):5–11.
- [35] Costello JF, Plass C. Methylation matters. *J Med Genet* 2001;38:285–303.
- [36] Antequera F, Bird A. Number of CpG islands and genes in human and mouse. *Proc Natl Acad Sci USA* 1993;90:11995–9.
- [37] Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. *J Natl Cancer Inst* 2005;97:1498–506.

- [38] Bird A, Tate P, Nan X, et al. Studies of DNA methylation in animals. *J Cell Sci Suppl* 1995;19:37–9.
- [39] Monk M, Boubelik M, Lehnert S. Temporal and regional changes in DNA methylation in the embryonic, extraembryonic and germ cell lineages during mouse embryo development. *Development* 1987;99:371–82.
- [40] Kafri T, Ariel M, Brandeis M, et al. Developmental pattern of gene-specific DNA methylation in the mouse embryo and germ line. *Genes Dev* 1992;6:705–14.
- [41] Issa JP. CpG-island methylation in aging and cancer. *Curr Top Microbiol Immunol* 2000;249:101–18.
- [42] Waterland RA, Jirtle RL. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. *Mol Cell Biol* 2003;23:5293–300.
- [43] Niculescu MD, Craciunescu CN, Zeisel SH. Gene expression profiling of choline-deprived neural precursor cells isolated from mouse brain. *Brain Res Mol Brain Res* 2005;134:309–22.
- [44] Li S, Washburn KA, Moore R, et al. Developmental exposure to diethylstilbestrol elicits demethylation of estrogen-responsive lactoferrin gene in mouse uterus. *Cancer Res* 1997;57:4356–9.
- [45] Newbold RR, Padilla-Banks E, Jefferson WN. Adverse effects of the model environmental estrogen diethylstilbestrol are transmitted to subsequent generations. *Endocrinology* 2006;147:S11–7.
- [46] Li S, Hansman R, Newbold R, et al. Neonatal diethylstilbestrol exposure induces persistent elevation of c-fos expression and hypomethylation in its exon-4 in mouse uterus. *Mol Carcinog* 2003;38:78–84.
- [47] Anway MD, Leathers C, Skinner MK. Endocrine disruptor vinclozolin induced epigenetic transgenerational adult onset disease. *Endocrinology* 2006;147:5515–23.
- [48] Huang TH, Laux DE, Hamlin BC, et al. Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique. *Cancer Res* 1997;57:1030–4.
- [49] Wu M, Ho SM. PMP24, a gene identified by MSRF, undergoes DNA hypermethylation-associated gene silencing during cancer progression in an LNCaP model. *Oncogene* 2004;23:250–9.
- [50] Lo KW, Tsang YS, Kwong J, et al. Promoter hypermethylation of the EDNRB gene in nasopharyngeal carcinoma. *Int J Cancer* 2002;98:651–5.
- [51] Lv Z, Zhang M, Bi J, et al. Promoter hypermethylation of a novel gene, ZHX2, in hepatocellular carcinoma. *Am J Clin Pathol* 2006;125:740–6.
- [52] Rodic N, Oka M, Hamazaki T, et al. DNA methylation is required for silencing of ant4, an adenine nucleotide translocase selectively expressed in mouse embryonic stem cells and germ cells. *Stem Cells* 2005;23:1314–23.
- [53] Hatada I, Hayashizaki Y, Hirotsune S, et al. A genomic scanning method for higher organisms using restriction sites as landmarks. *Proc Natl Acad Sci USA* 1991;88:9523–7.
- [54] Akama TO, Okazaki Y, Ito M, et al. Restriction landmark genomic scanning (RLGS-M)-based genome-wide scanning of mouse liver tumors for alterations in DNA methylation status. *Cancer Res* 1997;57:3294–9.
- [55] Yoshikawa H, de la MS, Nagai H, et al. Chromosomal assignment of human genomic NotI restriction fragments in a two-dimensional electrophoresis profile. *Genomics* 1996;31:28–35.
- [56] Costello JF, Plass C, Cavennee WK. Aberrant methylation of genes in low-grade astrocytomas. *Brain Tumor Pathol* 2000;17:49–56.
- [57] Matsuyama T, Kimura MT, Koike K, et al. Global methylation screening in the *Arabidopsis thaliana* and *Mus musculus* genome: applications of virtual image restriction landmark genomic scanning (Vi-RLGS). *Nucleic Acids Res* 2003;31:4490–6.
- [58] Rouillard JM, Erson AE, Kuick R, et al. Virtual genome scan: a tool for restriction landmark-based scanning of the human genome. *Genome Res* 2001;11:1453–9.
- [59] Asaga S, Ueda M, Jinno H, et al. Identification of a new breast cancer-related gene by restriction landmark genomic scanning. *Anticancer Res* 2006;26:35–42.
- [60] Wu R, Lin L, Beer DG, et al. Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas. *Am J Pathol* 2003;162:1603–10.
- [61] Motiwala T, Ghoshal K, Das A, et al. Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas. *Oncogene* 2003;22:6319–31.
- [62] Sato K, Fukata H, Kogo Y, et al. Neonatal exposure to diethylstilbestrol alters the expression of DNA methyltransferases and methylation of genomic DNA in the epididymis of mice. *Endocr J* 2006;53:331–7.
- [63] Lisitsyn N, Lisitsyn N, Wigler M. Cloning the differences between two complex genomes. *Science* 1993;259:946–51.
- [64] Schutte M, da Costa LT, Moskaluk CA, et al. Isolation of YAC insert sequences by representational difference analysis. *Nucleic Acids Res* 1995;23:4127–33.
- [65] Toyota M, Ho C, Ahuja N, et al. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. *Cancer Res* 1999;59:2307–12.
- [66] Koinuma K, Kaneda R, Toyota M, et al. Screening for genomic fragments that are methylated specifically in colorectal carcinoma with a methylated MLH1 promoter. *Carcinogenesis* 2005;26:2078–85.
- [67] Yamada Y, Toyota M, Hirokawa Y, et al. Identification of differentially methylated CpG islands in prostate cancer. *Int J Cancer* 2004;112:840–5.
- [68] Ueki T, Toyota M, Skinner H, et al. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. *Cancer Res* 2001;61:8540–6.
- [69] Asada K, Asada R, Yoshiji H, et al. DNA cytosine methylation profile in various cancer-related genes is altered in cultured rat hepatocyte cell lines as compared with primary hepatocytes. *Oncol Rep* 2006;15:1241–8.
- [70] Cross SH, Charlton JA, Nan X, Bird AP. Purification of CpG islands using a methylated DNA binding column. *Nat Genet* 1994;6:236–44.
- [71] Huang TH, Perry MR, Laux DE. Methylation profiling of CpG islands in human breast cancer cells. *Hum Mol Genet* 1999;8:459–70.
- [72] Yan PS, Perry MR, Laux DE, et al. CpG island arrays: an application toward deciphering epigenetic signatures of breast cancer. *Clin Cancer Res* 2000;6:1432–8.
- [73] Ahluwalia A, Yan P, Hurteau JA, et al. DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. *Gynecol Oncol* 2001;82:261–8.
- [74] Yan PS, Shi H, Rahmatpanah F, et al. Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer. *Cancer Res* 2003;63:6178–86.
- [75] van Doorn R, Zoutman WH, Dijkman R, et al. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. *J Clin Oncol* 2005;23:3886–96.
- [76] Day JK, Bauer AM, DesBordes C, et al. Genistein alters methylation patterns in mice. *J Nutr* 2002;132:2419S–23S.
- [77] Yan PS, Wei SH, Huang TH. Differential methylation hybridization using CpG island arrays. *Methods Mol Biol* 2002;200:87–100.
- [78] Craig JM, Kraus J, Cremer T. Removal of repetitive sequences from FISH probes using PCR-assisted affinity chromatography. *Hum Genet* 1997;100:472–6.
- [79] Heisler LE, Torti D, Boutros PC, et al. CpG Island microarray probe sequences derived from a physical library are representative of CpG Islands annotated on the human genome. *Nucleic Acids Res* 2005;33:2952–61.
- [80] Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. *Proc Natl Acad Sci USA* 1992;89:1827–31.
- [81] Gitan RS, Shi H, Chen CM, et al. Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis. *Genome Res* 2002;12:158–64.
- [82] Shi H, Wei SH, Leu YW, et al. Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. *Cancer Res* 2003;63:2164–71.
- [83] Yang H, Chen CM, Yan P, et al. The androgen receptor gene is preferentially hypermethylated in follicular non-Hodgkin's lymphomas. *Clin Cancer Res* 2003;9:4034–42.

- [84] Hou P, Shen JY, Ji MJ, et al. Microarray-based method for detecting methylation changes of p16(Ink4a) gene 5'-CpG islands in gastric carcinomas. *World J Gastroenterol* 2004;10:3553–8.
- [85] Yu YP, Paranjpe S, Nelson J, et al. High throughput screening of methylation status of genes in prostate cancer using an oligonucleotide methylation array. *Carcinogenesis* 2005;26:471–9.
- [86] Guo J, Burger M, Nimmrich I, et al. Differential DNA methylation of gene promoters in small B-cell lymphomas. *Am J Clin Pathol* 2005;124:430–9.
- [87] Zhou D, Qiao W, Yang L, Lu Z. Bisulfite-modified target DNA array for aberrant methylation analysis. *Anal Biochem* 2006;351:26–35.
- [88] Kramer JA, Pettit SD, Amin RP, et al. Overview on the application of transcription profiling using selected nephrotoxicants for toxicology assessment. *Environ Health Perspect* 2004;112:460–4.
- [89] Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. *Nat Genet* 2002;31:141–9.
- [90] Chiba T, Yokosuka O, Arai M, et al. Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells. *J Hepatol* 2004;41:436–45.
- [91] Dannenberg LO, Edenberg HJ. Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation. *BMC Genomics* 2006;7:181.
- [92] Li L, Shi H, Yiannoutsos C, et al. Epigenetic hypothesis tests for methylation and acetylation in a triple microarray system. *J Comput Biol* 2005;12:370–90.
- [93] Holliday R, Ho T. DNA methylation and epigenetic inheritance. *Methods* 2002;27:179–83.
- [94] Boyle GM, Martyn AC, Parsons PG. Histone deacetylase inhibitors and malignant melanoma. *Pigment Cell Res* 2005;18:160–6.
- [95] Glaser KB, Staver MJ, Waring JF, et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. *Mol Cancer Ther* 2003;2:151–63.
- [96] Weber M, Davies JJ, Wittig D, et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. *Nat Genet* 2005;37:853–62.
- [97] Gebhard C, Schwarzfischer L, Pham TH, et al. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia. *Cancer Res* 2006;66:6118–28.
- [98] Shi H, Guo J, Duff DJ, et al. Discovery of novel epigenetic markers in non-Hodgkin's lymphoma. *Carcinogenesis* 2007;28:60–70.
- [99] Wojdacz TK, Hansen LL. Techniques used in studies of age-related DNA methylation changes. *Ann N Y Acad Sci* 2006;1067:479–87.
- [100] Kuras L. Characterization of protein–DNA association in vivo by chromatin immunoprecipitation. *Methods Mol Biol* 2004;284:147–62.
- [101] Davuluri RV, Grosse I, Zhang MQ. Computational identification of promoters and first exons in the human genome. *Nat Genet* 2001;29:412–7.
- [102] Weinmann AS, Yan PS, Oberley MJ, et al. Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microarray analysis. *Genes Dev* 2002;16:235–44.
- [103] Ren B, Robert F, Wyrick JJ, et al. Genome-wide location and function of DNA binding proteins. *Science* 2000;290:2306–9.
- [104] Ren B, Cam H, Takahashi Y, et al. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. *Genes Dev* 2002;16:245–56.
- [105] Mao DY, Watson JD, Yan PS, et al. Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression. *Curr Biol* 2003;13:882–6.
- [106] Oberley MJ, Tsao J, Yau P, Farnham PJ. High-throughput screening of chromatin immunoprecipitates using CpG-island microarrays. *Methods Enzymol* 2004;376:315–23.
- [107] Wilson IM, Davies JJ, Weber M, et al. Epigenomics: mapping the methylome. *Cell Cycle* 2006;5:155–8.
- [108] Karimi M, Johansson S, Stach D, et al. LUMA (LUMinometric Methylation Assay)—a high throughput method to the analysis of genomic DNA methylation. *Exp Cell Res* 2006;312:1989–95.
- [109] Cedar H, Solage A, Glaser G, Razin A. Direct detection of methylated cytosine in DNA by use of the restriction enzyme *MspI*. *Nucleic Acids Res* 1979;6:2125–32.
- [110] Ronaghi M. Pyrosequencing sheds light on DNA sequencing. *Genome Res* 2001;11:3–11.
- [111] Tost J, El Abdalaoui H, Gut IG. Serial pyrosequencing for quantitative DNA methylation analysis. *Biotechniques* 2006;40, 721–2, 724, 726.
- [112] Shiao YH, Crawford EB, Anderson LM, et al. Allele-specific germ cell epimutation in the spacer promoter of the 45S ribosomal RNA gene after Cr(III) exposure. *Toxicol Appl Pharmacol* 2005;205:290–6.
- [113] Mill J, Dempster E, Caspi A, et al. Evidence for monozygotic twin (MZ) discordance in methylation level at two CpG sites in the promoter region of the catechol-O-methyltransferase (COMT) gene. *Am J Med Genet B Neuropsychiatr Genet* 2006;141:421–5.
- [114] White HE, Durston VJ, Harvey JF, Cross NC. Quantitative analysis of SNRPN (correction of SRPN) gene methylation by pyrosequencing as a diagnostic test for Prader-Willi syndrome and Angelman syndrome. *Clin Chem* 2006;52:1005–13.
- [115] Shaw RJ, Liloglou T, Rogers SN, et al. Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. *Br J Cancer* 2006;94:561–8.
- [116] Xinarianos G, McDonald FE, Risk JM, et al. Frequent genetic and epigenetic abnormalities contribute to the deregulation of cytoglobin in non-small cell lung cancer. *Hum Mol Genet* 2006;15:2038–44.
- [117] Kang S, Kim J, Kim HB, et al. Methylation of p16INK4a is a non-rare event in cervical intraepithelial neoplasia. *Diagn Mol Pathol* 2006;15:74–82.
- [118] Mirmohammadsadegh A, Marini A, Nambiar S, et al. Epigenetic silencing of the PTEN gene in melanoma. *Cancer Res* 2006;66:6546–52.
- [119] Smith LM. The future of DNA sequencing. *Science* 1993;262:530–2.
- [120] Hillenkamp F, Karas M, Beavis RC, Chait BT. Matrix-assisted laser desorption/ionization mass spectrometry of biopolymers. *Anal Chem* 1991;63:1193A–203A.
- [121] Puapai boon U, Jai-Nhuknan J, Cowan JA. Characterization of a multi-functional metal-mediated nuclease by MALDI-TOF mass spectrometry. *Nucleic Acids Res* 2001;29:3652–6.
- [122] Fu DJ, Tang K, Braun A, et al. Sequencing exons 5 to 8 of the *p53* gene by MALDI-TOF mass spectrometry. *Nat Biotechnol* 1998;16:381–4.
- [123] Schatz P, Dietrich D, Schuster M. Rapid analysis of CpG methylation patterns using RNase T1 cleavage and MALDI-TOF. *Nucleic Acids Res* 2004;32:e167.
- [124] Tost J, Schatz P, Schuster M, et al. Analysis and accurate quantification of CpG methylation by MALDI mass spectrometry. *Nucleic Acids Res* 2003;31:e50.
- [125] Sauer S, Lechner D, Berlin K, et al. A novel procedure for efficient genotyping of single nucleotide polymorphisms. *Nucleic Acids Res* 2000;28:E13.
- [126] Ehrich M, Nelson MR, Stanssens P, et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. *Proc Natl Acad Sci USA* 2005;102:15785–90.
- [127] Fraga MF, Esteller M. DNA methylation: a profile of methods and applications. *Biotechniques* 2002;33:632, 634, 636–42, 649.
- [128] Ramsahoye BH. Measurement of genome wide DNA methylation by reversed-phase high-performance liquid chromatography. *Methods* 2002;27:156–61.
- [129] Chakrabarty D, Yu KW, Paek KY. Detection of DNA methylation changes during somatic embryogenesis of Siberian ginseng (*Eleutherococcus senticosus*). *Plant Sci* 2003;165:61–8.
- [130] Sun Y, Deng D, You WC, et al. Methylation of p16 CpG islands associated with malignant transformation of gastric dysplasia in a population-based study. *Clin Cancer Res* 2004;10:5087–93.
- [131] Luo D, Zhang B, Lv L, et al. Methylation of CpG islands of p16 associated with progression of primary gastric carcinomas. *Lab Invest* 2006;86:591–8.
- [132] Tryndyak VP, Muskhelishvili L, Kovalchuk O, et al. Effect of long-term tamoxifen exposure on genotoxic and epigenetic changes in rat liver: implications for tamoxifen-induced hepatocarcinogenesis. *Carcinogenesis* 2006;27:1713–20.

- [133] Song L, James SR, Kazim L, Karpf AR. Specific method for the determination of genomic DNA methylation by liquid chromatography-electrospray ionization tandem mass spectrometry. *Anal Chem* 2005;77:504–10.
- [134] Gama-Sosa MA, Midgett RM, Slagel VA, et al. Tissue-specific differences in DNA methylation in various mammals. *Biochim Biophys Acta* 1983;740:212–9.
- [135] Fisher DH, Giese RW. Determination of 5-methylcytosine in DNA by gas chromatography-electron-capture detection. *J Chromatogr* 1988;452:51–60.
- [136] Leonard SA, Wong SC, Nyce JW. Quantitation of 5-methylcytosine by one-dimensional high-performance thin-layer chromatography. *J Chromatogr* 1993;645:189–92.
- [137] Cortacero-Ramirez S, Segura-Carretero A, Cruces-Blanco C, et al. Simultaneous determination of multiple constituents in real beer samples of different origins by capillary zone electrophoresis. *Anal Bioanal Chem* 2004;380:831–7.
- [138] Zhu X, Leav I, Leung YK, et al. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. *Am J Pathol* 2004;164:2003–12.
- [139] Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. *Proc Natl Acad Sci USA* 1996;93:9821–6.
- [140] Derks S, Lentjes MH, Hellebrekers DM, et al. Methylation-specific PCR unraveled. *Cell Oncol* 2004;26:291–9.
- [141] Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. *Nucleic Acids Res* 1997;25:2532–4.
- [142] Bian YS, Yan P, Osterheld MC, et al. Promoter methylation analysis on microdissected paraffin-embedded tissues using bisulfite treatment and PCR-SSCP. *Biotechniques* 2001;30:66–72.
- [143] Clement G, Bosman FT, Fontollet C, Benhattar J. Monoallelic methylation of the APC promoter is altered in normal gastric mucosa associated with neoplastic lesions. *Cancer Res* 2004;64:6867–73.
- [144] Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. *Nucleic Acids Res* 2000;28:E32.
- [145] Ogino S, Kawasaki T, Brahmandam M, et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. *J Mol Diagn* 2006;8:209–17.

Developmental Exposure to Estradiol and Bisphenol A Increases Susceptibility to Prostate Carcinogenesis and Epigenetically Regulates Phosphodiesterase Type 4 Variant 4

Shuk-Mei Ho,¹ Wan-Yee Tang,¹ Jessica Belmonte de Frausto,² and Gail S. Prins²

¹Department of Environmental Health, University of Cincinnati, Cincinnati, Ohio and ²Department of Urology, University of Illinois at Chicago, Chicago, Illinois

Abstract

Early developmental perturbations have been linked to adult-onset prostate pathology, including excessive exposure to estrogenic compounds; however, the molecular basis for this imprinting event is not known. An important and controversial health concern is whether low-dose exposures to hormonally active environmental estrogens, such as bisphenol A, can promote human diseases, including prostate cancer. Here, we show that transient developmental exposure of rats to low, environmentally relevant doses of bisphenol A or estradiol increases prostate gland susceptibility to adult-onset precancerous lesions and hormonal carcinogenesis. We found permanent alterations in the DNA methylation patterns of multiple cell signaling genes, suggesting an epigenetic basis for estrogen imprinting. For phosphodiesterase type 4 variant 4 (PDE4D4), an enzyme responsible for cyclic AMP breakdown, a specific methylation cluster was identified in the 5'-flanking CpG island that was gradually hypermethylated with aging in normal prostates, resulting in loss of gene expression. Early and prolonged hypomethylation at this site following neonatal estradiol or bisphenol A exposure resulted in continued, elevated PDE4D4 expression. Cell line studies confirmed that site-specific methylation is involved in transcriptional silencing of the *PDE4D4* gene and showed hypomethylation of this gene in prostate cancer cells. Importantly, the *PDE4D4* alterations in the estrogen-exposed prostates were distinguishable before histopathologic changes of the gland, making *PDE4D4* a candidate molecular marker for prostate cancer risk assessment as a result of endocrine disruptors. In total, these findings indicate that low-dose exposures to ubiquitous environmental estrogens affect the prostate epigenome during development and, in so doing, promote prostate disease with aging. (Cancer Res 2006; 66(11): 5624-32)

Introduction

There are increasing human health and wildlife concerns about low-dose estrogenic exposures because hormonally active xenoestrogens are ubiquitous in the environment (1). Bisphenol A, initially synthesized as a synthetic estrogen (2), is widely used as a cross-linking chemical in the manufacture of polycarbonate plastics and

epoxy resins. Although bisphenol A binds to classic estrogen receptors with reduced affinity relative to 17 β -estradiol (3), it possesses equivalent activational capacity of the nonclassic membrane estrogen receptors (4). Importantly, bisphenol A leaches from food and beverage containers as well as dental sealants and is found in the serum of humans with higher concentrations in placental and fetal tissues (5). Thus, there is potential for this compound as a toxicant for developing human tissues, particularly the sensitive reproductive end organs (6, 7).

Prostate gland development, which occurs during fetal life in humans and the perinatal period in rodents, is exquisitely sensitive to estrogen imprinting. The *in utero* estrogen environment of African-American mothers has been suggested to affect the elevated prostate cancer risk of their offspring because they have higher estradiol levels during pregnancy when compared with their Caucasian counterparts (8, 9). In rodent models, brief perinatal exposure to pharmacologic doses of natural or synthetic estrogens permanently alters prostate growth and differentiation (10–12) and results in precancerous lesions and tumors with aging (13). However, although perinatal exposures to environmentally relevant doses of bisphenol A or estradiol have been shown to augment prostatic size (14), they have not, as yet, been shown to induce pathologic prostatic lesions. Thus, it remains unclear whether low-dose exposures to estradiol or environmental estrogens can influence prostate cancer risk.

Because early exposure to low-dose estrogen augments estrogen responsiveness of adult female reproductive organs (15, 16), we asked whether analogous circumstances exist in the prostate. This is particularly relevant because relative estradiol levels increase in the aging male, partly due to increased body fat content and aromatase activity, at a time when prostate cancer incidence increases (17). Furthermore, estrogens have been associated with increased prostate cancer risk in men (18), whereas, in the Noble rat model, prolonged adult exposure to conjoint estradiol and testosterone drives prostatic carcinogenesis (19). In this context, we established a carcinogenesis model that involved neonatal exposure to high- or low-dose estradiol or low-dose bisphenol A followed by adult exposure to elevated but nonpharmacologic testosterone plus estradiol in the Sprague-Dawley rat, a strain less sensitive to hormone-induced prostate carcinogenesis. Our goal was to determine if neonatal low-dose exposures to estradiol or bisphenol A might increase cancer susceptibility as a result of adult exposure to elevated estradiol. We herein present the first evidence that indeed low-dose as well as high-dose estrogenic exposures predispose to neoplastic prostatic lesions in the aging male.

We next sought to determine the molecular underpinnings by which developmental estrogenic exposures can imprint or transform the prostate long after the initial hormone exposure. One distinct possibility is through permanent epigenetic modifications

Note: Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

S-M. Ho and W-Y. Tang contributed equally to this work.

Requests for reprints: Gail S. Prins, Department of Urology, University of Illinois at Chicago, 820 South Wood Street, MC 955, Chicago, IL 60612. Phone: 312-413-9766; Fax: 312-996-1291; E-mail: gprins@uic.edu.

©2006 American Association for Cancer Research.

doi:10.1158/0008-5472.CAN-06-0516

of the genome by DNA methylation at CpG-rich regions (CpG islands), which can silence (hypermethylation) or activate (hypomethylation) gene transcription (20). Once established in somatic cells, CpG methylation patterns within the genome are stable and heritable through subsequent cell divisions, except during early embryonic development and tumorigenesis. Importantly, alterations in DNA methylation have been shown to contribute to both cancer initiation and promotion (20, 21). Furthermore, previous studies have revealed an association between aberrant CpG methylation of specific genes in the reproductive tract and neonatal exposures to phytoestrogens, diethylstilbestrol, and the environmental toxicants vinclozolin and methoxychlor (22–25). To determine whether neonatal estrogenic exposures imprint the prostate gland via this epigenetic modification, we did methylation-sensitive restriction fingerprinting (MSRF) followed by specific methylation analysis to identify and characterize candidate genes as methylation targets in prostate glands exposed to our two-hit model. We herein present evidence for altered methylation patterns of several candidate genes and characterize phosphodiesterase type 4 variant 4 (PDE4D4), the enzyme involved in cyclic AMP (cAMP) degradation, as an estrogen-imprinted gene directly associated with preneoplastic prostatic lesions.

Materials and Methods

Animal housing and treatments. All animal treatments were approved by the Animal Use Committee at the University of Illinois (Chicago, IL). Pregnant Sprague-Dawley rats (Zivic-Miller Laboratories, Pittsburgh, PA) were shipped on gestation day 12 and immediately transferred to strict housing conditions. Rooms were maintained at 21°C with 50% relative humidity and a 14-hour-light/10-hour-dark schedule. To avoid bisphenol A leaching from polycarbonate plastic, all rats were housed in new polysulfone solid-bottom cages with steel covers, and water was supplied from glass bottles. Animals were fed *ad libitum* a special soy-free, phytoestrogen-reduced diet (Zeigler Reduced Rodent Diet 2, Zeigler Brothers, Inc., Gardners, PA) with 12 ppm phytoestrogens as determined by high-pressure liquid chromatography. To avoid variability, a single feed lot was purchased for the entire study, packaged in 25-pound bags, autoclaved, and stored at –30°C to minimize growth of microbes that might contribute estrogenic by-products. Pregnant dams were monitored, and the day of birth was designated postnatal day 0. The pups were sexed by anogenital distance, and each litter was culled to 10 pups by removing or adding female pups as necessary.

The hormonal treatment regime, consisting of newborn rats briefly exposed to estrogens followed by prolonged adult exposure to elevated estradiol with appropriate controls, resulted in a total of eight animal groups. Newborn pups were assigned to one of four neonatal treatment groups with 20 to 30 pups per group: (a) controls given tocopherol-stripped corn oil vehicle alone (ICN Biomedicals, Inc., Aurora, OH), (b) high-dose 17 β -estradiol 3-benzoate (EB) at 25 μ g/pup (or 2,500 μ g EB/kg body weight), (c) low-dose EB at 0.001 μ g EB/pup (or 0.1 μ g EB/kg body weight), or (c) bisphenol A at 0.1 μ g/pup (or 10 μ g/kg body weight). All steroids were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO). The high-dose EB was chosen based on our published data of an estrogenized phenotype with adult-onset prostatic intraepithelial neoplasia (PIN; ref. 13). The low-dose EB was chosen because this dose delayed puberty and permanently affected other reproductive structures in our dose-response study (26). An environmentally relevant dose of bisphenol A was chosen based on a predicted exposure range from leached bisphenol A in the environment (27). To avoid litter effects, male pups within each litter were randomly assigned to a treatment and toe clipped for permanent identification. Treatments were given on postnatal days 1, 3, and 5 by s.c. injections in the nape of the neck. The pups were weaned at postnatal day 21, and siblings were housed three per cage until postnatal day 90 and individually thereafter. At postnatal day 90, half of the rats from each treatment group

were given implants of Silastic capsules (inside diameter 1.5 mm, outer diameter 2.0 mm; Dow Corning, Midland, MI) packed with estradiol (one 1-cm tube) and testosterone (two 2-cm tubes) for 16 weeks (replaced after 8 weeks), whereas the remaining half were given empty tubes. The testosterone capsules were necessary to maintain physiologic levels of testosterone because estradiol treatment alone results in hypothalamic-testicular feedback inhibition of endogenous testosterone secretion with resultant prostatic involution. These testosterone plus estradiol capsule lengths result in ~75 pg/mL serum estradiol and 3 ng/mL serum testosterone (28) and produce PIN in the dorsolateral prostates at 100% incidence in Noble rats (29) but only 33% incidence in Sprague-Dawley rats (30). At 28 weeks of age, the animals were sacrificed by decapitation, and prostate glands were quickly removed and microdissected into ventral, lateral, and dorsal lobes. Half of each lobe was snap frozen and stored in liquid nitrogen for subsequent methylation analysis, whereas the contralateral lobe was fixed in 10% buffered formalin overnight and stored in 70% ethanol for histopathologic diagnosis. In addition to the above animals sacrificed on day 200, rats from the four neonatal treatment groups were sacrificed, and prostates were removed on postnatal days 10 and 90 ($n = 5$ –7 per group) for DNA methylation analysis.

Histopathology. Fixed prostatic tissues were processed, paraffin embedded, and sectioned along the longitudinal axis at three levels of the tissue block (10 sections per lobe). The sections were coded to prevent reader bias and stained with H&E. Each lobe was scored in a blinded fashion for epithelial and stromal hyperplasia, inflammation, and the presence of PIN and other notable pathology (adenoma, metaplasia, basement membrane breakdown, microinvasion, etc). PIN lesions were characterized by the presence of nuclear atypia (enlarged and elongated nuclei, hyperchromasia, and prominent nucleoli) with or without aberrant cellular piling and ductal formation (31). PIN lesions were graded on a scale of 0 to 3 (0, no atypia; 1, low-grade PIN; 2, focal high-grade PIN; and 3, extensive high-grade PIN). For PIN lesions, the incidence and the mean PIN score per treatment group were determined. Incidence was analyzed by χ^2 , and PIN scores were analyzed by ANOVA after square root transformation of the data followed by Fisher's exact test with significance accepted at $P < 0.05$.

Immunohistochemistry and *in situ* apoptosis labeling. Proliferation was measured by immunohistochemistry using a polyclonal Ki-67 primary antibody (1:2,500; Novocastra, Newcastle upon Tyne, United Kingdom). For apoptosis assessment, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining was used with ApopTag peroxidase *in situ* apoptosis detection kit (Chemicon International, Temecula, CA). To calculate the proliferation and apoptotic indices, multiple representative areas of each lobe were captured with a color digital AxioCam camera on an Axioskop microscope (Carl Zeiss, Inc., Thornwood, NY). Positive and negative Ki-67-stained or TUNEL-labeled epithelial cells were counted using Zeiss Image version 3.0 (Carl Zeiss), with an average of 1,000 cells counted per slide. Data were analyzed by ANOVA and *post hoc* Bonferroni tests, and $P < 0.05$ was considered significant.

Methylation-sensitive restriction fingerprinting. MSRF was done as described (32), with minor modifications. In brief, 1 μ g genomic DNA extracted from tissues with the DNeasy Tissue kit (Qiagen, Valencia, CA) was digested with *Mse*I alone or double digested with *Bst*UI and *Mse*I (New England Biolabs, Beverly, MA). Digested DNA was amplified by PCR using 2 μ Ci [α -³²P] dCTP (3,000 Ci/mmol; NEN, Boston, MA) with various combinations of paired arbitrary primers chosen from the following: *Bs7*, 5'-GAGGTGCGCG; *Bs11*, 5'-GAGAGGCGCG; *Bs17*, 5'-GGGGACGCGA; *PCG1*, 5'-AAGGAAGACG; and *PCG4*, 5'-TCCTTCCTCG. PCR products were separated on 6% nondenaturing polyacrylamide gels, which were dried and exposed to Kodak MS film (Kodak, New Haven, CT) to visualize the labeled bands. Candidate bands displaying the appropriate differential methylation status among "control" and "comparative" samples were cut, reamplified, and cloned directly into pCR2.1 vector (Invitrogen, Carlsbad, CA) for sequencing. The sequence obtained was aligned with database from Genbank and RefSeq using BLAST, expressed sequence tag homology (National Center for Biotechnology Information), and BLAT search (University of California Genome Research, Santa Cruz, CA).

5'-Rapid amplification of cDNA ends. The first-strand cDNA of *PDE4D4* was amplified using a reverse specific primer (5'-AAAGACGAGGCCAGGACAT-3') and the GeneRacer 5' Primer (Invitrogen). Nested PCR was done, and products were subcloned into pCR4-TOPO vector (Invitrogen). At least 10 clones were chosen and sequenced.

Bisulfite genomic sequencing. Genomic DNA (200 ng) from rat prostate tissue samples or rat cell lines was modified with sodium bisulfite using CpGenome DNA Modification kit (Chemicon International) and used in nested PCR for bisulfite sequencing. Primers for amplifying the *PDE4D4* gene promoter/exon 1 region in completely converted DNA were designed with Primer3 and MethPrimer (33). First PCR was done using forward (5'-AGTGGTTTGGAGAAGTTAGAGTTTA-3') and reverse (5'-CCAAAACATCCTAAATTTCTTCAAA-3') primers. Nested PCR was done with forward (5'-TTATGTGTTGAAGAGTAGATTTGTG-3') and reverse (5'-ATCCTAAATTTCTTCAACCTAAC-3') primers. Both PCRs were done at 94°C for 9 minutes, 40 cycles of denaturing (94°C for 30 seconds), annealing (56°C for 1 minute), and extension (72°C for 1 minute) followed by a 12-minute final extension. The PCR product was gel purified and cloned into pCR2.1 vector. Six clones were picked from each sample for sequencing (Macrogen, Rockville, MD), and at least three sets of samples from each group were used. The DNA methylation data from sequencing were analyzed by BiQ Analyzer (34).

Methylation-specific PCR. PCR was done on bisulfite-treated DNA samples (40 ng) using primers specific for methylated (5'-GGTACGAGTAGTATTATTAGTATTCGTTTC-3' and 5'-CACGACAATACAAATAACGCTCCGT-3') or unmethylated (5'-GGTATGAGTAGTATTATTAGTATTTGTTT-3' and 5'-CACAACAATAACAATAACTCCAT-3') DNA. Forty PCR cycles were done with the following conditions: denature at 94°C for 30 seconds, anneal at 58°C for 1 minute, and extension at 72°C for 1 minute followed by 12-minute final extension. PCR products were separated on 2% agarose gel and visualized with ethidium bromide.

Real-time reverse transcription-PCR. Total RNA was isolated and reverse transcribed, and *PDE4D4* expression was quantitated by a fluorogenic method with 2× SYBR Green Master Mix using an iCycler iQ Real-time PCR Detection System (Bio-Rad Laboratories, Hercules, CA) as described previously (35). Primers specific for *PDE4D4* (AF031373) were designed in the exon/exon spanning region and were as follows: *PDE4D4*, 5'-ACGAGCAGCACCAGTA-3' (forward) and 5'-CTTGAGCGTAGC-GACCAC-3' (reverse). *PDE4D4* mRNA levels were normalized to RPL19 and the postnatal day 10 oil-treated control value was arbitrarily assigned an abundance value of 1. All data groups were analyzed by ANOVA followed by *post hoc* Bonferroni tests.

Prostate cell cultures and demethylation assay. Normal prostate epithelial NbE-1 cells and tumorigenic AIT cells were established from the Noble rat and immortalized as described previously (36). Cell cultures were treated with 0.5 or 1 μmol/L 5-aza-2'-deoxycytidine (5-Aza-dC; Sigma-Aldrich) for 8 days. Drugs were replenished every 4 days, and equivalent concentrations of DMSO were added in replicate control samples. At the end of the treatment, DNA and RNA were extracted from the cells and subjected to bisulfite genomic sequencing to determine the methylation status of the 5'-flanking region of the *PDE4D4* gene and real-time reverse transcription-PCR (RT-PCR) to quantitate *PDE4D4* gene expression.

Results

Low-dose estradiol and bisphenol A increase susceptibility to prostate neoplastic lesions. Responses to neonatal and adult hormone treatments were similar among the separate prostate lobes with only minor lobe-specific differences noted, and representative data are presented from the dorsal prostate (see Supplementary Fig. S1 for ventral and lateral data). Similar to our previous studies with rats (26), neonatal exposure to high-dose estrogen decreased adult prostate weights, whereas developmental exposure to low-dose estradiol or bisphenol A did not affect prostate size (Fig. 1A). Adult testosterone plus estradiol increased prostate weights but did not change the response pattern to

neonatal exposures (Fig. 1A). Prostate histopathology was assessed in a blinded manner for hyperplasia, chronic inflammation, and PIN, the precursor lesion of prostate cancer. PIN scores, based on grade and frequency, and PIN incidence showed marked differences across treatment groups (Fig. 1B-D). The oil-control group had a low PIN incidence (11%) and score (0.11) and normal prostate histology. Neonatal exposure to high-dose EB alone resulted in a 66% incidence of high-grade PIN and a markedly increased PIN score (1.12; $P < 0.05$). Areas of severe nuclear atypia, adenoma, and cellular piling were typically observed (Fig. 1D). Importantly, exposure to low-dose estradiol alone also increased the PIN incidence to 56% with mixed low-grade and high-grade PIN and elevated the PIN score (0.8). Focal areas of mild nuclear atypia were frequently observed in low-dose estradiol prostates. In contrast, neonatal low-dose bisphenol A alone did not induce PIN lesions in the aged prostates. Stromal and epithelial hyperplasia as well as inflammatory cell infiltration were observed in the high-dose EB prostate but not in the low-dose EB or the bisphenol A-exposed animals (data not shown).

As expected (19), prolonged adult testosterone plus estradiol exposure increased PIN incidence (40%) and score (0.52) in oil-control prostates (Fig. 1B and C), and this was further increased (incidence, 100% and score, 1.3; $P < 0.05$) by initial early exposure to high-dose EB. Neonatal low-dose EB before adult hormones did not augment PIN lesions further than that seen with adult testosterone plus estradiol or neonatal low-EB exposures alone. In contrast, neonatal exposure to low-dose bisphenol A significantly increased the PIN incidence (100%, mostly high-grade PIN) and score (1.3; $P < 0.01$) following adult exposure to elevated testosterone plus estradiol. Further, the neoplastic severity produced by bisphenol A was equivalent to high-dose EB exposures. Histologically, severe atypia was common with nuclear elongation and irregular size, cellular piling, and adenoma formation (Fig. 1D).

The prostatic tissues were assessed for alterations in epithelial cell proliferation and apoptosis, which are normally low in the adult prostate gland. Low rates of proliferation and apoptosis were consistently observed in all areas of the treated prostates, except for those exposed neonatally to high-dose EB or bisphenol A (Fig. 2A-B). Neonatal high EB treatment alone or with adult hormones increased basal proliferation rates throughout the tissue, with a higher rate observed in high-grade PIN regions (Fig. 2B, *inset*). Bisphenol A exposure followed by adult hormones also significantly increased proliferation in regions with high-grade PIN (Fig. 2A and B, *inset*). Similarly, low basal rates of apoptosis were detected throughout the prostate tissues, except for regions of high-grade PIN in the animals exposed neonatally to high-dose EB or bisphenol A with adult hormones (Fig. 2C-D). This provides support for the hypothesis that developmental estrogenic exposures initiate or activate precancerous pathways, resulting in an imbalance in cell proliferation and apoptosis that may contribute to prostatic pathology with aging. Taken together, the present experimental paradigm suggests that early low-dose estrogen exposures predispose the prostate to PIN with aging and that environmentally relevant doses of bisphenol A during development increase prostatic susceptibility to carcinogenesis following additional adult insults.

Neonatal estrogens epigenetically modify the prostate through alterations in DNA methylation. We sought to determine whether permanent alterations in prostate growth and carcinogenic susceptibility long after early estrogenic exposures could be mediated through epigenetic alterations. To examine genome-wide methylation changes, MSRF was done using DNA




Figure 1. Effects of neonatal estrogens on adult prostate.

Representative data for the dorsal prostate at 6 months.

A, dorsal prostate weights at day 200. *, $P < 0.05$ versus oil/testosterone + estradiol ($T + E$). **B**, columns, mean PIN scores; bars, SE. *, $P < 0.05$ versus oil alone; **, $P < 0.05$ versus oil/testosterone + estradiol; †, $P < 0.01$ versus bisphenol A (BPA) alone. **C**, incidence of PIN lesions across treatment groups at day 200. LGPIN, low-grade PIN; HGPIN, high-grade PIN. **D**, representative H&E sections from dorsal prostates of the eight treatment groups. Bar, 50 μ m.

from the neonatally exposed tissues removed on days 10, 90 (before adult hormone treatment), and 200 (schematized in Supplementary Fig. S2). Differential methylation changes were sought between control versus neonatally treated tissues across time. We were additionally interested in identifying candidates with early onset methylation changes that can potentially be used as markers for risk assessment. More than 50 candidate bands were chosen for cloning and sequencing, and 28 unique DNA candidate clones were identified (Table 1). Of the identified candidates, 16 showed no homology with known rat genes, 6 were identified once, and 2 (*CARX1* and *SLC12A2*) were identified multiple times with similar methylation patterns observed each time. Importantly, these eight candidate genes were homologous (>95%) to known genes involved in signal transduction pathways: Na-K-Cl cotransporter (*SLC12A2*), mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway (*GPCR14* and *PDGFR α*), phosphoinositide 3-kinase (*PLC β 3*), cAMP pathways (*PDE4D4* and *HPCAL1*), and neural or cardiac development (*CARX1* and *CARK*).

PDE4D4, which breaks down intracellular cAMP, was chosen for further characterization because the differentially methylated candidate clone corresponded to the 5'-region of the gene, and the methylation differences between control and estrogen-exposed tissues were observed as early as postnatal day 10.

The 5'-flanking/promoter region of *PDE4D4* was first identified by 5'-rapid amplification of cDNA ends and a 700-bp CpG island with 60 CpG sites was found to encompass its transcription and translation start sites (Fig. 3A). Importantly, multiple transcription factor response elements, including cAMP response element, estrogen response element half-site, and Sp1, were computationally identified in this CpG island (Supplementary Fig. S3).

Methylation site mapping of this CpG island was done by bisulfite genomic sequencing in prostates from all treatment groups at postnatal days 10, 90, and 200. Figure 3B shows an example of methylation mapping at the 60 CpG sites in day 200 oil (Fig. 3B, top) and bisphenol A-treated prostates (Fig. 3B, bottom), whereas Fig. 3C shows the percentage methylation at the 60 CpG sites in all dorsal prostate tissues calculated over time for the different treatment groups. Although most CpG sites were unmethylated, a methylated cluster was noted between CpG sites 49 to 56 (Fig. 3B, boxed region), and methylation frequency at these sites progressively increased in the oil-control prostates as the animals aged, reaching 100% methylation by day 200 (Fig. 3C, solid diamonds). In contrast, the CpGs 49 to 56 remained relatively hypomethylated in aging prostates exposed neonatally to high- or low-dose estradiol or low-dose bisphenol A (Fig. 3B-C).

Direct association of DNA methylation at CpGs 49 to 56 and its resultant effect on *PDE4D4* gene expression were shown by using methylation-specific PCR and real-time RT-PCR. There were no differences in DNA methylation or gene expression between treatment groups at day 10 (Fig. 4A-B). However, as the animals aged, CpGs 49 to 56 became entirely methylated in oil-control prostates, whereas neonatal high EB-treated, low EB-treated, and bisphenol A-treated prostates possessed completely unmethylated sequences (Fig. 4A). Importantly, these differential methylation patterns were inversely correlated to *PDE4D4* gene expression (Fig. 4B). *PDE4D4* message levels in prostates exposed neonatally to estradiol or bisphenol A were markedly higher at day 90 than control tissues and remained elevated with aging. We thus conclude that the prostatic *PDE4D4* gene is normally silenced with aging through promoter hypermethylation but remains expressed in neonatally estrogenized prostates by virtue of hypomethylation at CpGs 49 to 56. Notably, this phenomenon was observed in all neonatal high- and low-dose EB and low-dose bisphenol A groups before the "second hit" of hormones and before adult-onset PIN lesions. Thus *PDE4D4* may have potential as a marker for prostate cancer risk assessment.

We further showed that *PDE4D4* transcription is dependent on the methylation status of its promoter region, specifically at CpGs 49 to 56, by using rat prostate NbE-1 cells, an immortalized normal epithelial cell line, and AIT, a dorsal prostate tumor-derived cell line. We found low levels of *PDE4D4* expression and a methylated 49 to 56 CpG cluster in NbE-1 cells but high levels of gene expression in AIT cells and unmethylated cluster at CpGs 49 to

56 (Fig. 5A-C). These *in vitro* findings mirror the *in vivo* data of control versus estrogenized prostate tissues. Treatment of NbE-1 cells with 5-Aza-dC induced loss of methylation at CpGs 49 to 56 and increased *PDE4D4* gene expression ($P < 0.01$; Fig. 5A and C). Similar treatment of AIT cells completely demethylated these previously hypomethylated CpG sites; however, it did not further increase the already high levels of *PDE4D4* expression (Fig. 5B-C). Taken together, these data provide direct evidence that hypermethylation of the *PDE4D4* promoter at CpGs 49 to 56 is involved in *PDE4D4* transcriptional silencing and that deregulation of methylation at this locus occurs in prostate cancer cells.

Discussion

The present findings provide the first evidence of a direct link between developmental low-dose bisphenol A or estradiol exposures and carcinogenesis of the prostate gland. Specifically, the data show that exposure to low doses of estradiol or environmentally relevant doses of bisphenol A during the neonatal developmental period in rats increases susceptibility to precancerous prostatic lesions as the animals aged and sensitizes the prostate gland to adult-induced hormonal carcinogenesis. This data thus contribute to the increasing body of evidence for a link between fetal exposures to endocrine disruptors and cancer (37–39). The human male fetus is exposed to elevated levels of maternal and exogenous estrogenic compounds, including bisphenol A (5, 40), and these estrogens could sensitize the prostate, perhaps through epigenetic mechanisms. Furthermore, relative increases in estradiol levels in the aging male




Figure 2. Proliferation and apoptosis rates following estrogenic exposures. **A**, proliferation index for dorsal prostate epithelial cells as determined by Ki-67 immunostaining. Black and red-hatched columns, counts in histologically normal regions; red-striped columns, areas of high-grade PIN. Basal proliferation was elevated in high-dose EB prostates. Proliferation rates were further elevated in high-grade PIN lesions of high-dose EB and bisphenol A/testosterone + estradiol prostates. *, $P < 0.05$ versus oil and low-dose EB; **, $P < 0.01$ versus oil and high-dose EB/testosterone + estradiol/PIN region; †, $P < 0.05$ versus bisphenol A/testosterone + estradiol/normal region; ††, $P < 0.001$ versus normal regions of all testosterone + estradiol treatment groups. **B**, representative regions of histologically normal dorsal prostates immunostained for Ki-67. Inset, regions of high-grade PIN within each group. **C**, apoptotic index for dorsal prostate epithelial cells as determined by TUNEL. Areas of high-grade PIN in high-dose EB and bisphenol A/testosterone + estradiol tissues showed increased apoptosis. *, $P < 0.05$ versus bisphenol A/testosterone + estradiol; **, $P < 0.01$ versus normal regions of all testosterone + estradiol treatment groups; ***, $P < 0.001$ versus normal regions in all treatments. **D**, representative TUNEL-labeled dorsal prostates. Normal region for oil and high-grade PIN region for all others. Bar, 50 μ m.

Table 1. Differentially methylated candidate genes identified with MSRF

Clone name	Primer 1	Primer 2	Hypermethylation	Chromosomal band	Gene homology	Location	Related pathways
2p717	7	17	Low estradiol, high estradiol, bisphenol A (10, 90, 200)	1q22	CAR-XI	5'-End	Neural cell development
3p717	7	17	Low estradiol (200)	1q22	CAR-XI	5'-End	Neural cell development
1P11G1	11	G01	Low estradiol, bisphenol A (200)	1q43	PLC β 3	Exon19	PKC and phospholipase signaling
3p11G1	11	G01	Low estradiol, bisphenol A (200)	7q12	NA		
4p11G1	11	G01	Low estradiol, bisphenol A(90,200)	18q12.1	SLC12A2	Exon17	Na-K-2Cl cotransport
5p11G1	11	G01	Low estradiol, bisphenol A (200)	18q12.1	SLC12A2	Exon17	Na-K-2Cl cotransport
6p11G1	11	G01	Low estradiol, bisphenol A (200)	18q12.1	SLC12A2	Exon17	Na-K-2Cl cotransport
8p11G1	11	G01	Control (10, 90)	6q32	NA		
9p11G1	11	G01	Low estradiol, bisphenol A (200)	6q16	HPCAL1	Intron1	cAMP signaling
10p11G1	11	G01	Low estradiol, bisphenol A (200)	18p12	NA		
11p11G1	11	G01	Control (10, 90)	2q14	NA		
12p11G1	11	G01	Low estradiol (10, 90, 200)	6q32	NA		
3p11G4	11	G04	Low estradiol, high estradiol, bisphenol A (90,200)	7q34	NA		
5p11G4	11	G04	Low estradiol, high estradiol, bisphenol A (90, 200)	6q24	NA		
6p11G4	11	G04	Low estradiol, high estradiol, bisphenol A (90,200)	18q12.1	SLC12A2	Exon17	Na-K-2Cl cotransport
7p11G4	11	G04	Low estradiol, high estradiol, bisphenol A (90, 200)	8q22	NA		
8p11G4	11	G04	Low estradiol, high estradiol, bisphenol A (90, 200)	2q45	CARK	5'-End	Ca ²⁺ dependent signaling
9p11G4	11	G04	Low estradiol (90, 200)	4q31	NA		
10p11G4	11	G04	Low estradiol, bisphenol A (90, 200)	4q31	NA		
11p11G4	11	G04	Low estradiol, bisphenol A (90, 200)	4q31	NA		
14p11G4	11	G04	Low estradiol (90, 200)	4q31	NA		
15p11G4	11	G04	Low estradiol (90, 200)	19q12	NA		
17p11G4	11	G04	Low estradiol (90, 200)	8q32	GPCR14	5'-End	G-protein coupled receptor signaling
18p11G4	11	G04	Control (10, 90, 200)	2q14	PDE4D4	5'-End	cAMP signaling
2p1117	11	17	Low estradiol, high estradiol, bisphenol A (200 testosterone + estradiol)	20q13	NA		
3p1117	11	17	bisphenol A (10)	7q11	NA		
4p1117	11	17	Low estradiol, high estradiol, bisphenol A (10)	17p12	NA		
5p1117	11	17	Control (10)	114p11	PDGFR α	Intron4	MAPK, ERK signaling

NOTE: Fragments were identified based on SWISS-PROT, TrEMBL, mRNA, and RefSeq search. Shown for each candidates are MSRF primers used, the hypermethylation pattern observed in the control, high and low estradiol, and bisphenol A samples (days of adult testosterone + estradiol treatment), the chromosomal band to which the fragment localized, the gene homology, and the location of the methylated fragment on the gene and the known related pathways.

Abbreviation: NA, not available.

(17) are adequate to promote carcinogenesis in a sensitized organ. Alternatively, a neonatally sensitized organ may be more vulnerable to adult exposures to bisphenol A or other xenoestrogens that bioaccumulate in fat cells. In this regard, recent evidence has shown that low-dose bisphenol A inappropriately activates the androgen receptor and mitogenesis in prostate adenocarcinoma cells *in vitro* and sensitizes cells with previous mutations (41). It is particularly relevant that the developmentally estrogenized rodent has accurately modeled multiple male and female reproductive tract lesions in humans (42). Thus, the present findings may have implications for human prostatic adenocarcinoma, which occurs with a relatively high frequency in the aging population and whose etiology remains unclear.

Although the mechanism(s) by which developmental exposures to endogenous and environmental estrogens alter the carcinogenic potential of the prostate have not been fully clarified, the present findings support the hypothesis, initially proposed by McLachlan (43), that altered epigenetic memory by endocrine disruptors may play a critical role. In this study, we have provided direct evidence in support of this premise. Our data show that several genes exhibit methylation changes in response to the neonatal estrogen treatments, many of which are permanent. It is noteworthy that several of these genes encode signaling pathway proteins that are involved in cell cycle and/or apoptosis, suggesting that neonatal estrogen exposures may perturb proliferation/apoptosis equilibrium through epigenetic gene

(de)regulation. It is also interesting that overlapping as well as unique methylation alterations were observed for high- and low-dose estrogen and bisphenol A. This suggests two important points. First, common prostatic genes may be epigenetically imprinted by different estrogenic compounds and doses, suggesting common pathways that predispose to prostate carcinogenesis with aging. Second, unique candidate genes specific to the neonatal estrogenic exposure and/or dose may mediate the subtle differences in phenotypes that were observed following the separate neonatal exposures.

The epigenetic regulation of gene expression by neonatal estrogen exposure was confirmed by detailed analysis of the *PDE4D4* gene. The estradiol and bisphenol A-initiated alterations in *PDE4D4* gene methylation occurred at a CpG island that spans the promoter/exon 1 region, a site typically involved in epigenetic regulation. Importantly, the degree of methylation at




Figure 3. Bisulfite genomic sequencing of prostatic *PDE4D4* gene methylation. **A**, schematic of CpG content (%) in the 5'-flanking region of the rat *PDE4D4* gene identifies a CpG island (blue) between -310 to +390 bp. Vertical lines, individual CpG sites and the translation start site (ATG+1) and transcription start site (TSS). **Blanket**, 700-bp nested PCR-amplified region used for bisulfite sequencing. **B**, bisulfite genomic sequencing data from 4 to 6 clones each of three individual DNA samples taken from day 200 oil/testosterone + estradiol and bisphenol A/testosterone + estradiol dorsal prostates. Methylation status of specific CpG sites. ○, unmethylated; ●, methylated. **Boxed region**, potential CpG sites epigenetically altered by bisphenol A. **C**, percentage methylation at each CpG site within the 5'-CpG island of *PDE4D4* in the separate treatment groups at days 10, 90, and 200 with or without adult testosterone + estradiol. The percentage methylation at each site was averaged from three individual sample sets. ◆, oil control; □, high-dose estradiol; △, low-dose estradiol; ×, bisphenol A.




Figure 4. Comparison of *PDE4D4* CpG methylation and mRNA transcript levels. **A**, methylation-specific PCR analysis: dorsal prostate genomic DNA was bisulfite treated followed by methylation-specific PCR using methylated specific (M) or unmethylated-specific (U) primer sets. The amplified region is indicated in Fig. 3. The PCR products are representative data from three individual sets of samples. **B**, *PDE4D4* mRNA transcript levels as determined by real-time RT-PCR. Relative expression of day10 oil samples was set to 1. **Columns**, mean; **bars**, SD. All EB/bisphenol A groups at days 90, 200, and 200/testosterone + estradiol were significantly different ($P < 0.05$) from respective groups at day 10. *, $P < 0.05$; **, $P < 0.01$ versus oil controls at the same time interval; †, $P < 0.05$ versus day 200 oil controls; ††, $P < 0.05$ versus day 10 oil controls.

this site was inversely related to *PDE4D4* gene expression in the prostate tissues. Thus, the *PDE4D4* promoter undergoes gradual hypermethylation with aging in normal prostates, resulting in *PDE4D4* gene repression in the adult gland. In contrast, it remains hypomethylated in animals briefly exposed to neonatal estradiol or bisphenol A, thus engendering persistent *PDE4D4* overexpression throughout life. This pattern of *PDE4D4* methylation and transcriptional regulation was also observed in normal and malignant prostate epithelial cells where normal NbE-1 cells with hypermethylated *PDE4D4* gene had low gene expression, whereas tumorigenic AIT cells had hypomethylation at the CpG island and elevated *PDE4D4* expression. Taken together, these findings suggest the potential involvement of epigenetically mediated *PDE4D4* dysregulation in prostate epithelial cell transformation.

At present, it is premature to suggest that *PDE4D4* dysregulation is a direct mediator of the prostatic dysgenesis as a result of early exposures to low- and high-dose estradiol or low-dose bisphenol A, particularly because the phenotypic response to the hormonal agents has specific differences widely, whereas the *PDE4D4* methylation and expression alterations are quite similar. Nonetheless, PDE4 is a promising lead candidate that deserves further discussion. PDE4 is a member of a large family of intracellular PDE enzymes involved in cyclic nucleotide monophosphate breakdown, and it specifically degrades cAMP (44). There are multiple downstream signals for cAMP in the cell, including




Figure 5. Alterations in *PDE4D4* CpG methylation and gene expression in NbE-1 and AIT cell lines by a demethylating agent. **A**, percentage CpG methylation for *PDE4D4* CpGs 49 to 56 in normal NbE-1 cells without (◆) or with 5-Aza-dC treatment (□, 0.5 μ mol/L 5-Aza-dC; Δ, 1 μ mol/L 5-Aza-dC). **B**, percentage CpG methylation for *PDE4D4* CpGs 49 to 56 in tumorigenic AIT cells without (◆) or with 5-Aza-dC treatment. **C**, relative *PDE4D4* mRNA levels in NbE-1 and AIT cells. White columns, control cells (A0); bars, SD. Black columns, cells treated with 5-Aza-dC. Expression of control NbE-1 cells was set to 1. **, $P < 0.01$ versus controls; †, $P < 0.05$ versus control NbE-1 cells.

activation of protein kinase A with resultant phosphorylation of cAMP-responsive element binding protein, which regulates transcription of genes involved in cell growth and differentiation (45). PDE4D has been shown to regulate cAMP levels in hormone-

targeted cells, and the PDE4D4 variant, which localizes to the cytoskeletal structures, is itself activated by hormones (46). Sustained expression of *PDE4D4* by hypomethylation could thus result in decreased intracellular cAMP in specific subcellular locations, creating a potential for aberrant cell signaling and potentially neoplastic transformation. In this regard, recent studies have shown a tight association between PDE4 expression and cancer cell proliferation, including glioma cells (47), osteosarcomas (48), and chronic lymphocytic leukemia (49). Importantly, PDE4 is currently being pursued as a possible chemotherapeutic target (50).

In addition to providing insight into the molecular underpinnings of estrogen imprinting, the methylated candidate genes identified herein have potential to serve as molecular markers for risk assessment of prostate disease due to early environmental exposures. *PDE4D4* shows particular promise in this regard because alterations in both gene methylation and expression were apparent before adult hormonal exposures and, importantly, before the onset of histopathologic changes in the prostate gland. This suggests that subtle alterations in gene expression may be more sensitive indicators of underlying pathology than the histologic alterations that occur when the disease is further progressed. Future studies are planned to develop a panel of methylated genes that may be used as markers for prostatic disease following early bisphenol A exposures.

In summary, we have shown that a range of estrogenic exposures during the developmental critical period, from environmentally relevant bisphenol A exposure to low-dose and pharmacologic estradiol exposures, results in an increased incidence and susceptibility to neoplastic prostatic lesions in the aging male, which may provide a fetal basis for this adult disease. Furthermore, the present findings provide evidence that developmental exposure to environmental endocrine disruptors (bisphenol A) and natural estrogens impacts the prostate epigenome during early life, which suggests an epigenetic basis for estrogen imprinting of the prostate gland. Methylation patterns and/or expression of candidate genes, such as *PDE4D4*, may serve as early biomarkers of prostate malignancy due to developmental exposure to endocrine disruptors or the *in utero* estrogenic environment.

Acknowledgments

Received 2/9/2006; revised 3/20/2006; accepted 3/29/2006.

Grant support: NIH grants ES12281 (G.S. Prins and S-M. Ho) and DK40890 (G.S. Prins) and the Department of Defense awards DAMD W81XWH-04-1-0165 (S-M. Ho) and W81XWH-06-1-0373 (W-Y. Tang).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank the Department of Surgery of the University of Massachusetts (Worcester, MA), David Hepps, MD, and Lynn Birch for technical contributions.

References

- Colborn T. Environmental estrogens: health implications for humans and wildlife. *Environ Health Perspect* 1995;103:135-6.
- Dodds EC, Lawson W. Synthetic estrogenic agents without phenanthrene nucleus. *Nature* 1936;137:996-7.
- Krishnan AV, Stathis P, Permuth SF, Tokes L, Feldman D. Bisphenol-A: an estrogenic substance is released from polycarbonate flasks during autoclaving. *Endocrinology* 1993;132:2279-86.
- Quesada I, Fuentes E, Viso-Leon MC, Ripoll C, Nadal A. Low doses of the endocrine disruptor bisphenol-A and the native hormone 17 β -estradiol rapidly activate the transcription factor CREB. *FASEB J* 2002;16:1671-3.
- Schonfelder G, Wittfoht W, Hopp H, Talsness CE, Paul M, Chahoud I. Parent bisphenol A accumulation in the human maternal-fetal-placental unit. *Environ Health Perspect* 2002;110:A703-7.
- Howdeshell KL, Hotchkiss AK, Thayer KA,

- Vandenbergh JG, vom Saal FS. Environmental toxins: exposure to bisphenol A advances puberty. *Nature* 1999;401:763-4.
7. Markey CM, Wadia PR, Rubin BS, Sonnenschein C, Soto AM. Long-term effects of fetal exposure to low doses of the xenoestrogen bisphenol-A in the female mouse genital tract. *Biol Reprod* 2005;72:1344-51.
 8. Henderson BE, Bernstein L, Ross RK, Depue RH, Judd HL. The early *in utero* oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. *Br J Cancer* 1988;57:216-8.
 9. Powell IJ, Meyskens FL, Jr. African American men and hereditary/familial prostate cancer: intermediate-risk populations for chemoprevention trials. *Urology* 2001; 57:178-81.
 10. Rajfer J, Coffey DS. Effects of neonatal steroids on male sex tissues. *Invest Urol* 1979;17:3-8.
 11. Prins GS. Neonatal estrogen exposure induces lobe-specific alterations in adult rat prostate androgen receptor expression. *Endocrinology* 1992;130:3703-14.
 12. Huang L, Pu Y, Alam S, Birch L, Prins GS. Estrogenic regulation of signaling pathways and homeobox genes during rat prostate development. *J Androl* 2004;25:330-7.
 13. Prins GS. Developmental estrogenization of the prostate gland. In: Naz RK, editor. *Prostate: basic and clinical aspects*. Chapter 10. Boca Raton: CRC Press; 1997. p. 247-65.
 14. vom Saal FS, Timms BG, Montano MM, et al. Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. *Proc Natl Acad Sci USA* 1997;94: 2056-61.
 15. Newbold RR, Jefferson WN, Padilla-Banks E, Haseman J. Developmental exposure to diethylstilbestrol (DES) alters uterine response to estrogens in prepubescent mice: low versus high dose effects. *Reprod Toxicol* 2004;18:399-406.
 16. Munoz-de-Toro M, Markey CM, Wadia PR, et al. Perinatal exposure to bisphenol-A alters peripubertal mammary gland development in mice. *Endocrinology* 2005;146:4138-47.
 17. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. *Endocr Rev* 2005;26:833-76.
 18. Modugno F, Weissfeld JL, Trump DL, et al. Allelic variants of aromatase and androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. *Clin Cancer Res* 2001;7:3092-6.
 19. Leav I, Ho S, Ofner P, Merk F, Kwan P, Damassa D. Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. *J Natl Cancer Inst* 1988;80:1045-53.
 20. Mompalmer R, Bovenzi V. DNA methylation and cancer. *J Cell Physiol* 2000;183:145-54.
 21. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. *Annu Rev Pharmacol Toxicol* 2005;45:629-56.
 22. Lyn-Cook BD, Blann E, Payne PW, Bo J, Sheehan D, Medlock K. Methylation profile and amplification of proto-oncogenes in rat pancreas induced with phytoestrogens. *Proc Soc Exp Biol Med* 1995;208:116-9.
 23. Li S, Washburn KA, Moore R, et al. Developmental exposure to diethylstilbestrol elicits demethylation of estrogen-responsive lactoferrin gene in mouse uterus. *Cancer Res* 1997;57:4356-9.
 24. Alworth LC, Howdeshell KL, Ruhlén RL, et al. Uterine responsiveness to estradiol and DNA methylation are altered by fetal exposure to diethylstilbestrol and methoxychlor in CD-1 mice: effects of low versus high doses. *Toxicol Appl Pharmacol* 2002;183:10-22.
 25. Anway MD, Cupp AS, Uzumcu M, Skinner MK. Epigenetic transgenerational actions of endocrine disruptors and male fertility. *Science* 2005;308:1466-9.
 26. Putz O, Schwartz CB, Kim S, LeBlanc GA, Cooper RL, Prins GS. Neonatal low- and high-dose exposure to estradiol benzoate in the male rat. I. Effects on the prostate gland. *Biol Reprod* 2001;65:1496-505.
 27. Nagel SC, vom Saal FS, Thayer KA, Dhar MG, Boechler M, Weshons WV. Relative binding affinity-serum modified access (RBA-SMA) assay predicts the relative *in vivo* bioactivity of the xenoestrogens bisphenol A and octylphenol. *Environ Health Perspect* 1997;105:70-6.
 28. Lee C, Prins GS, Henneberry MO, Grayhack JT. Effect of estradiol on the rat prostate in the presence and absence of testosterone and pituitary. *J Androl* 1981;2: 293-9.
 29. Yu M, Cates J, Leav I, Ho S. Heterogeneity of [3H]estradiol binding sites in the rat prostate: properties and distribution of type I and type II sites. *J Steroid Biochem* 1989;33:449-57.
 30. Bosland MC, Ford H, Horton L. Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 β or diethylstilbestrol. *Carcinogenesis* 1995;16:1311-7.
 31. Shappell S, Thomas D, Roberts R, et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Biology Committee. *Cancer Res* 2004;64:2270-305.
 32. Huang TH, Laux DE, Hamlin BC, Tran P, Tran H, Lubahn DB. Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique. *Cancer Res* 1997;57:1030-4.
 33. Li LC, Dahiva R. MethPrimer: designing primers for methylation PCRs. *Bioinformatics* 2002;18:1427-31.
 34. Bock C, Reither S, Mikeska T, Paulsen M, Walter J, Lengauer T. BiQ Analyzer: visualization and quality control for DNA methylation data from bisulphite sequencing. *Bioinformatics* 2005;21:4067-8.
 35. Lau KM, LaSprina M, long J, Ho SM. Expression of estrogen receptor (ER)- α and ER- β in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. *Cancer Res* 2000;60:702-6.
 36. Chang SM, Chung LW. Interaction between prostatic fibroblast and epithelial cells in culture: role of androgen. *Endocrinology* 1989;125:2719-27.
 37. Newbold RR, Bullock BC, McLachlan JA. Uterine adenocarcinoma in mice following developmental treatment with estrogens: a model for hormonal carcinogenesis. *Cancer Res* 1990;50:7677-81.
 38. Shibata A, Minn AY. Perinatal sex hormones and risk of breast and prostate cancers in adulthood. *Epidemiol Rev* 2000;22:239-48.
 39. Birnbaum LS, Fenton SE. Cancer and developmental exposure to endocrine disruptors. *Environ Health Perspect* 2003;111:389-94.
 40. Baik I, Devito WJ, Ballen K, et al. Association of fetal hormone levels with stem cell potential: evidence for early life roots of human cancer. *Cancer Res* 2005;65: 358-63.
 41. Wetherill YB, Petre CE, Monk KR, Puga A, Knudsen KE. The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. *Mol Cancer Ther* 2002;1: 515-24.
 42. Greco T, Duello T, Gorski J. Estrogen receptors, estradiol, and diethylstilbestrol in early development: the mouse as a model for the study of estrogen receptors and estrogen sensitivity in embryonic development of male and female reproductive tracts. *Endocr Rev* 1993;14:59-71.
 43. McLachlan JA. Environmental signaling: what embryos and evolution teach us about endocrine disrupting chemicals. *Endocr Rev* 2001;22:319-41.
 44. Conti M, Swinnen JV. Structure and function of the rolipram-sensitive, low-K_m cyclic AMP phosphodiesterase: a family of highly related enzymes. In: Houslay MD, Beavo JA, editors. *Molecular pharmacology of cell regulation: cyclic nucleotide phosphodiesterase structure, regulation, and drug action*. New York: Wiley; 1990. p. 243-66.
 45. Fimia GM, Sassone-Corsi P. Cyclic AMP signalling. *J Cell Sci* 2001;114:1971-2.
 46. Jin S-LC, Bushnik T, Lan L, Conti M. Subcellular localization of rolipram-sensitive, cAMP-specific phosphodiesterases. *J Biol Chem* 1998;273:19672-8.
 47. Chen TC, Wadsten P, Su S, et al. The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells. *Cancer Biol Ther* 2002;1:268-76.
 48. Narita M, Murata T, Shimizu K, et al. Phosphodiesterase 4 in osteoblastic osteosarcoma cells as a potential target for growth inhibition. *Anticancer Drugs* 2003;14: 377-81.
 49. Lerner A, Kim DH, Lee R. The cAMP signaling pathway as a therapeutic target in lymphoid malignancies. *Leuk Lymphoma* 2000;37:39-51.
 50. Hirsh L, Dantes A, Suh B-S, et al. Phosphodiesterase inhibitors as anti-cancer drugs. *Biochem Pharmacol* 2004;68:981-8.